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Beta-thromboglobulin is a platelet specific protein of
molecular weight 35,000, stored in the alpha granules and released
during aggregation. Its precise function is unknown but it may
act as a 'packing protein' in the alpha granules. Radioimmuno¬
assays to measure it in plasma and urine have been developed.
Meticulous techniques of processing and sampling are necessary
to prevent artefactual release. In healthy subjects the upper
limit of the normal range is 80 ng/ml in plasma and 0.21 ng/ml in
urine.
If the (3TG concentration of the plasma is artificially
elevated it is cleared exponentially with a plasma half life of
about 80 mins. Only a tiny proportion of the infused dose appears
in the urine.
Many drugs are known to affect platelet function but Aspirin,
although it has a potent anti-aggregatory action, has no effect on
the plasma 3TG concentration. Heparin, however, may produce
raised plasma $TG concentrations some hours after injection.
Only 65% of patients with venous thromboembolism had elevated
$TG concentrations on the day of presentation. The degree of rise
in concentration was related to the presence of pulmonary embolism
but not to the duration of symptoms or the extent of the thrombus.
However, 85% of patients with venous thromboembolism had elevated
urinary $TG concentrations and so the urinary 0TG concentration is
a more valuable diagnostic test of venous thromboembolism than the
plasma concentration.
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Operation had a considerable effect on plasma STG concentration
which was most marked in patients undergoing vascular surgery.
Many factors affected the plasma concentrations following operation
but major infections produce the greatest rise. A small, but
statistically insignificant rise occurred at the time of development
125
of deep vein thrombosis diagnosed by the I fibrinogen uptake
test. The other factors affecting the plasma STG concentration in
the post operative period grossly limited its value in the diagnosis
of post operative deep vein thrombosis. It was likewise of little
value in the identification of graft thrombosis in those undergoing
arterial reconstructions. The urinary STG assay had similar
disadvantages to the plasma assay in the post operative period.
The study on patients with atherosclerosis revealed that many
had elevated plasma concentrations regardless of the clinical extent
of the disease but most patients had normal urine concentrations.
The assessments of plasma and urinary STG concentrations are
a sensitive measure of platelet activity in experimental situations
but the many factors which affect them and the relatively short
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1.
INTRODUCTION
THE PROBLEM OF THROMBOEMBOLIC DISEASE
189
In 1846 Rudolph Virchow first described venous thrombo-
190
embolism and in 1856 published his theory of the origin of
intravascular thrombosis which became known as 'Virchow's Triad'.
He attributed the development of a thrombus to one or more of
three factors, namely, damage to the vessel wall, hyper¬
coagulability of the blood and retarded blood flow. This theory
formed the basis of most of the subsequent research on the
17
aetiology of intravascular thrombosis. Bizzozero in 1882
demonstrated that injury to a vein wall resulted in the adherence
of platelets to the damaged area with superimposed aggregation and
75
Hayem, in the same year, described the haemostatic platelet plugs
that developed at the sites of puncture wounds in veins. Following
the excellent description of the morphology of intravascular
197
thrombus by William Welch, it has been apparent that thrombosis
is merely a pathological extension of the normal haemostatic
mechanism. The development of phlebography and arterio-
12 47 43 126
graphy ' ' ' led to the study of the pathological anatomy of
thrombosis during life and, with increasingly sophisticated
techniques, very precise visualisation of thrombi has become
possible.
The incidence of diseases associated with intravascular
thrombosis appears to be increasing. Deep vein thrombosis
following surgery became more frequently recognised in the early
years of this century but it probably occurred less often than it
2.
does today. If one looks at the reported incidence of death from
pulmonary embolism - a late and serious complication of venous
thrombosis - there was a nine-fold increase in the 34 years between
161
1945 and 1978 (Fig. 1). The rise in females was slightly
higher (x 10) than in males (x 7) and it is unlikely that this
increase was due purely to a greater awareness of the disease. The
increasing incidence of thrombotic disease was not confined to the
venous circulation. Death from coronary artery disease, a very
much commoner cause of death than pulmonary embolism,increased
161
four-fold in the same 34 year period (Fig. 1).
The seriousness of these trends has stimulated further
research into the mechanisms of thrombosis and the diagnosis of
thrombotic disease.
197
Welch showed that thrombus consists of fibrin, platelets,
erythrocytes and leukocytes in varying proportions and the following
section summarises the current understanding of the mechanisms of
formation of this complex structure.
THE MECHANISM OF THROMBOSIS
There are two principal processes involved in the formation of
a thrombus - the fibrin generation system and the adhesion and
aggregation of platelets - and they are very closely inter-related.
Endothelial damage exposing subendothelial collagen is an
important precipitating factor in at least some forms of intra-
176
vascular thrombosis and is well demonstrated in the arterial
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Fig 1: Mortality from coronary artery disease, cerebrovascular
disease and pulmonary embolism, 1945-1978, in Scotland.
(Registrar General's Annual Reports for Scotland)
4.
atherosclerotic endothelial damage. In venous thrombosis,
however, it is often difficult to demonstrate changes in
endothelial cells and it has been postulated that in this situation
192
thrombosis may occur in the absence of endothelial damage.
Stasis leading to the activation of coagulation factors and relative
hypoxia in the valve cusps may be responsible. However, damage to
the endothelium may be present but only recognisable at an electron
179
microscopic level, as Stewart et al.3 using scanning electron
microscopy, have demonstrated areas of endothelial damage associated
with leucocytes in a canine venous stasis model. They describe the
attachment of thrombus by fibrin strands to leucocytes which have
migrated through the endothelium.
The earliest stage of thrombus formation in response to
endothelial damage is the adhesion of platelets to the exposed
6
collagen which is a potent stimulator of adhesion and aggregation.
Endothelial damage also results in the activation of factor XII
leading to the production of thrombin which will enhance platelet
198 196
adhesion. Factor VIII related antigen may also be involved.
The adhesion and/or aggregation of platelets results in the
80
platelet release reaction. This involves the release from the
platelet of the contents of the storage granules by a process
similar to the secretion of the adrenal medullary hormones. These
contents include adenosine diphosphate (ADP), serotonin (5HT),
fibrinogen, platelet factor (PF4>, betathromboglobulin (£TG),
platelet derived growth factor (PDGF) and vascular permeability
enhancing factor (VPEF). The release of ADP results in the
further aggregation of platelets to those already adherent.
5.
The coagulation cascade, originating with factor XII activation
by collagen, proceeds simultaneously and results in the production
of thrombin which in turn converts fibrinogen to fibrin. Further
stimulus to the production of thrombin is provided by PF , a
o
membrane phospholipid released during platelet aggregation which
90
catalyses the activation of factor X. The released PF^ will help
by neutralising any heparin-like activity present. Fibrinogen is
also released from platelets and this seems to be chemically
86
distinct from the plasma fibrinogen. Although it is present in
very small amounts relative to plasma fibrinogen, it will increase
the local concentration around the platelets producing added
199
substrate for the thrombin. The thrombin splits
fibrinopeptides A & B (FPA & FPB) from fibrinogen to form fibrin
monomer which then polymerises under the influence of factor XIII
to produce the stable fibrin polymer.
The fibrinolytic system is stimulated at the same time as the
fibrin generation system. Plasminogen, the inactive precursor of
plasmin, is incorporated in the thrombus as it forms. Thrombin
and intravascular fibrin stimulate the release of plasminogen
activator from the vessel wall which converts plasminogen to plasmin
and which in turn lyses fibrin with the production of fibrin
3
degradation products (FDP). As well as lysing the fibrin in the
thrombus a mild plasma proteolytic action is generated which will
produce some degradation of circulating plasma fibrinogen.
Thrombus is, therefore, a dynamic structure with fibrin
generation and lysis occurring at the same time. One or other
may predominate at different stages in the life of a thrombus.
6.
This enormously complex biochemical process results in the
release of many substances into the circulation which may be
potential indicators of thrombotic disease. It would also be
useful if some method of differentiating between venous and
arterial thrombosis could be identified. However, the content of
150
both types of thrombus is remarkably similar. Olson et al.
showed that in experimental conditions arterial thrombi contained
68 times the platelet content of blood, slightly less red cells
than blood and twice the fibrin equivalent of plasma fibrinogen.
Venous thrombi had similar fibrin and red cell contents but only
28 times the platelet content of blood. The assessments of these
experimental thrombi give a somewhat artificial impression of their
content in that thrombi in the venous circulation can have a very
variable composition in different parts of the same thrombus. A
good example of this is coralline thrombus with its alternating
70
layers of platelet rich and platelet poor thrombus. Therefore,
at any point during the formation of such a thrombus there may be
predominantly platelet or fibrin deposition and this may alter the
types of substances detectable in the circulation.
THE PREDICTION AND DIAGNOSIS OF INTRAVASCULAR THROMBOSIS
Are diagnostic tests of thrombosis necessary? In the venous
94
circulation, Kakkar has demonstrated that clinical diagnosis of
calf vein thrombosis is unreliable. Fifty per cent of those with
125
evidence of thrombus on an I fibrinogen uptake test had no
symptoms or signs and 30% of those with symptoms or signs of calf
DVT had normal deep veins on phlebography. However, in iliofemoral
7.
thrombosis clinical accuracy over 80% if possible. Does it
matter if one fails to detect these apparently trivial calf
thrombi? The majority of these thrombi lyse spontaneously but
about a quarter of them will propagate above the knee and these
may give rise to major pulmonary embolism. Early diagnosis and
treatment can prevent this serious complication. Even the thrombi
that remain confined to the calf are not without problems, as
22
Browse and Clemenson have shown that many cause longstanding leg
pain and swelling.
Arterial disease is also common in the UK as evidenced by the
161
increasing incidence of death from myocardial infarction (Fig. 1).
Many of these deaths occur suddenly in people without previous
symptoms or signs of arterial disease. Clinical examination may
demonstrate major lesions of the mainstream arterial supply to the
limbs and in the neck but tells us little about disease of smaller
vessels such as those in the heart or brain. A simple method of
detecting minor thrombotic disease in its early stages could
possibly lead to earlier treatment with, hopefully, the prevention
of major complications.
There is, therefore, a pressing need for the development of a
satisfactory technique of detecting early intravascular thrombosis.
A satisfactory test is one which reliably differentiates those with
thrombosis from those without (i.e. it is sensitive and specific).
Ideally it should also be non-invasive and harmless, cause no
discomfort, able to be frequently repeated and inexpensive.
The currently available diagnostic tests are based on two
different principles. The first type detects physiological changes
8.
produced by the alterations in blood flow which result from intra¬
vascular thrombosis. Examples of these are the detection of
173,180,206
alterations in blood flow by ultrasound velocity meters
45,131,200
or by plethysmography; detection of altered tissue
174 14
perfusion by isotope clearance, thermography, or by reduced
174
arterial pressure; or by the imaging of the thrombus by
u-i w u , , . 12,47,48,126,171phlebography or arteriography.
The most satisfactory delineation of the thrombus is provided
by angiological techniques but these investigations have a small
incidence of serious complications; they are unpleasant for the
patient and are expensive. They are, therefore, unsuitable for
screening. The tests which detect changes in blood flow are
simpler, cheaper and non-invasive but less sensitive and specific
than angiography, and fail to differentiate between new and old
thrombus.
I do not wish to pursue this aspect of diagnostic techniques
but will discuss further the second type of investigation which has
attempted to use biochemical changes as indicators of thrombus
formation.
These investigations may be divided into predictive tests
(which identify individuals at particular risk of developing
thrombotic disease) and diagnostic tests (which diagnose the
presence of thrombus).
9.
PREDICTIVE TESTS OF THROMBOSIS
39
Dawbarn's paper in 1928 is perhaps the earliest attempt to
correlate haematological change with thrombosis. He demonstrated
a rise in platelet count following surgery and parturition and
suggested that it was a precipitating factor in the development of
deep vein thrombosis. The extent of the rise was not related to
patient age but was related to the extent of surgery. Payling-
153
Wright showed that, as well as a rise in platelet count following
surgery and parturition, there was an increase in adhesiveness of
138
the platelets. However, in 1969, Negus et al. who used Wright's
205
rotating bulb method of assessing platelet adhesiveness, were
unable to demonstrate any difference in adhesiveness before or
immediately after surgery between those who developed DVT and those
g
who did not. Becker, however, using a different method (platelet
retention in a glass bead column) showed that there was a signifi¬
cant relationship between the development of post-operative DVT and
the platelet adhesiveness measured immediately after operation. In
patients with recurrent venous thromboembolic disease, Steele et
178
al. were able to demonstrate a shortened platelet survival in 18
out of 28 patients but increased adhesiveness in only 8. Hirsch
77
and McBride also showed increased platelet retention in a glass
bead column in these patients.
Whole blood viscosity may be related to thrombogenesis.
Several factors contribute to viscosity but the most important
53 46
appear to be haematocrit and the fibrinogen content. Dormandy
showed a significant relationship between pre-operative whole blood
viscosity (haematocrit corrected) and the development of DVT. The
10.
patients who developed DVT had viscosities 29% higher than those who
did not but the specificity of the test was poor.
The fibrinolytic system has been the subject of a great deal
of research in the last 25 years and there is now good evidence that
the fibrinolytic activity of the blood is derived from the release
of plasminogen activators by the endothelium of small blood
3
vessels. Venous occlusion stimulates the release of vessel wall
activator and this is the basis of a test of fibrinolytic activity.
The resultant fibrinolytic activity can be measured by either
191 58
euglobulin lysis time or the dilute blood clot lysis time.
152
Pandolfi et al. have also described a technique for assessing
vessel wall fibrinolytic activity in vein biopsies which is a
183
modification of the original fibrin plate method of Todd.
115
Using these techniques Mansfield was able to show a significant
relationship between post-operative DVT and reduced fibrinolytic
10
activity in the blood on the first day after surgery but Becker
could not confirm this. In patients with recurrent idiopathic
85
venous thrombosis, Isacson and Nilsson showed defective
87
fibrinolysis in both blood and vein wall and Jarrett et al. were
able to reverse the abnormalities with the fibrinolytic enhancer,
24
Stanozolol. Browse et al. reported similar findings in patients
with recurrent superficial thrombophlebitis and venous liposclerosis.
The coagulation system has also been investigated for
potential predictive value. Patients with a high kaolin activated
partial thromboplastin time (indicating a degree of inhibition of
thrombin generation) before operation appear to have a low risk of
post-operative DVT whereas those with a high level of plasmin
11.
64
inhibitor activity on the day after surgery have a high risk.
51
In 1965 Egeberg described a thrombophilic family who had an
inherited deficiency of antithrombin III (which inhibits thrombin
and activated factor X) and since then several other such thrombo¬
philic families have been identified in Europe and North America.
Antithrombin III levels fall following surgery but ^berg"'" was
unable to correlate this with post-operative DVT. However, Okuno
148
and Crockatt were able to demonstrate reduced antithrombin III
levels in 67% of patients with a recent DVT (within 4 months).
Similar studies have been performed on patients with arterial
disease, with most interest being in the investigation of platelet
function. An increased aggregability of platelets in response to
ADP and collagen has been demonstrated in atherosclerotic
.
^ 133,149,194 . .. , 2 . , . . .. . .. . .patients, and Abrahamsen was able to show that they had
abnormal platelet survivals. He also showed shortened survival in
patients with acute myocardial infarction with return to normal on
170
clinical recovery, a finding confirmed by Sano who found similar
changes in acute stroke patients. On young acute stroke patients
172
Sharma demonstrated increased platelet adhesiveness as well as
increased plasma fibrinogen concentration.
Atherosclerotic patients have numerous areas of endothelial
damage which may have an effect on both the platelets and the
coagulation system. The increased platelet adhesiveness detected
in the patients with acute stroke or myocardial infarction may be
secondary to a recent thrombus rather than the cause of that
thrombus.
12.
Reduced platelet survival is found in patients with prosthetic
heart valves and this seems to correlate with the incidence of
195
arterial thromboembolism. Finally, in vascular surgery,
increased platelet adhesiveness has been associated with premature
, • 55,72graft occlusion.
These tests are concerned with the identification of populations
at risk from thrombotic disease and are of little value in the
diagnosis of acute or established thrombus.
DIAGNOSTIC TESTS OF THROMBOSIS
Diagnostic tests which assess the biochemical changes
associated with acute thrombosis are of two types. The first type
measures the incorporation of certain materials into the thrombus
whereas the second type is dependent on the detection of substances
released from or by the thrombus.
As shown earlier, the formation of a thrombus involves the
deposition of platelets and fibrin in concentrations greater than
in the circulating blood. Plasminogen and plasminogen activators
are also incorporated. By labelling any of these substances with
radioisotopes the label is incorporated into the developing thrombus
and the thrombus can be detected by an area of increased radio-
125
activity. The most widely used of these tests, the I
(125 125 7,21,52,137
fibrinogen uptake test IFT), utilises I fibrinogen
and this has become the standard technique for diagnosing DVT in the
major trials of prophylactic agents. It is relatively cheap, safe,
125
simple and accurate but does have certain disadvantages. The I
13.
fibrinogen must be present in the circulation as the thrombus forms
or propagates and, therefore, is of little value in diagnosing
established non-propagating thrombi. It is also of little value
in diagnosing thrombus above the inguinal ligament as the back¬
ground radiation from the pelvic veins and the bladder obscures the
radioactivity in iliac thrombus. Other substances have also been
131 151 99m_ 121 99m_
tried such as I plasmin, Tc urokinase and ic
99
streptokinase. Although these techniques have certain advantages
125
over the IFT, such as better delineation of established thrombus,
their difficulties of manufacture, limited effective isotope half
life or their unreliability have prevented their widespread
acceptance. A more promising recent development has been the use
111 59.100
of In-labelled platelets. The diagnostic accuracy of the
test appears to be good when compared to phlebography and it has
125
the advantage over the IFT in that there appears to be a
9
continual deposition of platelets even on established thrombus.
Another potentially valuable aspect of the use of labelled platelets
is that they are deposited on areas of endothelial damage and thus
may be of some value in the study of arterial disease.
The second type of test - detecting changes in the circulating
blood produced by thrombus formation - has been widely investigated.
Attempts to detect elevated levels of activated clotting
factors in the circulating blood of patients with thrombosis are
unlikely to be successful as they are very rapidly cleared from the
176




The end result of the coagulation cascade is the conversion of
fibrinogen to fibrin. Most of the fibrin then polymerises but
some escapes into the circulation as soluble fibrin monomer
complexes and can be detected in the plasma. Gurewich and
68
Hutchinson reported on the use of a serial dilution protamine
sulphate test to detect soluble fibrin monomer complexes in the
diagnosis of DVT. The test was commonly positive in those with
positive venograms but rarely so in those with negative venograms.
64
However, Gallus et at., who used the same test and the ethanol
gelation test, were unable to show any useful correlation between
125
these tests and the IFT.
A chromatrographic technique for detecting fibrinogen/fibrin
6 3
complexes in the plasma was developed by Fletcher et at. and they
showed that hypercoagulable patients tended to have lower elution
volumes than normal patients.
During the formation of fibrin, thrombin cleaves two peptides
from fibrinogen, and a radioimmunoassay has been developed to
I
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detect the first of these - fibrinopeptide A (FPA). ' Nossel
has shown that FPA has a half life in the circulation of only 3^
minutes and may be a marker of active fibrin deposition. High
concentrations were detected in patients with DVT, PE, arterial
thrombosis and myocardial infarction but he also found elevated
concentrations in meningitis, thrombocytopenia and atherosclerosis.
Other authors have also found elevated FPA concentrations in DVT
155 89
and PE and in patients with myocardial infarction. There was
some correlation between the FPA concentration and the size of the
infarct. High concentrations of FPA have also been identified in
15.
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patients with metastatic carcinoma and Davies et al. have
shown elevated concentrations following cardiopulmonary bypass.
The FPA concentration can be used as an indicator of the adequacy
155
of anticoagulant therapy in patients with thromboembolism but,
if the patient has a pulmonary infarct or a pleural effusion, the
FPA concentration remained permanently elevated despite adequate
142
anticoagulation. Nossel also demonstrated the ability of
heparin to reduce the FPA concentration but noted that FPA
generation was never completely prevented which suggests that
either FPA is formed somewhere out of the sphere of influence of
heparin or that there is another mechanism for FPA generation not
dependent on thrombin. This may explain the elevated concentra¬
tions detected in other conditions such as metastatic carcinoma and
obviously limits the specificity of the test for thromboembolic
disease.
With the activation of the fibrinolytic system fibrin and
fibrinogen are broken down into smaller molecules with the generic
name of Fibrin/Fibrinogen Degradation Products (FDPs). Patients
with actively lysing thrombus are likely to have elevated concentra¬
tions of FDPs. These breakdown products were first described by
144
Nussenzweig in 1960 and since then they have been extensively
29
studied in many disease states. In 1969 Cash et al. showed
striking elevations of FDP in patients with suspected pulmonary
embolism and this was confirmed by others. Using the staphy¬
lococcal clumping test (SCT) for FDPs and the serial dilution
protamine sulphate test for fibrin monomer complexes, Gurewich et
69
al. showed that all patients with symptomatic, venographically
16.
proven DVT had at least one test positive and 96% of their patients
169
with proven PE had positive SCTs. Ruckley et al. showed
significantly elevated FDP concentrations in patients with PE but
203
not in those with DVT alone and in 1972 Wood et al. reported
higher FDP concentrations in patients with congestive cardiac
failure, sepsis or metastatic carcinoma than in those with DVT.
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Subsequently, Jones et al. in a follow-up of Ruckley's work,
confirmed the high levels in patients with PE, but there was a
considerable overlap with patients who had other conditions. The
highest concentrations were detected in those with disseminated
intravascular coagulation. A possible explanation for some of the
79
discrepancies found in the literature is provided by Hirsh et al.
In experimental pulmonary emboli in dogs they demonstrated that the
high FDP concentrations were derived from lysis of fibrin deposited
on the emboli rather than from the emboli, themselves. The
elevated FDP concentrations could be prevented by treating the dogs
with heparin. The concentration of FDP seems to be a measure of
further fibrin deposition (or propagation) rather than of the
established thrombus or embolus.
The measurement of FDP is, therefore, of some value in the
diagnosis of PE but is insufficiently sensitive or specific to be
useful in the diagnosis of DVT.
Platelet aggregation is another important aspect of thrombus
formation. When they aggregate they release a variety of
substances. This 'release reaction' can also be induced without
aggregation and, in fact, platelets that have released may survive
30,80,163
and perform normally in the circulation. Release occurs
17.
of both the contents of the granules and of substances located in
the cytoplasm, mitochondria or membranes. Certain of the release
factors, such as potassium, zinc, mucopolysaccharides, ADP, ATP and
lysosomal enzymes are common to many different types of cell and
are of little interest as indicators of thrombosis. Other
substances, however, can be described as 'platelet specific'
release products. I use specific as an operational definition,
meaning that the activity or substance is antigenically distinct
from any plasma protein and/or possesses a biological activity not
found in native platelet poor plasma. Such platelet specific
products could be indicators of intravascular thrombosis. As
shown earlier, platelets are involved in the very earliest stage of
thrombus formation and these release products could be extremely
valuable as early indicators of thrombosis.
Various activities of these release products have been
127
described, including antiplasmin and antiplasminogen activator,
34
heparin neutralising activity, vascular permeability enhancing
136 165 202
factor, tissue culture stimulant factor ' and thromboplastic
186
activity. The thromboplastic activity, platelet factor 3
90
(PF ) was recognised as a property of the membrane lipoproteins.
u
Heparin neutralisation is the activity of one of the granule
release proteins - platelet factor 4 (PF^) and a radioimmunoassay
19
has been developed. Some doubt exists, however, as to whether
the plasma heparin neutralising activity is assessing the same
substance as the radioimmunoassay for PF^. Using the heparin
thrombin clotting time (HTCT) to measure plasma heparin
neutralising activity (HNA) , Ludlam et al.^^ showed that patients
18.
with myocardial infarction had markedly elevated HNA but normal PF4»
They suggested that the HTCT measured HNA of other plasma proteins
140
as well as that of PF^. Niewiarowski used a technique of
isoelectric focusing to separate released platelet proteins and
described a 'low activity' form of PF^ which was immunologically
distinct and suggested that it could be converted to $ thrombo-
globulin by proteolysis.
Significantly increased concentrations of PF^ were detected in
the plasma of patients with DVT 7 - 240 days after onset of symptoms
146
by O'Brien et al. who used the HTCT. There was, however, a
148
considerable overlap with the control group. Okuno and Crockatt
showed that only 30% of patients within 4 months of a DVT had
elevated PF^ as well as a similar proportion of patients with
110
recent myocardial infarction. However, Ludlam et al., although
confirming the raised PF^ concentrations in patients with DVT,
could not demonstrate elevated concentrations in those with MI.
146,148
A major criticism of the papers of both Okuno and O'Brien
is that the DVT patients were not all studied in the acute phase of
their illness (i.e. as soon as symptoms occurred) and, therefore,
they may have been studying patients who were not actually laying
down thrombus. A further problem is that some of the patients
were anticoagulated and we have shown that plasma concentrations of
PF^ measured by radioimmunoassay are markedly elevated following
40
heparin injection.
Therefore, with the doubt about what one is actually measuring
with the heparin neutralising activity or the radioimmunoassay for
PF^ and the considerable overlap between patients with and without
19.
thrombosis, the assessment of PF^ is still unsatisfactory in the
diagnosis of the thrombotic disease.
IDENTIFICATION OF BETA-THROMBOGLOBULIN AND DEVELOPMENT
OF THE RADIOIMMUNOASSAY
67
Grette reported the presence of proteins in the soluble
material released during thrombin induced aggregation of washed
37
human platelets and Davey and Luscher showed that this material
contained platelet specific alpha and beta globulins. In 1975 an
127
attempt was made to characterise these proteins. Moore et al.
used platelet suspensions less than 24 hours old obtained from the
SE Scotland Regional Blood Transfusion Service. These platelet
suspensions were washed to remove plasma proteins, suspended and,
after aggregation by bovine thrombin, the supernatant was removed
for analysis. Preliminary chromatography on a Biogel A15M column
separated the low and high molecular weight proteins. Further
separation of the low molecular weight proteins on a Sephadex G200
column produced three distinct peaks. Peak 1 corresponded to IgG
and peak 2 to albumin but peak 3 did not correspond to any known
plasma or serum component. Electrophoresis on cellulose acetate
confirmed that peak 3 consisted of a globulin with mobility between
that of the beta and gamma globulins. Using sucrose density
gradient ultracentrifugation, a sedimentation coefficient of 3.0
was calculated for the peak 3 proteins giving a molecular weight
of 35,800. Immunodiffusion experiments using rabbit antiserum
detected one major and at least three minor platelet antigens not
20.
detected in fresh human plasma. The major antigen which became
known as beta-thromboglobulin (BTG) was also detected in serum
prepared from fresh whole blood, in the supernatant from 48 hours
old platelet rich plasma and in plasma from citrated whole blood
stored for 28 days at 4°C. However, BTG could not be identified
in the supernatant of thrombin aggregated, washed, 48 hours old
platelets suggesting that it is released from the platelets during
aging in vitro. With the immunodiffusion experiments two
precipitation lines were seen in some samples indicating the
possibility of two antigenically distinct forms of BTG.
1.06
Using the isolated BTG, Ludlam et al. developed a radio¬
immunoassay which could detect plasma BTG in the range 2.5 - 150
ng/ml. They studied the release of BTG during platelet aggrega¬
tion and showed that there was a small release associated with
warming the sample from 0°C to 37°C, followed by a massive release
as the platelets aggregated in response to collagen. Platelet
poor plasma from normal individuals had concentrations of
19 ± 7.5 ng/ml with much higher concentrations in serum (17,400 ±
6,300 ng/ml) and the supernatant from platelet transfusion
concentrates (247,000 ± 120,000 ng/ml). Studies of patients with a
recent history of thromboembolism (venous and arterial) diagnosed
clinically, showed elevated concentrations relative to the normal
patients studied. Of 17 patients with prosthetic heart valves, 9
had levels greater than the normal range. They did, however, add
the cautionary comment that BTG may not be a constituent of normal
plasma but may be merely a manifestation of platelet release
21.
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occurring during sampling. Later that year Ludlam et al.,
using a rapid refined version of the standard immunoassay,
investigated a group of patients with proven venous thromboembolism.
They showed that 6 patients with evidence of DVT on phlebography
125
or I fibrinogen uptake tests all had elevated pTG concentrations
but a further 8 patients without evidence of DVT had similar
concentrations to a group of 35 normal individuals. They suggested
that the 0TG assay may be of value in the diagnosis of DVT.
18
The following year Bolton et al. described further refine¬
ments of the $TG assay including a sensitive and a 'rapid' version
of the standard assay, which had been described initially by
107
Ludlam et al. Further investigations into sampling and
processing of blood specimens for 3TG were reported by Ludlam and
108
Cash. They showed that the use of a mixture of EDTA,
theophylline and prostaglandin E^,with the blood cooled to 0-4°C,
resulted in the lowest 0TG concentrations. If the blood was kept
at this temperature, centrifugation could be delayed for up to 48
hours. Centrifugation of the blood at 1,900 g for 60 minutes
seemed to be essential as it produced results significantly lower
than centrifugation for 30 minutes but centrifugation beyond 60
minutes did not result in any further reduction in f3TG concentra¬
tion. If the blood was retained in the syringe, a significant
release did not occur until 7 minutes had elapsed and, therefore,
during a normal venepuncture, this was unlikely to contribute to
the 0TG concentration. They also showed that injecting blood at




In 1978 Dawes et al. showed that pTG was present in synovial
and amniotic fluid in slightly higher concentrations than in plasma.
As platelets are not present in either of these fluids, it is
suggested that plasma BTG concentrations are not, in fact, due
purely to release during sampling but are a normal constituent of
body fluids.
Further studies on the chemical structure of BTG by Begg et
al.^ have shown that BTG consists of four identical subunits of
amino acids with molecular weights of 8,851. This correlates well
with the molecular weight of 35,800 for the whole molecule
127 1
determined by Moore et al. by ultracentrifugation. Begg et al.
also found that the structure of PF^ was remarkably similar to BTG
in that 42 of the 81 residues of BTG are identical to PF„. This4
140
may support the contention of Niewiarowski that 'low activity'
PF^ is converted to BTG by proteolysis.
These researches suggest that BTG fulfils the criteria of a
'platelet specific' release factor. It is normally present in
the body fluids in small amounts and is released during the process
of platelet aggregation. Provided that blood samples are taken
with care and rapidly cooled and stabilised in the anticoagulant
mixture, the measured concentration of BTG will accurately
represent the in vivo plasma concentration.
As platelet aggregation is a very early event in the develop¬
ment of a thrombus, the BTG assay, unlike many of the other tests
for thromboembolism, has the very exciting potential of diagnosing
intravascular thrombosis at its inception.
23.
AIMS OF THE STUDY
In view of the interesting preliminary clinical data produced
107
by Ludlam it was evident that there was a need to study further
the use of the BTG assay in clinical situations. First, however,
it was necessary to carry out some further investigations into the
sampling techniques, the clearance of 8TG from the circulation and
to establish normal ranges for plasma and urine BTG.
The clinical study is divided into three parts. The first
part is concerned with the use of the plasma and urine BTG
concentrations to diagnose venous thromboembolism and to assess
their relative diagnostic accuracy. In the second part the value
of the BTG assay in the diagnosis of peri-operative thrombotic
complications is assessed. Finally, the BTG concentrations in
patients with atherosclerosis were studied.
24.
CHAPTER I
STUDIES ON THE SAMPLING OF BLOOD FOR PLASMA BETA-THROMBOGLOBULIN
AND OF ITS PLASMA AND URINARY KINETICS
1. SAMPLING METHODS
Platelet release occurring during sampling is a potential
limitation to the clinical value of the assay. The aim of this
phase of the project was to examine potential sources of error
associated with the withdrawal and storage of blood.
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Ludlam studied the effects of various substances in the
prevention of £TG release during sampling and concluded that a
mixture of EDTA, theophylline and prostaglandin E^ gave the most
reliable results. However, as prostaglandin E^ is expensive and
must be stored in a deep freeze, it was wished to eliminate it, if
possible, from the collecting medium.
The physical process of withdrawing blood from the subject may
stimulate platelet release. A possible solution was to have the
anticoagulant mixture in the syringe so that the blood is
immediately stabilised. Other potential influences are indwelling
catheters which are commonly used for blood sampling, and venous
stasis which is known to activate the fibrinolytic system.
Experiment i: The platelet stabilising anticoagulant mixture
Methods:
Samples of blood were obtained from eight normal subjects and
three patients with proven venous thromboembolic disease. Through
25.
a 19 gauge needle 30 ml of blood were drawn into a polypropylene
syringe and aliquots were inserted into siliconised glass tubes
containing three different anticoagulant and platelet stabilising
mixtures. The first set of tubes contained 0.1 ml of disodium
ethylene diamine tetra-acetate (E) in a concentration of 100 mg/ml;
the second, E and 0.1 ml theophylline in a concentration of 5.4
mg/ml (ET), and the third contained ET plus 0.1 ml of prostaglandin
E^ in a concentration of 1 yg/ml (ETP). The tubes were cooled in
melting ice before venesection and were filled immediately after
venepuncture in a different order for each subject. Four tubes of
each of the three mixtures were filled from every venepuncture.
The tubes were transported in melting ice and were maintained at
4°C until plasma separation. One tube of each anticoagulant
mixture from each subject was centrifuged at 4°C within 1 hour of
sampling and the top third of the plasma was withdrawn and deep
frozen prior to assay in batches. The other three tubes from each
group were similarly processed at 24 hour intervals up to 72 hours.
Results:
There was little difference in the normal individuals between
blood samples stabilised in ET and ETP up to 24 hours after
sampling (Fig. 2). Those stabilised in E alone were, however,
much higher by 24 hours. In the three DVT patients ETP performed
much better than E or ET which both failed to stabilise the plate¬
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Fig. 2: The stabilising effect of three different anticoagulant
mixtures in 8 healthy subjects and in 3 patients with DVT. Median
plasma gTG concentration plotted against time to plasma separation.
27.
Experiment ii: The anticoagulant mixture in the syringe
Methods:
Two samples of blood were obtained simultaneously from each of
20 healthy volunteers. A sample from one arm was withdrawn in the
normal fashion and placed in a cooled tube containing the anti¬
coagulant mixture. A second sample was drawn from the other arm
into a syringe containing the cooled anticoagulant mixture and then
placed in a cooled tube. Both sets of samples were then processed
in the normal way.
Results:
The effect of loading the syringe with the stabilising mixture
is shown in Fig. 3. The difference in the concentrations was not
significant (p > 0.l.Wilcoxon). The median of the group with ETP in
the tube was 24 ng/ml and of the group with ETP in the syringe was
21 ng/ml. One spuriously elevated value of 260 ng/ml was obtained
from the group with ETP in the tube. The ETP in the syringe
appeared to eliminate these spuriously high results.
Experiment iii: The effect of venous stasis
Methods:
Blood samples were drawn in the normal way without venous
stasis from 11 healthy volunteers. A venous tourniquet, inflated
to 60 mm Hg was then placed on the other arm and a second blood


















The effects of venous stasis are shown in Fig. 4. There was
no significant difference in (3TG concentration after 3 mins of
venous stasis (p > 0.1, Wilcoxon).
Experiment iv: Indwelling venous catheters
Methods:
Two normal volunteers and 3 patients with arterial disease were
studied. The latter group underwent central venous catheterisation
to facilitate monitoring during arterial reconstruction. A blood
sample was drawn using the standard technique from one arm and a
central venous catheter (Abbott Drum-cath) was then inserted, using
local anaesthesia (2% Lignocaine) into an ante cubital vein in the
other arm. The central venous catheter was continuously perfused
with 0.9% saline through a 3 way tap to prevent reflux of blood.
Blood samples were withdrawn every half hour for 3 hours, from the
catheter and by individual venepuncture from the other arm. Each
successive venepuncture was performed more distally on the arm to
avoid the effects of local platelet activity at the venepuncture
sites. The blood sample from the catheter was withdrawn through the
3 way tap after first withdrawing and discarding 5 ml of blood to
ensure that the catheter system was full of fresh venous blood.
The catheter was flushed with saline after sampling to prevent clots















Fig. 4: Venous stasis and plasma $TG concentration.
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Results:
Table 1 compares venepuncture with catheter sampling. In the
samples taken by individual venepuncture only one sample (3%)
exceeded 80 ng/ml whereas in the samples drawn through the catheter,
9 (26%) had concentrations exceeding 80 ng/ml. This difference was
significant (X2 = 5.72, p = 0.017). Using a paired t test the
concentrations obtained by venepuncture were significantly lower
than those obtained through the catheter (t = 3.61, p = 0.001). The
values in the individual venepuncture series were not different from
our normal range and there was no tendency for the $TG concentrations
to rise as the experiment progressed.
Discussion
Our findings in experiment i confirm that it is of value to use
EDTA, theophylline and prostaglandin as the platelet stabilising
anticoagulant cocktail. Although prostaglandin E^ contributed
little when sampling from normal individuals it did prolong the
period before release occurred with storage in patients with DVT.
This may be due to a need for an enhanced antiaggregating effect in
patients with DVT who have been shown to have an increased platelet
77 178
adhesiveness. ' Considerable release occurred, regardless of
anticoagulant used in all samples after 24 hours and, therefore,
samples should be processed within 24 hours of sampling.
The addition of the anticoagulant mixture to the syringe did
not significantly affect the results obtained. The mean concentra¬
tion when the mixture was in the tube was distorted by one rogue
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concentration (260 ng/ml). This is likely to be due to thrombin
generation inducing release in the syringe and in that particular
individual was prevented in the second specimen which had the
anticoagulant mixture in the syringe. However, although the
presence of the mixture in the syringe appeared to eliminate these
spuriously high results, the difference in concentration was not
sufficient to justify adopting this more expensive and inconvenient
method of sampling.
Venous stasis, similarly, did not affect the results obtained.
Sampling through long catheters proved to be unreliable although
the presence of the catheter does not appear to raise systemic $TG
concentrations as demonstrated by separate venepunctures. This
suggests that gTG release occurs actually in the catheter and is
probably due to the formation of small thrombi in the junctions
between the catheter and the 3 way tap despite flushing with
saline. Blood samples for $TG assay should, therefore, be taken
by individual 'clean' venepuncture and not through an indwelling
catheter. As the presence of the catheter did not affect the
systemic concentrations of $TG, it is unlikely that the small
catheters used to give intravenous fluids will significantly affect
the $TG concentrations in clinical studies.
34.
2. NORMAL RANGES
Prior to investigating 0TG concentrations in pathological
situations it was essential to ascertain the normal ranges of
plasma and urine in samples assayed in our local radio-immunoassay
laboratory. The assays were performed by the technique developed
106
in Edinburgh by Ludlam et al. and not by the commercially
available assay kit which was developed out of the Edinburgh work.
Several normal ranges quoted in the literature are summarised in
Table 2.
The urinary assay became available only in the latter part of
the study and, therefore, plasma and urine samples were obtained on
a smaller group of healthy subjects.
Experiment i: Assessment of normal range of plasma BTG
Methods:
From 26 individuals who had no overt evidence of any
pathological process, 94 plasma samples were obtained by separate
'clean' venepunctures. The ages of these individuals ranged
from 20 to 59 years (mean 29.4, SD 11.3 years).
Results:
Figure 5 shows the normal plasma |3TG concentrations. The
range was 8.9 to 98.3 ng/ml with a mean of 29.3 ng/ml and standard
deviation of 18.3 ng/ml. The median concentration was 23 ng/ml.
The distribution was considerably skewed by the preponderance of
results in the lower concentrations.




























































































































Fig. 5: Normal range of plasma $TG concentrations in 26
healthy subjects.
37.
Experiment ii: The normal range of urinary (3TG concentration and
its relationship to plasma BTG concentration
Methods:
Twelve healthy volunteers (4 female and 8 male) aged 22-57 years
(mean 30.8, SD 10.1 years) were studied for periods up to 60 hours.
The total volume of each urine specimen passed and the period over
which it was collected were recorded and an aliquot of 10 ml was
taken for BTG assay. The specimens were then deep frozen and
stored for assay in batches. This enabled calculations of the BTG
concentration, the hourly urine output and the hourly BTG excretion
to be made. At least one sample from each subject was tested
chemically for blood and protein using a dipstick (Labstix, Ames),
and all were negative. During the study periods 2-6 plasma
samples were also obtained from each subject. A total of 81
urine specimens and 38 plasma specimens were obtained.
Results:
The distribution of urinary concentrations is shown in Fig. 6
and summarised in Table 3. The urine BTG concentration varied
from <0.05 ng/ml to 0.46 ng/ml. In 54 of the 81 specimens the
concentration was below the lowest detection limit of the assay and,
therefore, it is impossible to calculate accurate values for the
mean and standard deviation. There is no difference in concentra¬
tion between males and females in both groups; the median
concentration was below the assay limit.
The low concentrations also prevented an accurate measurement
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Fig. 6: Normal range of urinary $TG concentrations in 12 healthy
subjects. Vertical axis represents the number of specimens.
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TABLE 3: NORMAL RANGES OF URINARY 0TG CONCENTRATIONS AND
EXCRETION RATES























TABLE 4: RELATIONSHIP BETWEEN URINARY 0TG CONCENTRATION AND URINE
FLOW RATE. FIGURES REPRESENT NUMBERS OF SPECIMENS.
Urine flow rate (ml/hr)
BTG concentration
(ng/ml) < 50 50-100 > 100 Total
< 0.05 14 22 18 54
0.05-0.1 4509
0.1-0.2 7 .8 0 15
> 0.2 3 0 0 3
Total 28 35 18 81
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concentration could be measured the excretion rate ranged from 1.2
to 13.8 ng/hr.
The hourly urine output varied from 18.5 to 1040 ml/hr. The
relationship between the urine flow rate and the 3TG concentration
is shown in Table 4. In none of the specimens in which a
measurable concentration was obtained did the urine flow rate
exceed 100 ml/hr. However, concentrations below the assay limit
were obtained in every specimen from 5 subjects even with flow rates
below 50 ml/hr.
In the group of 27 specimens in which accurate $TG concentra¬
tions and excretion rates could be measured it is possible to
calculate a correlation coefficient (r) for the different parameters
measured. The r values are as follows:-
Urine flow rate (ml/hr) and urine 3TG concentration (ng/ml) 0.40
Urine flow rate (ml/hr) and 3TG excretion rate (ng/hr) 0.28
3TG concentration (ng/ml) and $TG excretion rate (ng/hr) 0.81
The gTG concentration in 38 plasma samples withdrawn during
the period of sampling varied from 10.0 to 98.3 ng/ml (median
25 ng/ml). In one subject, who had two elevated plasma concentra¬
tions, the urine concentrations at the time of plasma sampling
were below the assay limit, despite low urine flow rates (< 50 ml/hr)
at the time. The subject, who had a considerably elevated urine
concentration in one sample, had a normal plasma concentration
(37.5 ng/ml) during that collection. There was no correlation
between plasma and urine 3TG concentrations (r = 0.042) or between
the plasma concentration and the 3TG excretion rate (r = 0.043).
41.
The urine and plasma concentrations, urine flow rates and BTG
excretion rates in one subject over a 60 hour period are shown in
Fig. 7.
Discussion
The mean plasma BTG concentration in these subjects correlates
well with those quoted in Table 2. However, in view of the skewed
nature of the distribution of plasma BTG concentrations, the normal
method of assessing the normal range (mean ± 2 x SD) gives a low
upper limit. Therefore, 80 ng/ml has been selected as the upper
limit of the normal range as this includes over 95% of the samples.
This is in keeping with the 95% confidence limit of 82.2 ng/ml
42
quoted by Denham et al. Three samples in two subjects fell
outside this limit. One subject was taking an oestrogen-
containing contraceptive pill but had no overt evidence of
thromboembolic disease. Nevertheless, elevated concentrations in
patients on oestrogen-containing contraceptive pills but without
50
apparent thrombotic disease have been reported. The other two
samples were from a male subject, apparently healthy, who showed
elevated concentrations on several subsequent occasions but with
no apparent cause. 'Syringe' testing (reported later) was carried
out on this subject and he showed no tendency to more rapid release
than the other subjects studied. BTG could be detected in all the
plasma samples.
There is some doubt as to whether the BTG detected in the
urine is the complete molecule or merely peptide fragments
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containing the antigen site. However, if one can correlate what
is measured in the urine with the plasma BTG, it is immaterial
whether this is the entire molecule or merely a fragment.
Urine sampling is potentially more attractive than plasma
sampling because it is not prone to artefacts of sampling and
processing. However, it is likely to be affected by haematuria
and possibly also proteinuria. At least one sample from each
subject was tested for blood and protein and all were negative.
As with plasma samples, the urine samples showed a skewed
distribution with two-thirds of the samples having concentrations
below the assay limit. An upper concentration limit was,
therefore, set to include at least 95% of the specimens. This
gave an upper limit of the normal range of 0.21 ng/ml.
This correlates well with the upper limit of the normal range
4
(0.25 ng/ml) quoted by Anderton et al. The measured excretion
rate varied from 1.2 to 13.8 ng/hr in the 27 specimens in which it
could be accurately calculated. However, an upper limit of 15
ng/hr will include all but two of the specimens, even if the
excretion rate in the unmeasurable specimens is calculated on the
lowest detectable concentration on the assay. This we propose as
the upper limit of the normal excretion rate.
All the urine specimens obtained during periods of urine flow
> 100 ml/hr were associated with BTG concentrations below the assay
limit but with flow rates of < 50 ml/hr only half of the specimens
had unmeasurable concentrations. All subjects, however, could
dilute the BTG concentrations below the assay limit with minimal
44.
diuresis.
In the 27 samples with measurable concentrations the BTG
concentration correlated more closely with the BTG excretion rate
(r = 0.81) than with the urine flow rate (r = 0.40). This suggests
that, provided the urine flow rate is not in excess of 100 ml/hr,
the urine concentration of BTG is a reasonable indicator of the BTG
excretion rate. At higher urine flows in normal subjects the
dilution effect negates the value of the BTG concentration. We
were unable to demonstrate any correlation between the plasma
concentration and either the urine concentration or the excretion
rate.
In one subject with high plasma concentrations the urine
concentration never reached measurable levels despite urine flow rates
as low as 33 ml/hr. Another subject, however, showed a urine
concentration of 0.46 ng/ml at a similar flow rate (31 ml/hr) and a
plasma concentration less than half that of the previous subject.
However, in normal subjects one is dealing with relatively narrow
ranges of BTG concentrations and excretion rates. In this
situation demonstration of correlation becomes more difficult.
Another important factor is that the plasma BTG measures the BTG
concentration at a moment in time whereas the urine BTG reflects its
excretion over the period that the urine was accumulating in the
bladder, which may be several hours. If one can demonstrate that
increased release of BTG in the body relates to increased excretion
in the urine, the urinary assay is potentially more valuable as it
will be affected less by any transient changes in plasma BTG. It
could reflect more accurately the platelet activity over a period of
time than a single plasma assay.
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3. RELATIONSHIP OF PLASMA BETA-THROMBOGLOBULIN CONCENTRATION TO
PLATELET COUNT AND SERUM BETA-THROMBOGLOBULIN CONCENTRATION
Since 0TG is released from platelets, the platelet count may
influence the plasma @TG concentration. If this is so, the
interpretation of any plasma BTG concentrations would need to take
account of variations in the platelet count. Similarly, the
actual BTG content of the platelets may also affect the plasma BTG
concentration. If blood is allowed to clot, maximal release from
the platelet occurs and, therefore, the assessment of the BTG
concentration in serum will reflect the BTG content of the
platelets.
Experiment i: The relationship between plasma BTG and platelet count
Methods:
a) Platelet counts are available on 72 out of the 94 specimens
from healthy individuals.
b) In a patient with alcoholic thrombocytopenia, daily BTG
concentrations and platelet counts were obtained during her
hospital stay.
Results:
a) The BTG concentrations plotted against the platelet counts are
shown in Fig. 8. This gives a correlation coefficient of
r = 0.46. There is, therefore, a slight positive correlation
between the platelet count and the plasma BTG concentration in




Plasma f3TG (ng/ml) = 3.6 + 0.14 x Platelet count x 109/litre
The regression line is shown in Fig.8.
b) Fig. 9 shows the parallel rise in platelet count and the BTG
concentration during the recovery from alcohol induced
thrombocytopenia. This correlation continued for the first
7 days but the BTG concentration then fell despite maintenance
of the platelet count.
Experiment ii: The relationship between gTG concentration in
plasma and serum
Methods:
Blood samples were obtained from 13 healthy volunteers and
aliquots were processed for plasma BTG assay. Further specimens
from each subject were allowed to clot and, after suitable dilution
of the serum, BTG assays were performed.
Results:
The serum BTG concentrations were approximately 1,000 x the
plasma concentrations (Table 5). There was no consistent relation¬
ship between the plasma and the serum BTG concentrations (r = 0.15),
nor between the platelet count and the serum BTG concentration
(r = 0.10), nor between the plasma BTG concentration and the serum
concentration corrected for the platelet count (r = 0.16).
48.
Fig. 9: Plasma $TG concentration and platelet count during recovery
in a patient with alcohol induced thrombocytopenia.
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TABLE 5: PLASMA 0TG CONCENTRATIONS, SERUM $TG CONCENTRATIONS
AND PLATELET COUNTS
Range Mean SD
Plasma 0TG ng/ml 8.9-32.0 15.5 7.8
Serum 0TG Ug/®»1 10.2-22.4 17.4 3.6
Platelet count
x 109/litre 100-182 134.2 25.1
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Discussion
There appeared to be a poor correlation between the platelet
count and the plasma $TG concentration (r = 0.46). Fig. 8 suggests
that the correlation is better at low platelet counts than at high
platelet counts and this is borne out by the findings in the
184
patient with alcohol induced thrombocytopenia (Fig. 9). Turpie
also reported a case of marrow aplasia with no detectable circulating
platelets in whom 3TG could not be detected in the plasma. However,
in other patients with thrombocytopenia, due to destruction of
platelets the plasma $TG may be normal in the autoimmune type or
73
even elevated in the thrombotic type.
The correlation between the serum and the plasma 3TG concentra¬
tions was very poor even after correction for the platelet count and
so it seems that the plasma 3TG in healthy subjects varies in
response to factors other than the platelet count and the platelet
content of 3TG.
Another interesting feature in the patient with alcoholic
thrombocytopenia was that the 3TG concentration rose in parallel
with the platelet count even into the abnormal range (140 ng/ml).
One could have expected that the plasma 3TG concentration would
cease to rise when the normal range was reached. A possible
explanation of this is that the majority of the platelets will be
98
young, large platelets which have been shown by Karpatkin to be
very much more active and to release more PF^ than small, old
platelets. As the platelets age they become less active and the
fall in plasma 3TG on day 8 may be a manifestation of an increasing
51.
population of older platelets with a reduction in the rate of
production of new platelets. With a high proportion of young
platelets, the measured 3TG concentration may be a less accurate
assessment of the plasma $TG concentration as these active
platelets will be more likely to release during sampling.
This study indicated that, provided the platelet count
approximated to the normal range, there was no need to correct the
plasma BTG for the varying platelet count.
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4. SYRINGE TESTS
Clumsy technique and delay during sampling can result in
spuriously high plasma f3TG concentrations due to release occurring
during the process of sampling.108 It was necessary, therefore,
to determine how long blood could be kept in a syringe before
significant release occurred and whether there was any difference
141
between individuals. Nossel has shown that it takes approxim¬
ately 7 mins before blood in a syringe will show a significant rise
in fibrinopeptide A concentrations. This suggests that there is a
delay before sufficient thrombin is generated to convert fibrinogen
to fibrin. This test, therefore, has potential value in assaying
the rate of thrombin generation and, if one uses the 0TG assay, it
may also assess the sensitivity of the platelets to thrombin.
Experiment i; Identification of normal release patterns
Methods:
Ten healthy volunteers aged 19-41 years (mean 28.5 years, SD
7.1 years) were studied. Through an 18 gauge needle 30 ml of blood
were drawn into a polypropylene syringe and 2.7 ml aliquots were
inserted into cooled tubes containing the anticoagulant cocktail,
at 1 min intervals. In all cases the venesection took < 1 min.
The samples were then processed in the normal fashion.
Results:
The results are shown graphically in Fig. 10. There appear to
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Fig. 10: syringe tests on 10 healthy subjects.
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and a late group (D,E,F,G & H). In order to compare syringe tests
on different individuals a point was selected, designated the
'Release Time', at which the amount of $TG released was likely to
be significant. This was the time at which the plasma $TG
concentration had risen by at least 50 ng/ml above the baseline.
The baseline was defined as the lowest plasma $TG concentration
detected and was not always in the first specimen. The slow release
group (type I) had release times of > 7 mins (mean 8.2 mins) and the
rapid release group (type II) had release times of 5-6 mins (mean
5.6 mins). The release times of the two groups are summarised in
Fig. 11.
Experiment ii: Syringe test reproducibility
Methods:
In 3 volunteers the syringe test was repeated on two occasions.
Results:
The reproducibility was poor (Table 6). The release time
tended to be shorter with higher basal concentrations.
Discussion
The pattern of release in normal subjects shows an almost
horizontal line initially indicating that the release reaction has
taken some time to become established. After a period varying
from 4-9 mins it suddenly progresses rapidly. These results
157
correlate well with those of Prowse et al. who selected the
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as their release time. They also showed a bimodal distribution
with rapid and slow types of release. Their patients showed a
very close correlation between $TG and FPA release lending support
to the theory that platelet release in this situation is due to
143
thrombin generation. Nossel has shown a similar parallel
release of £3TG and FPA, which he attributes to thrombin generation,
after intrauterine infusions of hypertonic saline. Prowse et
157
al. also showed that FPA generation in the syringe test could
be prevented by having a high concentration of heparin in the
syringe. This, however, did not prevent 3TG release but merely
delayed it. They suggest that the high affinity of thrombin for
65 187
platelets relative to fibrinogen and the resistance of
113
platelet bound thrombin to plasma inhibitors may permit thrombin
induced release even in the presence of heparin. The reason for the
two release patterns is obscure. It could be due to a differential
binding of thrombin to the two platelet populations. The tighter
binding might render the platelets more ready to release.
Alternatively, there might be a different ease of thrombin production
by the two populations. However, there is no evidence in studies of
thrombosis to suggest two discrete rates of thrombin generation.
Finally, there may be two different populations of platelets with
different sensitivities to thrombin. This could be of significance
in the clinical studies where spurious release was occasionally
noticed. Platelets of the rapid release type will probably be more
sensitive to errors of processing and sampling.
The reproducibility of the tests in the three subjects in
experiment ii was rather poor, in contrast to the rather better
57a.
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reproducibility obtained by Prowse et al. The tests which had
high baseline concentrations (samples 2 and 3 in subject 3) also
tended to have more rapid release, 5 and 1 mins. This may be due
to the presence of more active platelets at that time in the
subject. In subject 1, however, there was a variation in the
release time despite a constant baseline concentration.
The results of these syringe tests suggest that during normal
sampling there is unlikely to be significant release occurring in
the syringe.
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5. EFFECT OF ASPIRIN AND HEPARIN ON PLASMA AND URINE
BETA-THROMBOGLOBULIN CONCENTRATIONS
Aspirin is known to inhibit the platelet release reaction in
vitro by the acetylation of cyclo-oxygenase which prevents the
166
formation of the cyclic endoperoxides from arachidonic acid.
A single dose of Aspirin can produce a platelet defect lasting 7 to
10 days111 and Quick158 has shown that it will prolong the bleeding
time. The dose of Aspirin also appears to be critical as the
25
maximum effect may be obtained with a dose as low as 325 mg.
Heparin is also known to affect platelet function although there
is much contradictory and inconclusive evidence as to its actual
135
effect. Both these drugs were used in our patients: Aspirin
in those with carotid artery disease and Heparin in patients with
venous thromboembolism and in those undergoing vascular surgery.
It was, therefore, of interest to assess the effect of these drugs
on BTG concentrations.
Experiment i: The effect of Aspirin on plasma gTG concentrations
Methods: ~
Plasma BTG concentrations were measured in 9 healthy
individuals aged 19-41 years (mean 29.1 years, SD 7.6 years)
before, and 8 hours after, the ingestion of 300 mg Aspirin.
Results:
These are shown in Fig. 12. The concentrations were lower
before Aspirin (median 22.0 ng/ml) than after (median 36.0 ng/ml)
but this difference did not reach statistical significance using a









Fig, 12: Plasma 8TG concentration before, and 8 hours after,
300 mg Aspirin in 8 healthy subjects.
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Experiment ii: The effect of Aspirin on the syringe test
Methods:
Syringe tests were performed on 8 healthy individuals aged
20-41 years (mean 30.2 years, SD 6.9 years) before, and 8 hours
after, the ingestion of 300 mg Aspirin.
Results:
Figure 13 demonstrates the results. The release times
following Aspirin were shorter (median 5.5 mins) than before
Aspirin (median 6.0 mins) and this did reach significance using a
paired Wilcoxon test (p < 0.05). The basal concentrations rose
slightly after Aspirin (median rising from 21.5 ng/ml to 29.0
ng/ml) but this was not statistically significant.
Experiment iii: The effect of intravenous Heparin on plasma
and urine gTG concentrations
Methods:
Two healthy subjects aged 30 and 41 years, weighing 72 and
65 Kg respectively, were each given a single dose of 5,000 units
of sodium Heparin intravenously. Plasma and urine samples were
obtained at intervals before and up to 24 hours after injection.
The plasma samples were obtained from the contralateral arm to that
used for the injection of the Heparin and each sample was obtained
from a point more distally on the limb. The samples were assayed















Fig. 13: Syringe test release times before, and 8 hours
300 mg Aspirin in 8 healthy subjects.
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Results:
The effects of intravenous Heparin on subject 1 are shown in
Fig. 14. Immediately after injection there was a massive release
of PF^ producing plasma concentrations > 240 ng/ml. This rise in
the plasma concentration was associated with elevated urine
concentrations. The plasma concentrations returned to normal
within 1 hour and the urine concentrations within 2 hours. The
plasma (3TG concentrations, however, showed no significant rise
immediately after injection but a variable response later.
Subject 1 showed elevated concentrations (110 and 180 ng/ml) at
2 and 8 hours, with an intervening normal concentration (34 ng/ml)
at 4 hours. Between 3 and 6 hours the urine concentration also
reached the abnormal range (0.33 ng/ml) confirming that this was a
genuine in vivo release. The plasma PF^ concentrations were also
elevated at 8 hours but not at 2 hours.
Subject 2 showed identical PF^ release and urinary clearance.
3TG concentrations also showed late rises but to a lesser extent
than with subject 1 (87 ng/ml at 2 hours and 83 ng/ml at 4 hours).
At no stage did subject 2 show abnormal urine concentrations
(maximum - 0.19 ng/ml at 1 hour).
Experiment iv: The effect of subcutaneous Heparin on plasma
and urine gTG concentrations
Methods:
Five healthy subjects aged 20-41 years (mean 27.5 years, SD












Fig. 14: Plasma and urine $TG and PF4 concentrations before and
after 5,000 units of heparin intravenously in a healthy subject.
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sodium Heparin by deep subcutaneous injection into the abdominal
wall. Plasma samples were obtained before, and for 24 hours
after, injection. Urine samples were also obtained from each
voiding during the same period.
Results:
Fig. 15 illustrates the plasma (3TG concentrations in response
to a subcutaneous injection of Heparin. Again there was no
significant early release but, after 4 hours, several high
concentrations were obtained. Every subject had at least one
elevated plasma concentration after Heparin. The urine concentra¬
tions were all within the normal range except in subject 3 who
showed elevated concentrations (> 1.0 ng/ml) throughout the 24
hour period after injection and subject 6 who showed one elevated
concentration (0.33 ng/ml) immediately after injection. Neither
of these individuals had evidence of haematuria on testing
(Labstix).
Discussion
The dose of Aspirin required to produce a maximal effect on
25
platelets appears to be quite critical. Burch et al. have
shown that 325 mg of Aspirin will produce an 89% inactivation of
cyclo-oxygenase. This effect is at a maximum within 6 hours and
persists for 2 days. Higher doses of Aspirin produce less
inactivation. The dose used in this study (300 mg) and the time
sampled (8-10 hours after ingestion) would appear to be ideal for
detecting the maximal effect of Aspirin.
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10,000u
Fig. 15: Plasma (3TG concentrations before and after 10,000 units
of heparin given subcutaneously in 5 healthy subjects.
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There are much published data on the disturbance of platelet
function produced by Aspirin and some of it appears conflicting.
123
Mills et at. however, in a study of platelet function in patients
with gastrointestinal bleeding, concluded that the platelets of some
158
patients were much more sensitive to Aspirin than others. Quick
demonstrated that Aspirin prolonged the bleeding time and, in 1968,
57
Evans et at. showed that Aspirin would reduce platelet aggregation
in response to thrombin provided the thrombin concentration was low.
Release and aggregation occurred normally at higher thrombin
210
concentrations, a fact confirmed by Zucker and Peterson and
81 57
Holmsen et at. Evans et at. showed that Aspirin inhibited
the release of dense granule content in response to low
81
concentrations of thrombin and Holmsen et at. confirmed this but
could demonstrate no effect on alpha granule release which they
96
assessed by the release of acid hydrolases. Kaplan et at.
showed that, although Aspirin produced only a minimal reduction of
acid hydrolase release, it did inhibit the release of PF^, $TG,
PDGF and fibrinogen.
These data lead us to expect lower gTG concentrations
following Aspirin ingestion as there should be less platelet
reactivity. However, as well as inhibiting the production of
proaggregatory prostaglandin derivatives, Aspirin will also
inhibit the production of the antiaggregatory vessel wall
derivative PGI (Prostacyclin). Although the duration of effect
on PGI production is probably less than on Thromboxane AJ
188
production, it may be that the effect of Aspirin on the vessel
wall is greater. This could explain the slightly higher plasma
67.
BTG concentrations in the samples after Aspirin ingestion. If
this is so, it could have considerable bearing on the dosage of
Aspirin when used as a platelet inhibitor. A more frequent dose
of Aspirin would have a relatively greater effect on PGI
A
production. If one considers the maximum effective dose (300 mg)
and its duration of effect (the lifetime of the platelet) a dose of
300 mg only once or twice weekly may be the optimum for inhibition
of aggregation.
The effect of Aspirin on the syringe test was also contrary to
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what was expected but followed the trend shown by Prowse et al.
The mean release time in their patients after Aspirin was reduced
from 6.6 mins to 5.9 mins. The release reaction in the syringe
test is mediated by thrombin generation and it is likely that the
concentration of thrombin achieved exceeds that at which the
Aspirin will still have an effect. However, there is at present
no mechanism of action of Aspirin known which should make the
release time in this situation shorter than normal.
Heparin is a naturally occurring anticoagulant which is used
extensively in clinical practice. It is a potent inhibitor of
coagulation, an activity thought to be due to its ability to bind
111
to thrombin. Its effect on platelets has also been extensively
studied. As it has a potent antithrombin action it will obviously
have an effect on thrombin induced platelet aggregation but it also
105
affects cell membrane function and may, therefore, have a more
direct effect on platelet function.
Many papers describe an inhibitory effect on aggregation and
16
on release. Besterman and Gillet showed a reduction in the rate
68.
and extent of collagen and adrenaline induced aggregation following
52
1,000-5,000 units intravenously and Eika has described a platelet
refractory state following Heparin. It has also been shown to
inhibit platelet adherence to damaged and undamaged rabbit aorta
54
m vitro and in a study of pulmonary embolism in dogs. Thomas
181
et al. demonstrated that Heparin could prevent serotonin release
134
from platelets m vivo. Mustard and Murphy showed that
subcutaneous Heparin in a dose of 5,000 units b.d. had no effect
on platelet survival but, if the dose was increased to 8,000 units
t.i.d., survival was prolonged. At low concentrations in vitro
(25 u/ml), Heparin will inhibit thrombin induced aggregation but
33
not that induced by ADP or adrenalin. In higher doses (104 u/ml),
however, it will also inhibit in vitro aggregation in response to
collagen and adrenaline.
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Rowsell et al., in a study in dogs, confirmed the inhibitory
effect by showing that moderate doses of Heparin prolonged platelet
survival but, as the dose was increased, the survival reached a
peak and then fell off again. The dose at which this peak
occurred varied considerably from dog to dog with a range of 9 to
381 units/Kg. In the subjects in this study the Heparin dose
used was approximately 75 or 150 units/Kg and, therefore, some of
the subjects may have received Heparin doses beyond the peak value.
Rowsell et al. also studied the lymph of dogs receiving very
high doses of Heparin (600 units/Kg 8 hourly) and showed that,
after 12-16 hours, the lymph contained red cells followed about 4
hours later by platelets. At the time when platelets appeared in
the lymph, the blood platelets showed normal aggregation in response
69.
to ADP, delayed aggregation in response to collagen and no
aggregation with thrombin.
The passage of platelets into the lymph may be due to the
failure of the maintenance of vascular integrity by the fibrin
generation system and is likely to be associated with release as
the platelets come into contact with extravascular collagen.
Adherence of the platelets to extravascular collagen may explain
the delay in platelets appearing in the lymph in relation to red
cells. The gTG release I detected at various times after both iv
and sc Heparin may be a manifestation of this platelet leakage from
the circulation.
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However, Zucker has shown that Heparin will produce release
from platelet rich plasma in vitro, presumably by a membrane effect,
but whether this will occur in vivo is unknown. Enhanced primary
waves of ADP and adrenaline induced aggregation have also been
182
described in man after 10,000 units of Heparin iv. These
latter two effects may be contributing to the raised plasma 3TG
167
concentrations in this study. However, as detected by others,
the effect of Heparin varied considerably between individuals.
Subjects 1 and 3 showed considerable release and prolonged
elevation of urine concentrations in contrast to the normal
concentrations detected in most of the others.
The effect of Heparin on PF^ release is in marked contrast to
its effect on $TG release. There is an immediate and rapid rise
in PF^ concentration following Heparin which has returned to normal
in 1 hour. This suggests that PF^ is stored in a different
70.
subpopulation of these granules from $TG or that there is another
source of PF. such as vascular endothelium. PF, has an ability4 4
to neutralise Heparin by binding to it and thus release in response
to Heparin is likely to be a form of defence mechanism. The
Heparin neutralising activity of platelets has been recognised
34
since 1948 when Conley et al. showed that the concentration of
Heparin required to inhibit or delay coagulation is directly
related to the platelet count. In subject 1 8TG release occurred
at 2 hours but this was not associated with PF. release. At 8
4
hours, however, the BTG and PF^ concentrations rose in parallel.
This suggests that it takes up to 8 hours for the PF4 stores to be
replenished. The release of PF^ in response to Heparin may be of
significance in the development of relative resistance to Heparin
by some patients on Heparin therapy.
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6. CLEARANCE OF PLASMA BETA-THROMBOGLOBULIN AND ITS URINARY
EXCRETION PATTERN FOLLOWING AUTOLOGOUS SERUM INFUSION
The studies in part 2 did not demonstrate any relationship
between plasma and urine concentrations of 3TG in normal subjects.
In that particular study the ranges of concentrations of 3TG in
plasma and urine were narrow and in that situation demonstration of
mathematical correlation becomes more difficult. However, it may
be possible to demonstrate a correlation when the concentration
ranges are greater, such as in patients with thromboembolic disease.
If the plasma 3TG concentration is artificially increased by
infusing 3TG, it is possible to assess the rate at which it is
cleared from the plasma and also the rate at which it appears in
the urine. It should also be possible to calculate the proportion
of the infused dose which appears in the urine.
In serum and in the supernatant of platelet concentrate, 3TG
is found in high concentrations. Serum is technically easier to
prepare and this was selected. Platelet infusion was employed in
one subject who had undergone platelet and plasmapheresis for
another purpose.
Methods:
One unit of blood was withdrawn using standard aseptic
technique into a plastic transfusion bag without anticoagulant.
This was allowed to clot for 12 hours and the serum was drawn off
into a second plastic bag. It was then stored for 36 hours at 4°C
to remove the thrombin by binding to the plastic.
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The serum was infused into an ante cubital vein over 10 mins
and plasma samples for BTG assay were obtained before re-infusion,
immediately after re-infusion, every 10 mins for half an hour and
every 30 mins for 3 hours. Urine specimens were obtained every
half hour up to 4 hours after infusion.
Subject 1 underwent two serum and one platelet concentrate
infusions (experiments i, ii and iii) and subject 2 received only
two serum infusions (experiments iv and v).
Results:
All the infusion studies showed similar patterns of BTG
plasma clearance and urinary excretion. The results of the second
infusion study in subject 1 are shown in Fig. 16 and the plasma
clearance is shown plotted semi-logarithmically in Fig. 17.
The data for all the infusion studies are summarised in Tables
7 and 8. The half hourly urinary STG excretion rate in experiment
iv is shown in Fig. 18.
The dose of BTG varied between studies with the largest dose
being derived from the platelet concentrate as this gave the
highest plasma concentration and total urinary BTG output.
All plasma and urine concentrations were within the normal
range before each infusion and were again normal on completion of
the 3 hour post-infusion period.
Figures 16 and 17 show that, immediately following infusion,
BTG is rapidly cleared from the plasma with a half life varying
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commences. In subject I the rates of the plasma BTG clearance
in this second phase correlated quite well between studies with
half lives varying from 75 to 89 mins (mean 83 mins). In
subject II the clearance patterns were less consistent (64 and 101
mins) but the mean value (82.5 mins) correlated well with the mean
value for subject I.
The duration of the elevated plasma BTG concentration
correlated with the maximum plasma concentration and is,
therefore, related to total 0TG dose.
The correlation between the log of the plasma BTG concentra¬
tion and the time after infusion was good in all the studies
(r = 0.91-0.99) and, therefore, the clearance is truly exponential.
The urine excretion of BTG tended to follow the plasma
clearance. This was apparent in both the urine concentrations and
urinary BTG excretion rates in subject I, but in subject II the
urinary concentrations never reached the abnormal range and,
therefore, there was little correlation between the urine
concentration and the plasma clearance. However, if the BTG
excretion rate is shown in ng/£ hour (Fig. 18), the close
correlation with the plasma clearance can be demonstrated.
The total BTG excretion is a measure of the amount of BTG
excreted in excess of the normal excretion. The normal BTG
excretion rate was established by taking the mean of the excretion
rates for the half hour periods before and after the post-infusion
collections. By subtracting this value from the total excretion
for each half hour an approximation of the excess BTG excreted
79.
could be calculated. This is represented by the area above the
shaded area in Fig. 18.
The total gTG excretion is related to the peak excretion rate,
the maximum urine concentration and, in subject 1, to the duration
of elevated urinary concentration. The peak gTG excretion rate
always occurred within the first hour of infusion.
In two studies (1 and 4) accurate measurements were available
for the concentration of gTG in the infused serum (8,538 and
10,879 ng/ml). It was, therefore, possible to calculate that
approximately 0.002% of the infused gTG in each of these studies
appeared in the urine.
Discussion
The platelet concentrate produced the highest dose of gTG.
As the concentrate was derived from two units of blood, twice the
number of platelets were involved in the preparation of the
platelet concentrate compared to the serum. Another contributory
factor is the time of platelet release in relation to the
separation of the serum or platelets. In the preparation of
serum, the platelets release before the serum is separated and,
therefore, much of the gTG is lost in the clot that is separated
off. In the case of the platelet concentrate, the platelets were
separated in a cooled centrifuge immediately after collection and,
therefore, most of the release occurs after separation.
Consequently much less gTG is lost.
The early very rapid clearance observed within the first half
hour of completion of the infusion is typical of smaller protein
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molecules which do not remain solely in the plasma space. This
represents the distribution of the protein into extravascular
spaces combined with some excretion and metabolism. After about
30-40 mins this process reaches equilibrium and the subsequent
slower clearance represents the excretion and metabolism of the
protein. The half life of this phase for STG appears to be about
40
83 mins. This is significantly longer than the half life of PF^
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and of FPA which may be an advantage when used as a diagnostic
test. It may be long enough to enable one to detect short lived
episodes of platelet release but not so long as to interfere with
the detection of recurrent episodes of release over a period of
hours. However, from a clinical standpoint, this half life may be
too short to enable one to identify episodic release by once daily
sampling. The urinary excretion of $TG seems to follow the plasma
clearance fairly closely. In subject I this can be detected on the
urinary concentration alone but the urine flow rate tended to be low
in all three studies. Subject II had no elevated urinary
concentration at all and it was only possible to show the correla¬
tion by charting the actual $TG excretion rate. This is consistent
with the finding in section 2 of this chapter which demonstrated
that normal individuals can dilute their urinary $TG concentrations
with minimal diuresis. Subject II had urine outputs two to three
times those of subject I and this is the reason for the
discrepancies in urinary concentrations. The actual (3TG excretion
rates in subject II showed the same patterns as subject I.
The proportion of infused $TG which appears in the urine is
tiny (one fifty thousandth of the infused dose), and therefore it
81.
forms a very minor route of @TG clearance. However, it does
reflect quite closely the plasma concentrations of @TG and,
therefore, has potential value in the assessment of platelet
release in clinical and experimental situations.
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7. COMPARISON OF PLASMA BETA-THROMBOGLOBULIN CONCENTRATIONS
MEASURED BY THE ORIGINAL TECHNIQUE AND BY THE RADIOCHEMICAL KIT
When this study first commenced the Radiochemical Centre at
Amersham were developing the $TG radioimmunoassay kit and for a
short period samples from the study were assayed both by the MRC
Radioimmunoassay Laboratory in Edinburgh and by the Radiochemical
Centre Kit.
Methods:
A total of 174 samples were drawn from 38 patients in the
thromboembolism and post-operative surveys. After plasma separation
half of each sample was sent to the Radiochemical Centre at Amersham
and assayed there using their RIA kit. The other half was
processed in the normal fashion in Edinburgh.
Results:
Table 9 and Fig. 19 summarise the results. The correlation
between the two methods was significant (p < 0.01). The
concentrations measured by the MRC assay are approximately twice
those measured by the RIA kit. The arithmetical linear regression
/"MRC concentration = 27 + 0.123 x RIA. kit concentration was
markedly distorted by the poorly correlating high values and,
therefore, a regression line to Fig. 19 has been added on a purely
geometrical basis. This suggests that an upper limit of normal of
80 ng/ml on the MRC assay corresponds to about 40 ng/ml on the RIA
kit assay. On this basis, 52 of the samples had elevated
concentrations on both assays; 111 of the samples had normal
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Fig. 19: MRC plasma $TG concentrations v Radiochemical Centre RIA
Kit plasma $TG concentrations on 174 samples.
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concentrations on both assays; 5 had elevated concentrations on
the MRC assay alone and 6 had elevated concentrations on the RIA
kit assay alone. Only 9 samples had higher concentrations on the
RIA kit assay than on the MRC assay.
Discussion
The Radiochemical Centre kit is consistently less sensitive
than the MRC assay and this serves to reinforce the point that all
laboratories should establish their own normal range with a new
diagnostic test before using it clinically.
Our results are consistent with those quoted in the
Radiochemical Centre RIA Kit handbook where combined data from
four centres showed that 95% of normal subjects had concentrations
less than 52 ng/ml.
The good correlation between the two assays suggests that they
are measuring the same plasma constituent.
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CHAPTER II
STUDIES IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE
Plate aggregation has been known to be an integral part of
the formation of thrombi in the venous circulation since the
197
description of the histological appearance of thrombi by Welch.
Although the relative numbers of platelets in venous thrombi are
lower than in arterial thrombi, they are still present in very much
150
higher proportions than in blood. There is some evidence that
the aggregation of platelets in the valve cusps may be the earliest
192
event in the development of deep vein thrombosis. The subsequent
propagated thrombus has a widely varied content of platelets typified
by the classical laminated thrombus which is composed of alternating
70
bands of platelet rich and platelet poor thrombus. As platelet
aggregation is associated with 0TG release, elevated 3TG concentra¬
tions may, therefore, be the earliest manifestation of a developing
venous thrombus.
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Further support for this theory came from Ludlam et at. who
studied patients with calf pain undergoing ascending phlebography.
In patients with positive phlebograms the plasma 3TG concentrations
were all elevated in contrast to the normal concentrations in a
further 8 patients with negative phlebograms.
An ideal diagnostic test for venous thrombosis is one which will
accurately define those patients with DVT and those without (i.e.
it should be sensitive and specific). This preliminary study
suggested that the plasma 3TG concentration fulfils this criterion.
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It is also a simple, inexpensive and rapidly performed test which
may be readily repeated any number of times.
Experiment i: Plasma and urinary gTG concentrations in venous
thromboembolism
Methods:
Three groups of patients were studied.
Group 1: This group, which acted as controls, was composed of 18
patients presenting with leg pain whose symptoms were due to
conditions other than venous or arterial thrombotic disease. The
details of these patients are shown in Table 10. There were 8
males and 10 females aged 36-74 years (mean 60.1, SD 9.9 years) and,
of these, 8 had had symptoms for < 3 days and 10 had had symptoms
for > 3 days. Only 7 patients had phlebograms. The other
patients had no clinical evidence of thrombotic venous or arterial
disease but did have definite clinical and/or radiographic evidence
to support an alternative diagnosis. Plasma and urine samples were
obtained from all patients at the time of presentation and in 9
patients further specimens were obtained for up to 72 hours
afterwards.
Group 2: This comprised 46 patients presenting with leg pain and
swelling or chest pain and dyspnoea in whom a diagnosis of venous
thromboembolism could be substantiated. The details of these
patients are shown in Table 11. There were 17 males and 29 females
aged 26-81 years (mean 58.4, SD 12.3 years). In 39 the diagnosis































































































































TABLE 11: THROMBOEMBOLISM STUDY PATIENT DATA AND PLASMA
BETA-THROMBOGLOBULIN CONCENTRATIONS
Plasma BTG ng/ml
u y uipo . UUUg '
No. Age Sex Aetiology days Test Site scan Day 1 Range
19 60 M Post-op < 1 BAV Nil +ve 50 42-1410
20 55 F Post-op 1 BFV LFICv -ve 47 47-115
21 56 M Post-op 1 BAV BCF -ve 48 48-178
22 45 F Post-op > 3 BAV RCF +ve 112 17-211
23 51 F Post-op > 3 BAV LC -ve 31 14-39
24 37 M Post-op 1 BAV Nil +ve 17 17-20
25 68 M Spont. > 3 BFV LFI - 61 16-109
26 43 F Post-op 1 BAV
IFT
BC +ve 93 93-700
27 69 F Malig. > 3 BFV LFI - 563 -
28 41 F Spont. 1 LFV
RAV
LFI -ve 41 41-106
29 55 F Post-op > 3 BFV
IFT
RC +ve 2600 94-2600
30 55 F Spont. > 3 BAV BC -ve 47 33-98
31 33 F Spont. 1 BAV RCFI +ve 777 25-777
32 76 F Spont. > 3 LAV
RFV
LCFI -ve 93 24-111
33 67 F Spont. > 3 BAV RFI +ve 90 30-90
34 75 F Post-op 2 BFV
IFT
BC +ve 220 99-220
35 58 M Inflam. > 3 BFV RCFI +ve 15 15-32
36 50 M Inflam. 2 RAV RFI -ve 25 25-2549
37 57 M Malig. 1 BFV LFI +ve 698 67-698
38 59 F Malig. 1 BFV LFI +ve 258 29-258
39 26 F Trauma > 3 BFV RFI +ve 105 103-105
40 76 F Post-op 1 BFV RFI -ve 66 38-66
41 60 M Post-op 1 BAV BC -ve 90 51-90
42 72 F Spont. > 3 BAV
BFV
LCFI -ve 62 52-113
43 73 F Inflam. > 3 BAV LCFI -ve 80 23-166
44 68 F Spont. 1 BAV BC - 180 25-731
45 65 F Post-op > 3 BFV LFI -ve 64 38-576
46 66 F Inflam. 1 BFV LFI -ve 91 37-860
47 59 F Trauma > 3 BAV LC - 16 -
48 65 F Malig. 1 BFV LFI - 338 338-400
49 73 F Inflam. 2 BFV LFI +ve 135 49-135
50 52 M Post op > 3 BAV LFI +ve 94 50-2686
51 58 M Trauma 2 BAV LC - 41 -
52 57 M Post-op 3 BAV RCF +ve 106 -
53 43 F Post-op 1 BFV LFI +ve 89 78-300
54 50 F Post-op 1 IFT LF - 4000 -
55 63 F Post-op 1 US LF - 195 117-195
56 56 M Post-op 2 US LF - 55 55-103
57 76 M Malig. 2 IFT LC -ve 86 72-86
58 61 F Spont. 1 BAV RC - 99 -
59 46 M Post-op 3 BAV LC - 69 23-69
60 65 M Post-op 2 BAV RC - 201 -
61 81 M Inflam. 3 US LFI -ve 108 94-142
62 61 F Post-op 2 BAV RC - 163 -
63 42 M Post-op 3 BFV LFI +ve 187 160-360
64 63 F Post-op 1 LFV LFI -ve 450 310-450
Abbreviations:
B-bilateral, R-right, L-left, AV-ascending phlebogram, FV-femoral
phlebogram, IFT-1 "iodine fibrinogen uptake test, US-Doppler
ultrasound, C-calf, F-femoral, I-iliac, Cv-cava.
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detection and in 2 by the IFT. Thirty-two patients also had
99m
chest radiographs and perfusion lung scans using Tc labelled
microspheres of human albumin and in 17 the diagnosis of PE was
substantiated. Two patients had evidence of PE on lung scans
but negative ascending phlebograms.
The 46 patients were then grouped according to possible
aetiological factors. In 10 patients no apparent associated
factor was identified and these have been deemed 'spontaneous'.
None of the patients was on an oral contraceptive. Five patients
with disseminated malignant disease developed DVT; in 5 the
thrombus was associated with an inflammatory illness such as proctitis,
cholecystitis or pneumonia and in 3 it followed trauma; 23 patients
developed DVT following surgery: within 1-14 days of operation in
16 and between 14 and 32 days in 7. There were almost twice as
many females as males and this was most evident in the 'spontaneous'
group where males were outnumbered by a factor of 4. In 65% of
patients, symptoms had been present for < 3 days; in 30% the
thrombus was confined to the calf; in 5% no residual thrombus was
identified in the legs; and in 65% the iliofemoral segment was
involved.
Just over half (53%) of the 32 patients who had lung scans
showed evidence of PE and the incidence of positive lung scans
was highest (73%) in the early post-operative group.
There was no significant difference between the groups in any
of the aetiological factors studied.
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All patients had plasma samples for BTG assay taken at the time
of presentation and in 38 of the 41 patients undergoing phlebography
the first sample was obtained before the phlebogram. Sampling was
repeated daily for up to 7 days.
Seven patients received no active treatment; 2 were given
thrombolytic therapy and the remaining 37 were anticoagulated by
continuous intravenous infusion of heparin. The heparin was given
in a dose sufficient to maintain the thrombin time at 3-4 x the
control.
When group 1 was compared with group 2 there was no significant
difference between the groups in any of the population statistics,
i.e. they are statistically comparable.
Group 3: This was a subgroup of group 2 and consisted of patients
nos. 41 and 45-64 in whom urine samples as well as plasma samples
were obtained. There were 9 males and 12 females aged 42-81 years
(mean 58.2, SD 12.4 years). The diagnosis was confirmed by
125
phlebography in 16,by Doppler ultrasound in 3 and by IFT in 2.
Eleven patients also had chest radiographs and lung scans, of which
5 were positive.
Four patients developed DVT > 2 weeks after operation and 10
developed it within 2 weeks; in 2 it occurred during an
inflammatory illness; in 2 it followed trauma; in 2 it developed
in patients with disseminated malignancy and in 1 it developed
'spontaneously'.
In 57% of patients the thrombus involved the iliofemoral
segment but in 43% it was confined to the calf.
92.




The results in all these groups are shown in Tables 10 and 11
related to the investigative findings.
1. Plasma BrG on day of presentation. These data are shown
diagrammatically in Fig. 20 and summarised in Table 12. In 29 (63%)
of patients presenting with venous thromboembolism, the plasma 6TG
concentration was in the abnormal range (>80 ng/ml) but in only 19
(41%) did it exceed 100 ng/ml.
In group 1 two specimens have been excluded. They showed
concentrations > 1,000 ng/ml and were processed in the same batch as
two other specimens showing unexpectedly high concentrations. The
discrepancy has been attributed to release during faulty processing
of that particular batch of samples. Of the remaining 16 specimens,
7 (44%) had concentrations greater than normal.
There was no significant difference in incidence of abnormal
concentrations between groups 1 and 2 [y2 = 1.11, p = 0.29], nor was
there any difference in the absolute concentrations (p > 0.1,
Wilcoxon). In the 33 patients who had lung scans there was a
significantly greater incidence of elevated concentrations in those
with positive scans (82%) than in those with negative scans (38%)
[yz = 5.24, p = 0.0227. The absolute concentrations in those with
DVT and PE (median 106 ng/ml) were also significantly higher than in
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Fig. 20: Plasma 8TG concentrations in patients with venous
thromboembolism and in control subjects on day of presentation.
(Crosses represent those with symptoms for > 3 days; dots
represent those with < 3 days symptoms.)
TABLE12:PLASMA$TGCONCENTRATIONSITHROMBOEMBOLISMATI NTA DN R LSUBJ CDAY OFPRESENTATION(DAY1)ANDSUB QUENT3DAYS DAY1S-3 GroupNo.ofRangeMediani specimens(ng/ l)specimens/ l Control1622-2456307 DVT4615-1,00092441
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There was no relationship between the duration of symptoms
and the incidence of abnormal gTG concentrations. Of the 27,
18 (67%) with symptoms for less than 3 days and 11 of the 19 (58%)
with symptoms for more than 3 days had elevated concentrations
[X2 - 0.368, p = 0.547. There was also no difference in absolute
concentrations (p > 0.1, Wilcoxon).
Those with DVT involving the iliofemoral segment were no more
likely to have elevated concentrations (20/30) than those in whom
the DVT was confined to the calf (9/14) /"X2 = 0.024, p = 0.82J.
Phlebography did not appear to affect plasma $TG levels as
the 3 patients whose initial samples were obtained after phlebo¬
graphy showed the same distribution of initial concentrations as
those whose samples were obtained before phlebography. There was
also no significant difference in (3TG concentrations between the
days before and after phlebography (p > 0.1, Wilcoxon).
2. Follow-up and effect of therapy. Plasma 8TG concentrations
followed for up to 3 days in 5 patients prior to commencing heparin
therapy are summarised in Fig. 21. Four showed persistently
elevated concentrations despite quite large fluctuations and the
fifth showed normal concentrations.
In 28 patients results are available for one day prior to
heparinisation and for 2-6 days after commencing heparin therapy.
These data are summarised in Fig. 22. The median has been used
as a summary statistic because of the skewed distribution. After
commencing heparin therapy, 7 patients showed rising concentrations
but in 21 the concentrations either fell or remained unchanged.
96.
Fig. 21: Plasma $TG concentrations in 5 patients with venous
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Both the median 0TG concentration and the incidence of abnormal
concentrations fell over the first 4 days but rose to a peak
again on day 5 of heparin therapy. None of these changes reached
statistical significance. These trends are much less evident if
one looks at individual patient's results as the concentrations
tended to fluctuate quite widely from day to day. Fig. 23
demonstrates this in 5 patients with iliofemoral DVT and PE. Of
these 28 patients, 21 show this fluctuating pattern; 4 showed
consistently normal concentrations and 3 showed consistently
elevated concentrations. There was no correlation between the
presence of persistently elevated concentrations and the extent or
duration of the thromboembolic process.
Two patients (28 and 32) were treated by thrombolytic therapy.
Each day 60 mg plasminogen was given over 4 hours followed by
600,000 units of streptokinase over 30 mins. The 8TG concentra¬
tions are shown in Fig. 24. In both cases the concentrations rose
into the abnormal range after commencing therapy. Therapy for
patient 32 was discontinued after 3 days when she developed profuse
gastrointestinal haemorrhage and patient 28 showed no change in the
extent of the thrombus on repeat phlebography after 1 week of
therapy.
B. Urinary 8TG
The urinary 8TG concentrations and excretion rates in all 18
patients in group 1 (controls) are shown in Table 13 and for group
3 (thromboembolism patients) in Table 14.
99.
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Fig. 23: Plasma (3TG concentrations in 5 patients with iliofemoral
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Fig, 24: Plasma 3TG concentrations before and after the start of
thrombolytic therapy in 2 patients.
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TABLE 13: PLASMA AND URINE 3TG CONCENTRATIONS AND URINARY 0TG
EXCRETION RATE IN CONTROL SUBJECTS FOR UP TO 3 DAYS












































































































TABLE 14: PLASMA AND URINE 8TG CONCENTRATIONS AND URINARY 8TG







































































































































































1. Urine BTG concentration on day of presentation. The urine
BTG concentrations on the day of first presentation are summarised
in Fig. 25. The concentrations varied from 0.05 to 2.0 ng/ml in
the control group (1) and from 0.14 to 3.7 ng/ml in the thrombo¬
embolism group (3). Normal concentrations were found in 72% of
the 18 patients in group 1 but in only 5% of the 21 patients in
group 3. This difference was highly significant 7X2 = 21.37,
p = 0.0000137. The BTG excretion rate varied from 3.5 to 83.0
ng/hr in group 1 and from 14.4 to 187.0 ng/hr in group 3. The
difference in incidence of abnormal excretion rates was again highly
significant [\2 = 21.37, p = 0.0000127.
There was also a significant difference in the actual
concentrations between group 1 (median 0.12 ng/ml) and group 3
(median 1.02 ng/ml) and of the BTG excretion rates (medians 6.2
ng/hr and 82.0 ng/hr respectively) (p < 0.01, Wilcoxon). There
was no relationship between the extent of the thrombotic process or
the duration of symptoms and the BTG concentration or excretion rate.
2. Follow-up and effect of therapy. Urine samples were obtained
for at least 48 hours in group 3 and it was possible to relate the
duration of the elevated urine concentrations to the extent of the
thromboembolic process. These data are summarised in Fig. 26.
None of the patients with iliofemoral thrombosis had elevated
urinary concentrations for < 24 hours and only 22% of those with
calf thrombosis had elevated concentrations for > 48 hours. The
difference in incidence of an elevated urine concentration and of
elevated BTG excretion rates for < 24 hours was statistically
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Fig. 25: Urinary BTG concentrations in thromboembolism patients





Fig. 26: Duration of elevated urinary concentrations in
thromboembolism patients.
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between the presence of pulmonary embolism, the aetiology of the
DVT or the duration of symptoms and the duration of the elevated
urinary concentrations. The one subject who had normal 3TG
concentrations on admission showed significant elevations within
6 hours (Subject 41, Fig. 27). However, this followed the start
of heparin therapy and may be purely a heparin-related phenomenon.
The trends of the urinary concentrations tended to vary. In some
patients very high concentrations were obtained sometime after
initial sampling (patient 59, Fig. 28; patient 40, Fig. 27) whereas
in others, particularly those with calf thrombi, the concentration
tended to fall rapidly to normal (patient 47, Fig. 27). The (3TG
excretion rates followed the concentrations quite closely.
Follow-up samples are available in only 9 of the group 1
(control) patients. The 4 patients with abnormal concentrations
on presentation (Nos. 11, 12, 16 and 18) still showed elevated
concentrations on the following day and one other patient (No. 14)
with superficial thrombophlebitis developed elevated concentrations
after the first sample.
Seven patients with DVT received no anticoagulant therapy.
Six had calf DVT, one associated with pulmonary embolism and one had
an iliofemoral DVT. Two of those with calf DVT showed markedly
elevated concentrations after initial sampling but in the other 5
subsequent sampling showed lower concentrations. These patterns
are demonstrated by patients 59 and 61 (Fig. 28).
The other 14 patients all received heparin therapy. In 7 the
therapy had commenced prior to urine sampling and in the other 7
heparin therapy commenced during the period of urine sampling.
ng/ml
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Three patients from each group showed rising concentrations after
commencing heparin therapy and 4 showed reductions. Three
examples (patients 40, 41 and 47) are shown (Fig. 27). There were
38 plasma samples obtained during urine collections in 18 group 3
patients. There was no correlation between the plasma concentra¬
tion and the urine concentration (r = 0.054) or the |3TG excretion
rate (r = 0.091). The one patient with a normal urine concentra¬
tion had an elevated plasma concentration and 5 patients with
normal plasma concentrations had elevated urine concentrations.
There was a similar lack of correlation in 15 samples from 13
patients in group 1 (r = 0.082).
Experiment ii: Syringe testing on patients with venous
thromboembolism
Syringe tests described in Chapter 1, section 4, measure
the rapidity of in vitro BTG release. As the release is induced
by endogenous thrombin generation the test measures both the
rapidity of thrombin generation and the sensitivity of platelets to
thrombin.
Methods:
Syringe tests were performed on 3 groups of patients. Their
details are summarised in Table 15.
Group 4: consisted of 5 patients aged from 48 to 67 years
(mean 58.4 years) presenting with acute DVT. There were 3 women
and 2 men, of whom 2 had post-operative iliofemoral thrombosis
confirmed by ultrasound; 2 had calf and femoral vein thrombosis
110.
TABLE 15: SYRINGE TEST DATA ON THROMBOEMBOLISM PATIENTS
Basal Release
concentration time
Group No. Age Sex Diagnosis ng/ml mins
4 65 67 M Ilio-femoral DVT 188 5
66 59 M Ilio-femoral DVT 80 6
67 48 F Calf & femoral DVT 64 6
68 62 F Ilio-femoral DVT 70 6
69 56 F Calf & femoral DVT 83 4





femoral DVT & PE
5/12 after ilio¬
femoral DVT & PE
4/12 after ilio¬
femoral DVT & PE
2/12 after ilio¬





6 74 48 M Recurrent DVT & PE 34 5
75 50 M Recurrent DVT & PE 24 9
76 34 M Recurrent phlebitis 39 7
111.
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after surgery diagnosed by I fibrinogen uptake test and one had
'spontaneous' femoral vein thrombosis confirmed by phlebography.
Sampling was carried out as soon as the diagnosis was suspected
clinically.
Group 5: comprised 4 patients, 2 males and 2 females, aged
54 to 69 years (mean 61 years) studied 2.5 months after phlebo-
graphically-proven iliofemoral venous thrombosis. Patients 70, 72
and 73 also had pulmonary embolism confirmed by perfusion lung scan.
Two patients (70 and 71) had had inconsistently elevated plasma |3TG
concentrations at the time of the acute episode but the other 2
(72 and 73) had had consistently elevated concentrations. Sampling
was carried out at routine follow-up and none of them had had
recent acute symptoms. All were anticoagulated with Warfarin.
Group 6: consisted of 3 male patients aged 34 to 50 years
(mean 44 years) who had recurrent thromboembolic problems. Patient
76 had had numerous attacks of superficial thrombophlebitis and at
the time of sampling was on no medication. The other 2 patients
had each had at least 3 episodes of DVT and pulmonary embolism in
the previous 2 years and were on Warfarin therapy at the time of
sampling. None of the 3 patients had had acute symptoms within
the preceding 2 months.
Results:
Table 15 also shows the results of the investigation.
Group 4: (patients with acute DVT). The basal concentrations
were high with 3 falling in the abnormal range. The release times
112.
were all rapid. The mean release time was 5.4 mins which was much
shorter than our normal range (mean 7 mins).
Group 5: (patients after clinical recovery from acute DVT).
The patients in this group all had normal basal concentrations but
the release times varied from a very rapid 3 mins to a normal 8 mins
(mean 4.8 mins). The release time was not related to the time
elapsed since the DVT (r = 0.23) nor to the consistency with which
elevated plasma 0TG concentrations were detected during the acute
episode.
Group 6: (patients with recurrent thromboembolic disease).
All the basal concentrations and release times were within the
normal range.
DISCUSSION
The clinical diagnosis of DVT is notoriously unreliable,
especially if the thrombus is confined to the calf when 50% of
94
thrombi may be asymptomatic. It is, therefore, necessary to
perform a confirmatory diagnostic test.
Thirty-nine patients had the diagnosis of DVT confirmed by
phlebography which is accepted as the most accurate technique
171
available. The accuracy, however, depends on the skill of the
radiologist as it has been shown that up to 19% of phlebograms may
79,171
have some veins incompletely filled concealing minor thrombi.
We were fortunate in being associated with radiologists particularly
experienced in phlebography.
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The I fibrinogen uptake test, used in 2 patients, has a
137
well established place in the diagnosis of the developing DVT,
113.
but its use is confined to the leg below the inguinal ligament as
the background radiation from the pelvic blood vessels masks the
counts from the iliac veins. However, in our studies of large
numbers of patients with thromboembolic disease, it was extremely
rare to find iliac thrombus without co-existing thrombus below the
inguinal ligament (< 1% of patients with phlebographically-proven
DVT) .
Doppler ultrasound is also of value in the diagnosis of DVT
particularly in the iliofemoral segment where its accuracy is over
120
80%. We have found it to be very valuable in patients with
124
occlusive iliofemoral DVT. This test confirmed iliofemoral DVT
in 3 patients.
The clinical diagnosis of pulmonary embolism is similarly
unreliable and, therefore, chest radiographs and perfusion lung scans
99m
using Tc labelled microspheres of human albumin were performed.
False negative perfusion scans are exceptionally rare but false
positive scans commonly occur with conditions such as pneumonia,
atelectasis and pleurisy.103 However, if one accepts a perfusion
defect in the presence of a normal chest radiograph as evidence of
201
pulmonary embolism, the false positive rate is < 10%. The most
accurate way of excluding the false positives is to perform a
simultaneous ventilation scan which should be normal in pulmonary
embolism but show ventilation defects in most of the other
pathologies. Unfortunately ventilation scanning was not available.
However, I feel confident that the diagnosis of venous thrombo¬
embolism has been established beyond reasonable doubt in my 46
patients. In the 18 patients in the control group, only 7 patients
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were investigaged by phlebography to exclude a clinical diagnosis of
DVT. Clinicians were understandably unwilling to subject patients
to a rather painful and expensive investigation unless there were
definite clinical indications. The patient with superficial
thrombophlebitis had small amounts of thrombus in the superficial
veins but the deep veins were clear. The other patient with calf
pain and a history of two previous episodes of DVT showed poor
filling of the deep veins but no obvious thrombus. This illustrates
one of the deficiencies of phlebography in that, if there has been a
previous thrombosis, it can be difficult to differentiate between
old and new occlusive thrombus. The other 11 patients were
accepted into the control group on the basis of a definitive diagnosis
of a pathology other than venous thromboembolism, as a cause of the
symptoms. Therefore, in these 11 patients, DVT as a cause of
symptoms has not been completely excluded but is nevertheless
extremely unlikely. They also had no clinical evidence of arterial
disease.
The comparison of the thromboembolism groups with the control
group showed that the 3 groups were matched for age and sex and
duration of symptoms.
There was a high incidence of normal plasma BTG concentrations
in patients presenting with thromboembolism (35%) in contrast to
107
Ludlam's findings. Other authors have also found disappointingly
high incidences of normal concentrations in patients with acute DVT.
42
Denham showed that patients with acute DVT had significantly
elevated concentrations compared to controls but failed to record
the sensitivity which I regard as an important criterion for judging
115.
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the value of a test. O'Brien quoted similar results but his
plasma gTG concentrations in DVT (7-240 days after onset) showed
31
complete overlap with his control group. Cella et al.
produced similar results to the present study and showed that only
11 out of 24 patients with 'recent' DVT had elevated concentrations
although the concentrations of the group in general were
significantly greater than their control group. They made no
comment on how recently their patients had developed DVT. However,
the time of development of symptoms may not necessarily be the time
94
of origin of the thrombus. Kakker has shown that up to 50% of
125
legs with evidence of thrombus on IFT are asymptomatic and so
the development of symptoms may represent a relatively small
extension of the thrombus blocking a vital collateral pathway such
as the profunda femoris vein. In this situation the majority of
the thrombus is old and so the release of gTG will be relatively
insignificant. This could well be the reason for the high
proportion of false negative results on the samples obtained on the
day of presentation. Although many of our patients had recent
onset of symptoms we may, in fact, have been studying predominantly
107
old thrombi. Ludlam makes no comment on the duration of
symptoms in his patients.
I could detect no significant difference between the gTG
concentrations in the patients with calf or iliofemoral thrombosis.
Any differences, however, could be marked by the varying age of the
thrombus at time of presentation. However, the patients with
proven DVT and pulmonary embolism had significantly higher plasma
gTG concentrations than those with DVT alone. This is consistent
116.
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with the findings of Thomas et al. who demonstrated the deposi¬
tion of platelets on pulmonary emboli and the release of serotonin
which was responsible for the bronchoconstriction. They
suggested that this aggregation of platelets on the emboli was due
to residual thrombin in the embolus and showed that it could be
prevented by heparin. Thrombin will also release BTG and,
therefore, higher BTG concentrations in the presence of pulmonary
emboli should be expected.
The BTG concentrations in the control group were higher than
my normal range (Chapter I, Fig. 5). In three of the patients with
high concentrations (12, 13 and 14) there was acute pathology which
could have been associated with BTG release. Another three (2, 6
and 9) did not have acute processes but were older (aged 48, 61 and
60 years respectively) than the patients in my normal range (mean
109
29.4 years). Ludlam has shown a tendency to increasing BTG
concentrations with age and these values may merely be a manifesta¬
tion of platelet activity due to mild arterial disease not detected
clinically. The seventh was a post-operative patient and is
discussed in Chapter III.
During the follow-up period the BTG concentrations fluctuated
considerably in most patients possibly indicating episodic platelet
activity as new thrombus was laid down. There appeared to be no
difference between the patients who received heparin in the first 3
days and those who did not. In the study of normal individuals on
heparin therapy, one subject receiving intravenous heparin showed
elevated BTG concentrations 2 and 8 hours after injection but the
other had only minimal rises. However, the BTG concentration in
117.
the DVT patients on heparin therapy showed no rise immediately after
starting heparin therapy. The median concentration fell initially
but rose again on day 5 (4 days after commencing heparin therapy).
The rise was quite striking but did not reach statistical signifi¬
cance. Although no patients showed overt major bleeding disorders,
this secondary rise in (3TG concentration could be due to platelet
release in relation to sub-clinical internal haemorrhage. Mant et
116
al. have shown that breeding complications are rare in the first
2 days of therapy but that occult retroperitoneal haemorrhage is a
frequently unrecognised event in the subsequent days. The effect
of heparin on platelet function has already been reviewed in section
5 of Chapter I.
The response of the plasma j3TG concentrations to thrombolytic
therapy was quite striking but unfortunately only 2 patients were
available for study. In 1 patient (No. 32) profuse haemorrhage on
day 3 of therapy forced discontinuation of the regime. The rise in
BTG concentration in this patient could be merely a manifestation of
the developing haemorrhagic diathesis. The other patient, however,
showed no evidence of haemorrhage and had no significant changes of
haematocrit or platelet count.
Information in the literature on the effect of streptokinase,
plasminogen and fibrinogen degradation products (FDP) on platelet
102
function is also rather confusing. Kowalski et al. showed that
streptokinase and plasminogen or FDP inhibited platelet aggregation
and viscous metamorphosis. The early degradation products of
fibrinogen appeared to have a more pronounced effect than the later
ones. However, they also showed that the platelet count fell after
118.
a dose of streptokinase and plasminogen and demonstrated that this
101
was due to platelet clumping. Kopec et al. found that
streptokinase and plasminogen inhibited both aggregation and
128 122
release, as also did FDPs. Morse et al. and Millar et al.
both showed that plasmin inhibited aggregation but not release in
118
human platelets and Martin et al. were able to confirm that
plasmin had no effect on the release action. In a study with
78
rabbit platelets, Hirsh et al. showed that streptokinase infusion
had no effect on adhesion or aggregation of platelets. Early FDP,
however, inhibited thrombin induced aggregation. The consensus in
the literature so far reviewed suggests that thrombolytic agents
(streptokinase and plasminogen) and their products (plasmin and FDP)
either inhibit or have no effect on platelet function or release.
The only data giving evidence to the contrary that I can trace is
g
work by Barnhart et al. who showed that low concentrations of FDP,
especially segment D, would produce reversible aggregation and
95
release in dog platelets. Kakker, in a review article on
thrombolytic therapy comments briefly, without giving experimental
details, that low doses of urokinase can increase the tendency to
aggregation in animal and human platelets. Although these factors
may be responsible for the markedly elevated BTG concentrations
detected in subject 28, he did manifest evidence of immunological
response to the infused streptokinase with pyrexia and rigors
following each dose despite cover with hydrocortisone. This is
likely to be associated with circulating immune complexes and
129,130
these have been shown to induce ADP release from platelets.
It is possible that BTG could also be released by this mechanism.
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An alternative factor could be a diminished vascular integrity
similar to that seen with heparin therapy. If vascular integrity
167
is dependent on the fibrin system as suggested by Rowsell et al.
thrombolytic therapy, especially with the hyperplasminaemia induced
by streptokinase, is likely to have an adverse effect and could
result in significant 0TG release from the platelets escaping from
the circulation.
In the 21 patients with DVT in whom urine sampling was performed,
only one patient had a normal urinary $TG concentration on the day of
presentation. This contrasted with the 13 out of 18 control
patients who had normal urinary 8TG concentrations. The one
patient with DVT who had normal (3TG concentration had a localised
calf thrombus but subsequent sampling showed significantly elevated
concentrations on several occasions. In two patients with DVT the
only elevated concentration was obtained with the first specimen on
presentation. Therefore, in these two patients I was lucky not to
have missed the elevated urinary concentration. Two of the control
patients with elevated concentrations on presentation could well
have had intravascular thrombosis. Inflammation is associated with
193
a marked vascular response including endothelial cell damage and
altered capillary permeability. With particularly virulent
66
infections the inflammatory response may proceed to frank gangrene
which will be associated with extensive vascular thrombosis.
Immunological complexes may also be involved in altering platelet
reactivity and so there are ample reasons for platelet release to
be occurring in the patient with cellulitis. This topic will be
discussed more extensively in Chapter III. The other patient had
120.
had previous thromboembolic disease and, as I have indicated, the
phlebogram did not entirely exclude further thrombosis. One other
patient with superficial thrombophlebitis had normal concentrations
on admission but several elevated concentrations were detected on
subsequent samplings. This patient did have intravascular
thrombosis but in the superficial veins, not in the deep ones.
Abnormal urinary $TG, like plasma 0TG, is unable to differentiate
between DVT and other forms of venous thrombosis. Three other
patients studied in the post-operative period also had elevated
concentrations. This will also be discussed further in Chapter III.
In contrast to plasma @TG assay, the urinary assay was unable to
identify those with pulmonary embolism but the patients with ilio¬
femoral DVT had elevated concentrations and excretion rates for
significantly longer than those in whom the DVT was confined to the
calf. This probably represents a continuing slow turnover of
platelets in the more extensive thrombus leading to a continuous
hyperexcretion of 0TG over a longer period. The plasma |3TG assay
differentiated between those with and without pulmonary embolism on
the basis of |3TG concentration at presentation. This represents
greater activity, but in a shorter period. As the proportion of
plasma $TG actually excreted in the urine is minute, the difference
in plasma concentrations in those with and without pulmonary
embolism is insufficient to produce a significant difference in
urinary concentrations.
Heparin therapy did not appear to alter the widely differing
patterns of urinary 3TG concentrations seen in non-anticoagulated
patients with DVT. However, none of the patients in the urinary
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3TG study were followed for more than four days after presentation
and none of the patients reached the point at which the plasma BTG
concentrations peaked (five days after commencing therapy).
There appears to be no correlation between the plasma and
urine BTG concentrations. In the infusion study it has been shown
how good the correlation between plasma and urinary BTG
concentrations was but in that study frequent urine and plasma
samples were obtained. In the study on the DVT patients the plasma
was sampled at some stage during the period the urine was collecting
in the bladder, which could be as long as 6 hours. During such a
collection in a patient with DVT there may well be considerable
variations in the plasma BTG concentration which will be mirrored by
variations in the amount of BTG passing into the bladder. As the
urine is mixed in the bladder, the ultimate BTG concentration will
reflect the 'mean' urinary BTG concentration over the period the
urine has been accumulating. The plasma BTG, in contrast, measures
the BTG content of the plasma at the moment when sampling is
performed. I have shown how the plasma BTG may vary greatly from
day to day in patients with DVT. If one sampled during a period of
low BTG concentration, one could obtain a false negative result.
Urine sampling, however, helps to eliminate these spurious negative
results by compensating for periods of low excretion with periods of
high excretion.
Despite the disappointing results with the syringe tests in
normals, the studies in those with thromboembolism did seem to
confirm the findings of others. The patients sampled during the
acute phase of a DVT showed high basal concentrations and
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significantly shorter release times (p < 0.05, Wilcoxon) than the
normal group. This suggests that the platelets are more reactive
2 74
during the acute phase of DVT. Abrahamson, Harker and
146
O'Brien have all shown that platelet survival is decreased
during the acute phase of DVT. Therefore, the mean age of the
125
circulating platelets will be shorter. Minter and Ingram have
shown that, following acute blood loss in the dog, the mean
platelet size increases temporarily and they suggest that the newly
97 98
formed platelets are larger. Karpatkin ' supports this theory
and shows that young platelets are more active in that they
aggregate faster in response to thrombin and they secrete larger
117
amounts of ADP and PF^. Manucci and Sharp even believe that
only the young large platelets will aggregate. The shortened
release time may, therefore, be due purely to a younger platelet
population as a result of increased platelet production following
platelet consumption by the thrombus.
The release times in the patients convalescent one to four
months after acute DVT varied considerably but two of the patients
had shorter than normal release times. The release times did not
appear to be related to the extent of (3TG release during the acute
episode or to the time since the acute episode. The ultra short
release times (3 and 4 mins) seen in two patients may be significant
2
but the numbers studied are too small to show a trend. Abrahamson,
however, showed that platelet survival returned to normal after
clinical recovery in patients with DVT.
The release times in the three patients with recurrent thrombo¬
embolic problems were all within the normal range. This is probably
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to be expected as the majority of investigators have incriminated
abnormalities of the fibrin generation or fibrinolytic systems
51
rather than the platelet system in this condition. Egeberg
demonstrated an inherited deficiency of anti-thrombin and
85
Isaccson and Nilsson showed defective fibrinolysis in blood and
vein wall in these patients. The success of anabolic steroids in
8
the prevention of relapses in recurrent superficial thrombophlebitis
and their known ability to stimulate release of plasminogen activator
from vessel wall suggest that abnormalities of the fibrin genera¬
tion or fibrinolytic systems rather than platelets are involved.
77
However, Hirsch and McBride found an increased platelet adhesive-
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ness and Steele et al. also demonstrated reduced platelet
survival in patients with recurrent thromboembolic disease. These
changes, however, may be insufficient to produce any change in the
syringe tests.
This chapter has been mainly devoted to a study of the value
of BTG assays in the diagnosis of DVT and PE. How good are they?
If a patient presents with symptoms suggestive of DVT and/or PE,
what chance is there that the correct diagnosis will be reached
using the BTG assay alone? With one plasma concentration one
would have a 65% chance of reaching the correct diagnosis (probably
a similar chance to clinical examination) but one urine concentra¬
tion would correctly diagnose 85% of the patients. The plasma BTG
concentration would give a false positive diagnosis in 44% of
patients without DVT but the urine BTG assay would diagnose only
28% false positive.
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Other assessments for comparative purposes are the sensitivity,
207 . 5
specificity, Youden's Index J and the A value. The Youden's
Index is a method of aggregating the estimates of the sensitivity
and specificity of the tests. It is calculated by subtracing the
sum of the false negative and false positive proportions from 1.
Therefore, the higher the value the greater the discriminant
accuracy of the test. The A value is calculated by dividing the
difference of the means of the two samples by the square root of
the variance of the total population of the &TG concentrations.
The results are shown in Table 16. This confirms that in all
parameters measured, the urine assay is a better discriminant than
the plasma assay. It is also much more attractive because of its
simplicity of sampling but is seriously affected by haematuria,
proteinuria or operation. This will be discussed further in
Chapter III.
TABLE16:DI GNOSTICACCURACYOFPLASMADURINE3TGCONCENTRATIONSVE OUSTHROMBO MB LI M TestR sult_._J,Sensi-SpedTruepositive+ Group+-Totaltlvityficrueneg tiveJA DVT15621 Plasma0.715665.270 48 Control7916 DVT2011 Urine0.9572867. 9 Control5138
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CHAPTER III
STUDIES IN SURGICAL PATIENTS
The reliable diagnosis of pathological intravascular thrombosis
by a simple blood test would be of considerable benefit in patients
undergoing major surgery.
DVT is a common sequel to operation, the incidence varying
20
from 15% in patients undergoing gynaecological procedures to 35%
62
in general surgical patients and 75% in patients with pertro-
60
chanteric fractures. PE follows operation in about a quarter of
23
patients but is usually minor and asymptomatic. It may, however,
on occasions, be massive and fatal. Patients with evidence of DVT,
125 23
on IFT have almost a one in two chance of developing PE.
Early diagnosis of these at risk patients may enable early treatment
to prevent this potentially fatal complication.
In patients undergoing vascular reconstruction, assessment of
patency of the reconstruction may be difficult if distal occlusions
prevent the reappearance of distal pulses. A test for intra¬
vascular thrombosis might be of value in this situation to detect
occlusion or impending occlusion of a reconstruction, thus enabling
appropriate early remedial action. The aims of this study are,
therefore, twofold:-
1. To assess the value of plasma and urine $TG measurements
in the diagnosis of post-operative DVT.
2. To assess the value of plasma ftTG measurements in the
diagnosis of post-operative thrombosis of arterial
reconstructions.
127.
However, before assessing the BTG concentration in these
pathological situations, it is important to evaluate the effects
the operation and the many factors which may influence platelet
function in the peri-operative period.
The study is divided into six parts:-
1. Pre-operative plasma BTG
2. The effects of operation on plasma BTG
3. The effects of post-operative factors on plasma BTG
4. The diagnosis of post-operative DVT
5. The diagnosis of post-operative thrombosis of arterial
reconstructions






























following day in 73 of them.
Results:
The

















summarised in Table 17.
There was no
difference in age between the two
groups but there was a
significant
difference in sex






















groups are shown in Fig. 29.
Day 1 is the day of
admission and day
2 the
following day. On day 1, 27% of GS




range but by day 2 this had
fallen to 13% of GS




TABLE 17; POPULATION STATISTICS ON SURGICAL PATIENTS
Group Total Male Female Age range Mean
GS 68 25 43 22-87 60.3
PVD 49 36 13 42-82 60.7
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benign malignant vascular group
Fig. 29: Plasma 0TG concentrations before operation (median
concentrations indicated) on days 1 and 2.
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difference between the two groups of patients. The subgroup of
general surgical patients with malignant disease tended to have
lower concentrations than the others. The incidence of abnormal
concentrations suggests some temporary effect promoting f3TG
release on admission to hospital.
In 47 GS group patients, plasma concentrations were available
on both days and, of these, 60% showed no elevated concentrations;
36% had one elevated concentration but only 4% had both concentra¬
tions elevated. From day 1 to day 2 75% of the patients showed a
fall and 25% showed a rise. The correlation between the two days
was poor (r = 0.16). Similar results were obtained in the 26 PVD
group patients sampled on both days: 61% had no elevated
concentrations; 31% had one elevated concentration and only 8% had
both concentrations elevated. Between days 1 and 2 50% showed a
fall and 50% showed a rise. The correlation between the two days
in the vascular patients was much better (r = 0.60).
Statistical analysis has been performed on these results using
a t test on the logarithm of the concentration to normalise the
distribution.
GS patients had concentrations on day 1 (median 35 ng/ml,
range 10-810 ng/ml) significantly higher (t = 2.01, p = 0.047) than
those on day 2 (median 21 ng/ml, range 12-169 ng/ml) and than the
-5
normal range (t = 4.21, p = 4.2 x 10 ). The concentrations on day
2 were not different from the normal range (t = 1.32, p = 0.19).
The concentrations on day 1 in the PVD patients (median 60 ng/ml,
range 12-401 ng/ml^ however, were not different (t = 0.85, p = 0.40)
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from the concentrations on day 2 (median 45 ng/ml, range 12-491
ng/ml), nor were they different from day 1 of GS patients (t = 1.85,
p = 0.067). They were significantly higher than the normal group
-10
(t = 7.09, p = 2.3 x 10 ) and from day 2 of the GS patients
-5
(t = 4.09, p = 8.9 x 10 ). On day 2 the concentrations of PVD
patients were significantly higher than the normal group (t = 4.66,
-6
p = 8.5 x 10 ) and day 2 of the GS patients (t = 2.5, p = 0.015).
Discussion
There was a considerable variation in f3TG concentration detected
in patients on admission to hospital with about a third of patients
having abnormally high concentrations. By the following day only a
sixth of the patients still had abnormal concentrations. The
peripheral vascular patients showed a greater tendency to abnormal
concentrations than the general surgical patients and the concentra¬
tions did tend to remain elevated on the second day.
Several factors may be involved in these findings. The
patients studied here were much older than the normal group and
the rise in $TG concentration may be a manifestation of age as
109
shown by Ludlam. The cause of this may be the development of
the multiple endothelial lesions associated with aging arteries.
This is borne out by the close correlation between the |3TG
concentrations in these patients and those with peripheral arterial
disease in Chapter IV and by the greater tendency for the PVD
patients to have elevated concentrations on both days.
All these patients, unlike the normal group, had some form of
continuing pathological process which could contribute to $TG
release.
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However, this is not compatible with the fall in 0TG
concentrations seen in the GS patients between days 1 and 2. In
these patients some influence seems to be more active immediately
71
after admission than on the following day. Haft and Arkel, in a
study on junior doctors presenting papers at academic meetings, have
demonstrated that the emotional stress of that situation can affect
platelet function. By studying thrombin induced platelet
aggregation before and after the presentation of the papers, they
demonstrated that platelets aggregate during stress, de-aggregate
and are then refractory to re-aggregation.
Admission to hospital is psychologically stressful and this may
be sufficient to produce STG release. By the following day the
patient has adapted to his surroundings and should be more at ease
thus resulting in a fall in the gTG concentrations on day 2, as
shown in the general surgical patients.
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2. PLASMA BETATHROMBOGLOBULIN DURING OPERATION
Aim:
To study the effect of operation on plasma $TG.
Methods:
Thirty-nine patients undergoing abdominal or vascular
operations were studied. All patients were screened for DVT by
125
the IFT. A careful record was kept of all transfusions of
blood or blood products. Samples of blood were obtained for STG
assay and platelet count prior to operation, after induction of
anaesthesia, on completion of the preliminary dissection, within 10
mins of clamp release in arterial operations or just prior to
abdominal closure in general surgical operations, in the recovery
room within 30 mins of completing the operation, and daily
thereafter.
Results:
The 39 patients were divided into three groups.
Group 1: comprised 15 patients (12 males and 3 females) aged
49-75 years (mean 60 years) undergoing major arterial reconstruc¬
tions such as major endarterectomies or bypass grafts. Of these,
10 received blood transfusions during surgery and 6 developed post-
125
operative DVT, as diagnosed by the IFT.
Group 2: comprised 14 patients (11 males and 3 females) aged
42-70 years (mean 60 years) undergoing carotid endarterectomy. No
125
patients received blood transfusions or developed IFT diagnosed
DVT.
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Group 3: consisted of 10 patients (5 males and 5 females) aged
46-81 years (mean 62 years) undergoing major abdominal surgery such
as cholecystectomy or bowel resection. Two received a blood
125
transfusion and one developed IFT diagnosed DVT.
The median 3TG concentrations for each group are plotted in
Fig. 30 and the proportions of patients with abnormal concentrations
shown in Fig. 31. Only 4 patients (11%) had elevated concentra¬
tions before operation.
i) Effect of induction of anaesthesia. In 13 patients 3TG
concentrations were available before and after induction of
anaesthesia. There was a small and statistically insignificant
rise, with only 3 patients (1 from each group) showing rises of
> 30 ng/ml.
ii) Effect of operation. The plasma 3TG concentrations during
operation varied enormously (15-2,283 ng/ml) between individuals.
However, the concentrations on repeated sampling in individual
patients tended to follow a consistent pattern of release or lack
of release.
In those undergoing major arterial operations (group 1) there
was a significant rise in 3TG concentration relative to the pre-
operation levels detected in the first intra-operative specimen
(p < 0.01), continued through the second intra-operative specimen,
and at a lower level in the immediate post-operative specimen. By
day 1 after operation the plasma 3TG concentration was still slightly
elevated but not significantly so. In groups 2 and 3 significant
elevations relative to the pre-operative concentrations were found
136.
30: Median plasma (3TG concentrations during operation.
Group 1 - major arterial reconstruction
Group 2 - carotid endarterectomy
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in the intra-operative specimens only (p < 0.01).
In comparing the three groups, the patients in group 1 showed
higher concentrations than those in groups 2 and 3 but this only
reached significance in the immediate post-operation specimens
relative to group 2 (p < 0.01) and group 3 (p < 0.05). In 9
patients (2 in group 1, 5 in group 2 and 2 in group 3) the 8TG
concentrations never exceeded 80 ng/ml.
The proportions of abnormal concentrations at each point are
shown in Fig. 31. These data mirror the medians in Fig. 30.
iii) Effect of a vascular procedure. The median (3TG concentration
in group 1 rose by over 300 ng/ml after the circulation was
re-established through a graft or endarterectomised segment. This
change failed to reach statistical significance because of the small
numbers involved.
iv) Effect of blood transfusion. Plasma samples were obtained
during the infusion of whole blood or packed cells in 12 patients.
There was no difference in concentration between those samples and
samples obtained at the same point during the operation in patients
not receiving a transfusion.
Discussion
There was again a considerable variation in the $TG concentra¬
tions detected in all three groups: major arterial, carotid
endarterectomy, general surgical. In 23% of the patients no
abnormal concentrations were detected at any stage but all except
two of these patients did show rises which failed to reach 80 ng/ml.
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These patients all had pre-operative concentrations below 40 ng/ml
and it may be that with low initial concentrations the release
engendered by surgery was insufficient to raise the level above the
normal range. This phenomenon was commoner in patients undergoing
carotid surgery (a much less traumatic procedure than a laparotomy
or major arterial reconstruction) and is, therefore, related to the
extent of the surgical procedure. However, two patients under¬
going major arterial surgery (aorto-iliac endarterectomy and
prosthetic graft replacement of a femoral aneurysm) also failed to
show significant release. A syringe test (Chapter I, section 4)
was carried out several months after operation on the patient who
underwent aorto-iliac endarterectomy and this showed a release
pattern at the upper limit of type I (a very slow release).
The failure to release in some patients may be due to a
combination of less traumatic surgery and platelets which are
relatively insensitive to releasing effects.
There was a small but statistically insignificant rise in STG
concentration following the induction of anaesthesia and this can
be attributed to platelet activity associated with the insertion of
venous and arterial catheters and the intravenous injection of
irritant anaesthetic agents. Venous thrombosis is a well
recognised phenomenon after injection of sodium pentothal, the
induction agent used in all the study patients. Gaseous agents such
as halothene, diethyl ether and cyclopropane tend to inhibit aggrega-
185
tion of platelets, but the effect appears to be outweighed by the
other factors promoting release.
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Further release continued as the operations progressed and the
concentrations peaked in the second intra-operative specimen.
This was the point at which the trauma had reached its maximum.
In the vascular surgical patients, the graft or endarterectomised
segment had been perfused for 5-10 mins by this stage and this is
reflected by the considerable rise in concentration in group 1
between the first and second intra-operative specimens. Evans and
56
Mustard have shown how prosthetic surfaces will induce platelet
aggregation and it is likely that there will be extensive aggrega¬
tion on the surfaces of large prosthetic arterial grafts. Similar
activity will also occur on the areas of collagen exposed during
endarterectomy as collagen is known to be a potent stimulator of
83,84
aggregation.
In group 1, patients showed significantly elevated concentra¬
tions, continuing in the immediate post-operative specimen. It is
unlikely to be due to the effect of heparin (as described in
Chapter I) as the same dose of heparin was given to group 2 patients
who did not demonstrate this phenomenon. More patients in group 1
than in the other groups received blood transfusions but it was not
possible to demonstrate any difference between those receiving
blood and those not transfused in any of the groups. This, too,
is unlikely to explain the persistently elevated concentrations.
Another possible factor is the extent of the trauma of surgery but
group 3 had a similar extent of trauma to group 1. Therefore, this
persistently elevated concentration is most probably due to
persisting platelet activity in the graft or endarterectomised
segment. Both types of reconstruction had similar release patterns.
141.
Although the group 2 patients had similar endarterectomised segments,
the surface area was so small as to be unlikely to produce such a
marked effect as in the group 1 patients.
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3. PLASMA BETATHROMBOGLOBULIN CONCENTRATION IN THE POST-OPERATIVE
PERIOD
Aim:
To study the effects of various factors on plasma BTG after
operation.
Methods:
The 117 patients in part 1 of this chapter were also studied in
the post-operative period. All patients were screened for DVT by
125
the IFT using the technique described in Appendix A. Blood
samples were drawn daily for BTG assay and full blood count,
including platelet count, for 1-3 days before operation and for up
to 10 days afterwards. A careful record was kept of all drug therapy,
transfusions, infective complications and the presence of infusion
phlebitis. Also recorded were the temperature, pulse rate and
results of any investigations of thromboembolic phenomena.
Results:
The two groups, summarised in Table 18, were analysed separately.
i) Population statistics
a) General surgical patients (GS). Six patients in this
group were technically unsatisfactory leaving 62 patients of whom
125
48 (29 female and 19 male) had negative IFTs and 14 (10 female
125
and 4 male) had positive IFTs.
The operations performed on these patients are summarised in
Table 18. The incidence of DVT in patients with malignant disease
(70%) was higher than in those with benign disease (13%) .
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Cholecystectomy ± duct exploration 3 27
Gastric procedures 2 13
Division of adhesions 2 1




Colon resections 2 2
Exploratory laparotomy ± colostomy 3 1
Total 14 48
TABLE 19: VASCULAR OPERATIONS
Operation No.
Carotid endarterectomy 20
Aorto-iliofemoral Dacron graft 11
Aorto-iliac endarterectomy 6
Peripheral minor Dacron grafts 6
Femoro-popliteal vein bypass 6
Total 49
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b) Arterial surgical patients (PVD). Six patients in this
group who underwent femoro-popliteal bypass were excluded as it
was not possible to scan the operated leg and a further four
patients who developed major post-operative complications have been
analysed separately. This left 39 patients of whom 28 (21 male
125
and 7 female) had negative IFTs and 11 (6 male and 5 female) had
125
positive IFTs. The operations performed on these patients are
summarised in Table 19.
ii) Patients with uncomplicated post-operative progress
Sixteen GS patients and 9 PVD patients had no post-operative
complications and received no heparin in the post-operative period.
Their post-operative BTG concentrations are shown in Figs. 32 and
33. The post-operative follow-up in the PVD patients is short as
the majority of the carotid endarterectomies, who form the bulk of
this group, were discharged within 4 or 5 days of operation.
In the GS patients the BTG concentration shows an early fall
with a later rise to peak on day 6. The rise did not reach
statistical significance. The PVD patients showed a similar
pattern but peaked on day 4. If the effect of the post-operative
rise in platelet count is eliminated by plotting the results as the
BTG/platelet ratio, a similar pattern is obtained (Figs. 34 and 35).
This suggests that the rise cannot be attributed to an elevated
platelet count alone.
iii) Infusion phlebitis
Thirteen GS patients developed tenderness and/or erythema over












Fig. 32: Median plasma 8TG concentrations and platelet counts in
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Fig. 33: Median plasma $TG concentrations and platelet counts in
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concentration showed a small but statistically insignificant rise
2 days after the phlebitis became clinically apparent.
iv) Drugs and blood transfusion
Numerous drugs were given in the post-operative period and no
consistent relationship with 3TG release could be identified. Only
two patients received blood in the post-operative period. Both
showed slightly elevated concentrations (80 and 159 ng/ml) during
the transfusion.
v) Infection
Seven patients developed clinically significant infections. In
two of these the infection was minor and localised. One had a
cough with purulent sputum and pyrexia of 38°C but no changes were
detectable on chest radiograph. The other developed a localised
wound abscess which discharged spontaneously. The other five
patients developed serious infections: three had lobar pneumonia
with pulmonary consolidation on radiograph, one developed a
subphrenic abscess and one an empyema thoracis due to accidental
perforation of the oesophagus at operation. The two patients with
minor infections showed no change in their $TG concentrations but
the five with serious infections showed rises in plasma 3TG concen¬
trations coinciding with the development of symptoms or signs of
infection. The median $TG concentrations are shown in Fig. 36.
This rise became significant by the day symptoms or signs had
developed (p < 0.05, Wilcoxon). A further six patients showed
evidence of minor wound sepsis with some induration and erythema of
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Fig. 36: Median plasma 3TG concentrations in 5 patients with
severe infections.
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vi) Effect of DVT prophylaxis
Four standard methods of DVT prophylaxis were used in this
survey. One group received intermittent pneumatic calf compression
with Roberts pumps during operation; a second group received
Dextran 70 in a dose of 500 ml during operation with a second dose
of 500 ml within 8 hours of completing the operation; the third
group received subcutaneous heparin in a dose of 5,000 units 8
hourly, starting 2 hours before surgery and continuing for 1 week
after operation; the fourth group wore graduated compression
stockings throughout their hospital stay and the fifth group
received no prophylaxis. The incidence of DVT is summarised in
Table 20.
Of the GS patients who had no post-operative complications, six
received Dextran 70, one received subcutaneous heparin, two received
pneumatic calf compression and seven received no prophylaxis. For
analysis I have included those receiving calf compression which I
regard as unlikely to affect platelet function, with those receiving
no prophylaxis and compared them to those receiving Dextran 70.
There was no significant difference in gTG concentrations on any of
the post-operative days between the groups (p > 0.1, Wilcoxon).
Subcutaneous heparin became the method of prophylaxis in our
PVD patients. One patient received a continuous heparin infusion
instead. Eleven PVD patients who received post-operative heparin
and developed no complications have been compared with seven PVD
patients who received no prophylaxis. Although the median $TG
concentration for the first 4 post-operative days was higher in those
152.




Group Method Negative Positive
GS Pneumatic compression 4 1
Dextran 70 28 4
Subcutaneous heparin 1 2
TED stockings 1 2
No prophylaxis 14 5
PVD Subcutaneous heparin 18 8
Intravenous heparin 1 0
No prophylaxis 9 3
Total 76 25
153.
who received heparin (60 ng/ml) than in those who did not (43 ng/ml),
the difference was not significant (p > 0.1, Wilcoxon).
vii) Wound haematoma
Four PVD patients developed large wound haematomata but this
did not produce any detectable change in plasma (3TG concentration.
Discussion
The results in the GS patients have been analysed separately
from the PVD patients as it has been demonstrated in sections 1 and
2 of this chapter that the release patterns are slightly different
for the two groups. Although both groups had a similar age
distribution there was a preponderance of females in the GS group
but a preponderance of males in the PVD group.
A consistent feature in those whose post-operative progress
was uncomplicated was the tendency for the plasma BTG concentration
to fall initially after operation only to rise again, peaking on day
4 in the PVD group and day 6 in the GS group. The parallel rise
of the BTG/platelet ratio indicates that this was not due purely to
39
the well recognised rise in platelet count which follows operation.
However, during this period there is a concomitant rise in platelet
adhesiveness which has been attributed to an increased proportion
153
of juvenile platelets. After acute blood loss in dogs there is
125 97
an increased proportion of large heavy platelets and Karpatkin
regards large heavy platelets as juvenile. He has also shown that
they are more active and will release more PF^ than small light
98
platelets. The elevated BTG concentrations may, therefore, be a
154.
manifestation of these active, high secreting platelets. Also
during this period the process of wound healing is continuing and
193
this is associated with a proliferation of small blood vessels
as the granulation tissue develops. These vessels are initially
small and fragile and this may be associated with some platelet
activity contributing to the rise in |3TG concentration.
In the early post-operative specimens (days 1 and 2) the $TG
level tends to be lower than even the pre-operative concentrations.
This implies a failure of release for which there are two possible
causes. A platelet refractory state has been described after
145
operation by O'Brien and after emotional stress by Haft and
71
Arkel. This will, therefore, reduce the extent of the normal
continuing platelet activity.
Other workers have also demonstrated that platelets which have
released in response to small doses of thrombin or plasmin may have
30,163
a normal survival and function. If the massive release seen
during operation (section 2 of this chapter) is release of this type
without aggregation there may be a high proportion of platelets with
low granule content. Aggregation of these platelets would be
associated with much less BTG release. However, the patients who
showed little release during operation also had low concentrations in
the early post-operative period suggesting that these patients had
platelets that were relatively resistant to aggregation.
Various other factors may affect the 3TG concentration after
operation. Infusion phlebitis produces a small but insignificant
rise but blood transfusion has a more pronounced effect. Numerous
155.
drugs were given in the post-operation period but it was difficult
to associate particular drugs with 3TG release. Heparin has been
shown to have an effect on BTG release (Chapter I, section 5) and
patients receiving heparin did tend to have a higher BTG concentra¬
tion. Dextran, however, despite its known effect on platelet
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adhesiveness, release and aggregation and factor VIII activity,
produced no detectable change in BTG concentration when given on the
day of operation.
The other major effect on BTG concentration in patients without
thrombotic disease appears to be infection. Whilst minor local
sepsis had little effect, major infections produced significant
release. The release coincided with the development of symptoms or
signs. There are several mechanisms by which this effect may be
66
produced. Tissue necrosis may result from serious infections and
this will be associated with thrombosis and BTG release. However,
infection has a more direct effect on platelets as demonstrated by
162
Reimann as long ago as 1924. He showed a marked fall in platelet
count during the fever of pneumococcal pneumonia with a rise following
the 'crisis'. In a study of human and porcine platelets, Movat et
129
al. showed that the phagocytosis of antigen-antibody complexes
could result in platelet release and aggregation. Further studies
on bacterial toxins, especially staphylococcal toxins, have shown
15 114
that they can produce platelet aggregation directly. '
This study shows that many factors affect the BTG concentrations
in convalescent surgical patients of which the most significant non-
thrombotic factor appears to be major sepsis. The patients,
however, showed widely varying BTG concentrations even in the absence
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of an obvious cause. This will severely limit the value of the
3TG concentration in the diagnosis of thrombotic disease.
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4. THE PREDICTION AND DIAGNOSIS OF POST-OPERATIVE DEEP
VENOUS THROMBOSIS
Aim:
To study the value of plasma $TG as a diagnostic or predictive
test of post-operative DVT.
Methods:
The patients identified in parts 2 (the study of intra¬
operative 3TG concentrations) and 3 (the study of post-operative $TG
125
concentrations) who developed positive IFTs were separately
analysed to assess the value of the 3TG concentration in i)
predicting the development of post-operative DVT and ii) diagnosing
post-operative DVT.
Results:
i) Prediction of post-operative DVT
Seven patients were identified in the intra-operative study who
developed DVT. Six underwent major arterial reconstructions and
one a colectomy. There was no difference in intra-operative 3TG
between those who did and those who did not subsequently develop DVT.
ii) Diagnosis of post-operative DVT
General Surgical patients. Fourteen patients developed
125
positive IFTs from 1 to 6 days after operation (mean 3.8 days,
SD1.8 days) and on the day of presentation 1 to 12 points (mean
4.3 points, SD 3.9 points) on the scans showed increased uptake.
The thrombi continued to extend over periods up to 6 days (mean 2.8
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days, SD 2.0 days) to a maximum extent of 1 to 22 positive points
(mean 9.4 points, SD 7.4 points). Active therapy, depending on
the site of the thrombus, was commenced as soon as the diagnosis
was made. Patients with thrombi confined to the calf were normally
treated by support and mobilisation but those with thrombi
extending to the popliteal vein or above received heparin therapy.
The incidence of DVT related to age is shown in Fig. 37.
There was no correlation between the plasma ftTG concentration
125
and the number of positive points on the IFT on the day the test
became positive (r = 0.11) or on the day the thrombus reached its
maximum extent.
If the four patients with complications (3 infection and 1 blood
transfusion) are excluded, the median ftTG concentrations rose slightly
125
on the day before the IFT became positive (Day -1) , reached a peak
on the day the scans became positive (DVT day) and fell thereafter
(Fig. 38). Although the $TG concentrations on Day 1 and DVT day
were not significantly different from any of the other post¬
operative days, they were significantly higher than the pre¬
operative levels in the same patients (p < 0.05, Wilcoxon).
There was no progressive rise or even maintenance of the levels in
those patients whose DVT extended.
Arterial Surgical patients. The incidence of DVT related to
age is shown in Fig. 39. The 11 patients showed similar patterns
of onset and progression as the General Surgical patients and again
showed poor corelation between plasma $TG concentration and extent
of the DVT at the time of onset (r = 0.18) or at its maximum extent
■DVT
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(r = 0.13). The median BTG concentrations, including two patients
with wound haematomata and five patients receiving subcutaneous
heparin, are shown in Fig. 40. There was no rise detectable in
relation to the onset of the DVT and none of the days showed
concentrations significantly different from the pre-operative
levels.
Discussion
Intra-operative $TG concentrations were of no value in the
prediction of post-operative DVT. The effects of other factors on
BTG during operation would mask any detectable change.
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Nicolaides has shown that 45% of leg scans were positive on the
day of operation and a further 43% within the first 4 days.
However, in the present study only 3 of 25 patients with DVT had
125
developed positive IFTs within 1 day of operation and, therefore,
one would be unlikely to find DVT-related changes in plasma BTG
during operation.
There appeared to be no correlation between the extent of the
DVT at the time of onset or at its maximum extent and the plasma BTG.
As these patients had considerable BTG release in relation to their
post-operative state, the additional BTG released by the thrombus
will not be in a sufficient excess to render close correlation.
Although the plasma BTG did tend to rise about the time the
125
IFT became positive, it was insufficiently reliable to be of any
diagnostic value. It is interesting to note that the plasma BTG
125
rose on the day before the IFT became positive suggesting that
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that the sensitivity of the test may be potentially better than the
125
IFT for early thrombus formation. There was no correlation in
the PVD patients and this probably reflects the rather higher 8TG
concentrations in these patients post-operatively.
125
A major criticism of the study is that the IFTs were only
performed on alternate days. However, for a short period
additional funds were available to allow daily scanning. Thirty-
one patients were, therefore, examined daily and six developed DVT.
125
The correlation between positive IFTs and plasma pTG in these
patients was no better.
Conclusion:
The plasma 3TG concentration appears to be a sensitive indicator
of platelet activity but is so lacking in specificity in the post¬
operative period as to be valueless in the diagnosis or prediction
of DVT.
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5. THE PREDICTION AND DIAGNOSIS OF POST-OPERATIVE ARTERIAL
THROMBOSIS
Aim;
To study the value of plasma £TG as a diagnostic or predictive
test of thrombosis of a graft or endarterectomised segment following
reconstructive arterial surgery.
Methods:
Four patients in the major arterial surgery group occluded
their grafts or endarterectomised segments within 24 hours of
operation. Thrombosis was diagnosed by the loss of a restored
pulse or the deterioration in clinical state of the limb following
reconstructive operation.
Results:
Scrutiny of the intra-operative and post-operative plasma 0TG
concentrations failed to reveal any significant difference between
the four patients who thrombosed their grafts and the 11 others
whose progress was uncomplicated. The levels in the four patients
with thrombosis tended to be higher but the overlap with the non-
thrombotic group was such that the test was not diagnostic. Three
of the non-thrombotic group developed major haemorrhagic problems
and all of them (as well as one in the group with graft thrombosis)




Again, the factors other than thrombosis that affect platelets
in the peri-operative period render the plasma $TG concentration of
no value in the diagnosis or prediction of graft occlusion.
However, a plasma 3TG concentration in excess of 1,000 ng/ml on the
immediate post-operative specimen suggests imminent major thrombotic
or haemorrhagic complications. This, however, is of little value
as such complications are usually clinically obvious.
167.
6. URINARY BETA-THROMBOGLOBULIN CONCENTRATIONS FOLLOWING
MAJOR ABDOMINAL SURGERY
Aim:
To assess the effects of post-operative factors on the urinary
0TG concentrations in patients without DVT and so indicate whether
further studies of the use of urinary $TG in the diagnosis of post¬
operative DVT are justified.
Methods:
Six patients were studied following major abdominal surgery.
125
Five had negative IFTs and one had a negative phlebogram. In
three patients urine samples were obtained every time the patient
passed urine from before operation until 3 days afterwards. One
patient had an indwelling catheter and samples were obtained every
4 hours. The total volume of each sample and the time it was
passed were recorded and an aliquot removed for $TG assay. Plasma
samples were obtained at intervals during the urine sampling. The
other three patients developed painful calves at 4, 10 and 13 days
125
after surgery and had no evidence of DVT on phlebography or IFT.
Plasma and urine samples were obtained at the time of the calf pain.
Results:
i) Population statistics
Three males and three females aged 36-76 years (mean 66 years,
SD 7.5 years) were studied.
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ii) Urinary BTG
In the three patients intensively screened for 4 days all the
pre-operative concentrations were within the normal range. One
patient (3) had a urinary catheter inserted immediately after surgery
and, although his plasma $TG concentrations following surgery were
only just elevated, his urinary concentrations became very high.
Inspection of the urine revealed microscopic haematuria presumably
associated with the indwelling catheter. One patient (2) without
complications developed high urinary 0TG concentrations after
operation and the other patient (1), who developed a faecal fistula,
had normal urinary and plasma f3TG concentrations throughout. The
plasma and urine levels in patients 1 and 2 are shown in Fig. 41.
The three patients (4, 5 and 6) investigated for calf pain 4, 10
and 13 days after surgery all showed elevated urinary concentrations.
The data on these patients are summarised in Table 21.
Discussion
The urinary concentrations tended to follow the plasma
concentrations in the post-operative period. None of these
patients had detectable DVT but they all showed elevated plasma
and urine concentrations, except patient 1 who showed no release
during or after surgery. Despite the consistently elevated plasma
concentrations in patient 2, the urine concentrations showed very
marked fluctuations in concentration indicating a very variable
platelet activity. The patient with the indwelling catheter
showed quite markedly elevated urinary concentrations in the
specimens in which blood was detectable.
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In the patients studied late in the post-operative period the
urinary concentrations were still elevated despite some normal
plasma concentrations. This is evidence of persisting episodic
release continuing in these patients.
Conclusion:
The measurement of urinary 3TG, although of value in diagnosing
DVT, as I have shown in Chapter II, is beset by a similar lack of






The studies described in Chapter III showed that patients with
peripheral arterial disease tend to have more persistently elevated
plasma BTG concentrations than those without clinical evidence of
arterial disease. Why might this be so? There are two
possibilities.
1) Atherosclerosis develops as a result of increased platelet
49
activity. In 1946 Duguid suggested that many of the lesions we
now classify as atherosclerosis are arterial thrombi which, by the
ordinary processes of organisation, have been transformed into
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fibrous thickenings. More recently, Carstairs and Woolf have
been able to demonstrate platelet antigens in fibrolipoid plaques
but not in fatty streaks. Atherosclerosis may develop as a result
of increased platelet activity and, therefore, patients with more
extensive disease may have greater platelet activity detectable by
elevated plasma 0TG concentrations.
2) Atherosclerosis results in widespread endothelial damage which
causes increased platelet activity. A good example of platelet
activity resulting from atherosclerosis is the condition amaurosis
fugax where platelet emboli pass to the retina from the ulcerated
61
plaque in the internal carotid artery. Those with more extensive
disease may be expected to have more evidence of platelet activity.
133 2
Murphy and Abrahamsen have shown a reduced platelet survival in
173.
patients with atherosclerosis and spontaneous platelet aggregation
194 149
has also been demonstrated. Ward and Olcott have shown an
increased aggregability in response to ADP and adrenaline in
patients with more extensive disease than in those with minor forms.
Other authors have already shown some relationship between
92 119
plasma $TG concentration and arterial disease. '
If the extent of the atherosclerosis is related to plasma STG
it might be a useful screening test to detect those at risk of major
complications in whom appropriate therapy may limit progression.
Aims :
To answer the following questions:
1) Is atherosclerosis associated with evidence of platelet activity?
2) If so, is the 3TG level related to the extent of the disease?
METHODS:
Eighty-five consecutive patients attending a peripheral
vascular clinic with a complaint of limb pain were studied. Plasma
and urine samples were obtained from them in the standard fashion
and assays were performed for plasma and urine $TG and PF^. A
platelet count was performed on a portion of the sample. On the
basis of the history, physical examination and investigation, the
patients were allocated scores for the extent of their vascular
disease.
One point was scored for evidence of vascular disease in each
of the following areas:-
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Carotid or cerebral vessels
Each upper limb
Coronary vessels
Aorta and visceral branches
Each iliofemoral segment
Each leg below the common femoral bifurcation
The maximum possible score was 9 but no patient scored more than 7.
This scoring system therefore produced 8 groups of patients 0-7.
The criteria of arterial disease were as follows:-
in a limb - the presence of bruits, the absence of pulses or a
reduction in arterial pressure index.
in the carotid or cerebral circulation - the history of stroke
or transient ischaemic attack, the presence of carotid bruits
or the absence of carotid pulses.
in the coronary circulation - a history of angina or proven
myocardial infarction or the presence of ischaemic changes on
an electrocardiogram.
Patients with aneurysmal disease were excluded and angiographic
findings were not considered as few patients were subjected to this
investigation.
Group 0 (those without evidence of atherosclerosis) was divided
into two sub-groups. The first sub-group (A) was composed of 10
patients who acted as 'controls'. These patients were suffering
from limb pain due to predominantly musculo-skeletal disorder such
as lumbar spondylosis, osteoarthritis, cervical ribs or peripheral
neuropathy and had no evidence of vascular disease. The second
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sub-group (B) comprised 10 patients without major arterial disease
but who had vascular diseases such as varicose veins or vasospastic
disorders.
A record was also made of all the patients' smoking habits, any




The incidence of smokers in each group varied from 50% in group
OA to 100% in groups 6 and 7 (Fig. 42).
The mean age varied from 48.7 years in group OB to 74.7 years
in group 3. Again this variation did not reach statistical
significance between the control group OA and any of the other
groups. The mean age in group OB, however, was significantly lower
than in groups 3, 4 and 5 (Student's t test, p < 0.05).
No patients were on anticoagulants and only two received any
drugs known to affect platelet function - one patient in group 7 on
Aspirin and one in group 3 on Naprosyn.
ii) Plasma (3TG
Three patients - two in group OA and one in group 2 - had
plasma $TG concentrations > 1,000 ng/ml. These have been excluded
for reasons explained later.' The results have been shown in Fig.
43. There was no significant difference between any of the groups
with the exception of between group 2 and groups 1, OA and 0B
(p 0.05, Wilcoxon). However, when those with minimal disease
176.
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Fig. 43: Plasma 6TG concentrations by clinical group in athero-
sclerotics. Median concentration indicated in each group.
/
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(groups OA, OB and 1) were compared with those with more extensive
disease (groups 2-7), the difference was highly significant
(t = 3.36, p = 0.0012) .
Figure 44 shows the proportion of patients in each group who
had abnormal 0TG concentrations (> 80 ng/ml). This varied from 38%
in group 1 to 78% of group 3. There was no significant difference
between the groups (X2 distribution on 2 x 2 tables, p > 0.1),
although there was a slight tendency for a higher proportion of the
patients with more extensive disease to have abnormally high
concentrations compared to the control groups.
The plasma 0TG concentrations did not correlate with smoking
nor with age (r < 0.1) even in groups OA and 0B.
iii) Plasma PF :
The plasma PF^ results gave similar distributions to those of
0TG and did differentiate between those with extensive disease and
those with minimal disease. There was good correlation between
plasma 0TG and PF^ throughout the study with correlation coefficients
varying from 0.43 in group 1 to 0.98 in group 5. The correlation
coefficient for the whole series was 0.79.
iv) Urine 0TG:
Only six urine samples gave concentrations in excess of 0.21
ng/ml and these were distributed in groups 1-5. No abnormal
concentrations were detected in groups OA, 0B, 6 or 7.




OAOB 1 2 3 4 5 68.7 group
Fig. 44: Incidence of abnormal plasma $TG concentrations (per cent
> 80 ng/ml) by clinical group in atherosclerotics.
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DISCUSSION
The most difficult part of the study is the quantification of
the arterial disease as no satisfactory technique exists at present
apart from extensive autopsy dissections. Angiography gives a good
impression of the extent of vascular disease but total body contrast
radiology is impractical and, in fact, few of our patients required
any form of angiography.
Various authors have devised different ways of assessing the
extent of arterial disease and some of them have even classified
the extent of this generalised disease purely on the clinical
194
findings in one part of the body. Ward gave little indication
of how he classified his patients but he seemed to grade them on the
basis of clinical examination, the ankle pressure index, presence
of myocardial ischaemia and the history of smoking. However,
149
Olcott avoided the issue by classifying them into 'mild' if they
had detectable disease at one site and 'severe' if they had
31
detectable disease at more than one site. Cella et al.
classified the extent of the arterial disease on the claudication
distance. Severe claudication can be caused by very localised
lesions and this classification, too, seems unsatisfactory.
The classification devised for this study attempts to take
account of the generalised nature of the disease, but even so there
are major fallacies. It is based, along with the others quoted,
on the clinical consequences of significantly reduced blood flow.
However, one would expect platelet activity to be related to the
surface area of abnormal endothelium and in patients with
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atherosclerosis there may be extensive endothelial damage without
significant alterations in blood flow. This classification
depends on the assumption that larger areas of endothelial damage
are present in patients with tight stenotic lesions or occlusions.
Another problem with the classification is the interpretation
of the electrocardiogram. ST and T wave changes are entirely non¬
specific and were discounted unless they represented a change from
a previous ECG. The site of a lesion is also important. A minor
lesion in a cerebral vessel may produce a major clinical event
whereas a much more extensive lesion in the lower limb may be
entirely asymptomatic. This system of classification is,
therefore, a compromise.
The plasma assays in three patients have been excluded from
the analysis - two in group OA and one in group 2. All three had
0TG concentrations of 1,000 ng/ml or greater and are grossly
different from the other concentrations in the same groups. All
three samples were processed in the same batch and it is assumed
that there has been a technical error in the processing of the
specimens.
There did tend to be higher BTG concentrations associated with
more extensive disease and this reached significance for groups 2-7
compared to groups OA - 1. Less than the 50% of the patients in
groups OA, OB and 1 had abnormal BTG concentrations whereas groups
2-5 showed elevated concentrations in over 60%. There were
insufficient patients in groups 6 and 7 to allow valid analysis.
The plasma BTG concentrations did, therefore, tend to be higher in
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those with scores 2 and above than in those with minimal disease.
The 40% incidence of abnormal STG concentrations in the control
groups (OA and OB) is much higher than in the normal range.
However, the age range in group OA, although older than the normal
109
group, was similar to the atherosclerotic patients. Ludlam has
shown that $TG tends to rise with age and this may be a manifestation
of subclinical atherosclerosis. Group OB patients were younger but
they did have other vascular diseases (acrocyanosis and Raynaud's
disease) which may be associated with platelet activity. I was
unable to correlate the plasma $TG concentration with age unlike
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Ludlam. This may be due to the extensive vascular disease
present in many of these patients.
Only 7% of patients had abnormal urinary $TG concentrations
suggesting that the platelet activity detected by the plasma f3TG
concentrations is not sustained. Although significantly elevated
concentrations can be detected in patients with extensive disease,
some patients had normal concentrations. This implies that the
activity is episodic and insufficient to produce elevated urinary
concentrations. The DVT patients, although having similar plasma
concentrations, have more consistently elevated urinary concentra¬
tions indicating a more continuous platelet activity.
The wide scatter of abnormal plasma concentrations detected
throughout the study show either that the classification bears no
relationship to platelet activity or that the classification is not
a true measure of the severity or extent of the disease. The study,
in fact, may have been dealing with patients who had similar areas of
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abnormal endothelium despite widely varying clinical presentations.
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Cella et al. found a significantly increased plasma 0TG in a
group of patients with peripheral vascular disease compared to
controls but only a third of the patients had elevated concentra¬
tions. Their controls, however, were healthy and were approximately
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half the age of the patients. Zahavi and Kakkar were able to
relate the magnitude of the rise of 0TG to the ankle systolic
pressure index. Both these studies do not seem to relate the plasma
0TG to the true extent of the arterial disease. Zahavi, in fact,
may be correlating the rise in plasma 0TG to the extent of ischaemic
tissue.
Another aspect of the platelet-atherosclerosis relationship is
the role of the platelet in the development of the atherosclerotic
204
lesions. Woolf was able to demonstrate platelet antigens using
antiplatelet globulin in atherosclerotic plaques and it may be that
atherosclerosis is a late manifestation of mural platelet thrombus.
Enhanced platelet aggregability, reduced survival or elevated plasma
0TG may be an aetiological factor in atherosclerosis. However, as
we know there is extensive platelet activity on mature atherosclerotic
plaques, it is impossible to differentiate between causative and
resultant platelet abnormality. Only a prospective study of
patients as they develop atherosclerosis could solve that problem
and it is beyond the scope of this study.
All that can be concluded from this study is that patients with
extensive symptomatic atherosclerosis tended to have higher plasma
0TG concentrations than those with less extensive disease. No




THE INFLUENCE OF SAMPLING METHODS:
1. The addition of prostaglandin El to the combination of EDTA and
theophylline added little to the stability of normal platelets but
it was of value in the samples from patients with DVT. Even so,
the period of platelet stability in this mixture of three chemicals
was only about 24 hours at 4°C. In this study the plasma was always
separated within 12 hours and usually within 3 hours.
2. Adding the anticoagulant mixture to the syringe did not
significantly affect the plasma 0TG concentration but it did
eliminate the spuriously and inexplicably elevated results which
occurred occasionally throughout the study. A possible explanation
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of these high results has been provided recently by Rasi who
showed that there may be enrichment of the top third of the plasma
by platelet debris after centrifugation. He now recommends sampling
the middle third of the plasma supernatant whereas we sampled the top
third throughout the study. The syringe tests showed that little
release occurs until at least 4 mins have elapsed and most samplings
are completed in no more than 1 min.
3. Venous stasis for the purpose of blood sampling has no effect
on plasma (3TG, nor does the presence of indwelling catheters.
Sampling through an indwelling catheter however is unreliable due to
platelet release in the catheter system.
4. Because the distribution of $TG concentrations in normals was
grossly skewed, the normal range was arbitrarily set at a level to
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include 95% of the samples. This gives an upper limit of normal
for plasma (3TG of 80 ng/ml and for urinary $TG concentrations of
0.21 ng/ml. The Radiochemical Centre RIA Kit was consistently
less sensitive than the local MRC radioimmunoassay. The gTG
excretion rate in normals correlated well with the urinary 3TG
concentration but less well with the urine flow rate. Measurement
of urinary 3TG concentration alone gives a good indication of the
rate of 3TG excretion.
5. Following the infusion of a 3TG load the clearance of the
plasma 3TG is closely followed by its appearance in the urine.
Following an initial phase of redistribution it is cleared from the
plasma with a half life of about 80 mins. Only about one fifty-
thousandth of the infused dose appears in the urine.
6. The correlation between plasma 3TG concentration and platelet
count was poor at normal platelet counts but much better in
thrombocytopenic patients. There is no need to correct plasma 3TG
for platelet count unless the platelet count is unduly low. There
was no relationship between plasma and serum concentrations of 3TG.
7. Aspirin had no effect on plasma 3TG concentration or on the
syringe test in contrast to Heparin which was often followed 6-8
hours after injection by 3TG release. The interpretation of plasma




1. The plasma gTG concentration was of little value in the
diagnosis of venous thromboembolism. Only 63% of patients with DVT
had raised concentrations and 44% of those without had a positive
result. This test does not reach a useful level of diagnostic
accuracy. The urine gTG concentration is a more valuable test as
95% of those with DVT, but only 28% of those without, had elevated
concentrations. A normal concentration virtually excludes a diagnosis
of venous thromboembolism but a raised concentration indicates the
need for further more specific investigations such as phlebography.
This suggests that the measurement of the urine gTG concentration
would be a useful preliminary screening test in patients suspected
clinically of having venous thromboembolic disease.
2. Syringe tests on patients with acute DVT showed rapid release
patterns indicating a higher population of more active platelets.
PERIOPERATIVE PATIENTS:
1. Admission to hospital is associated with gTG release in about a
third of patients. The operation produces a marked rise in $TG
concentration depending on the extent of the surgical trauma. The
more extensive procedures - particularly arterial reconstruction -
tended to have higher levels and more prolonged periods of raised
plasma f3TG concentrations.
2. Following operation the plasma BTG concentration fell initially
but rose again to peak about days 4-6. Infusion phlebitis, blood
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transfusion and the use of subcutaneous heparin produced small rises
in plasma $TG concentration. Minor infections had little effect but
markedly elevated concentrations were found in patients with major sepsis.
125
3. Post-operative DVT diagnosed by the IFT was associated with
a small rise in plasma $TG but this was not diagnostic. Plasma &TG
also failed to predict or diagnose the thrombosis of arterial
reconstructions.
4. Urine |3TG concentrations were affected by the same factors as
plasma 0TG and hence were of no diagnostic value.
ARTERIAL DISEASE
The plasma |3TG concentrations could not be correlated with age
but patients with more extensive arterial disease detected clinically
tended to have higher concentrations. Some patients without
clinically detected arterial disease but with other conditions also
had elevated 3TG concentrations. Very few patients had elevated
urinary concentrations.
THE FINAL CONCLUSIONS OF THIS STUDY ARE:
1. The plasma STG concentration is a sensitive indicator of
platelet release and may be of value in carefully controlled
experimental situations.
2. The plasma (3TG concentration is of no value clinically in the
diagnosis of venous or arterial thromboembolic disease.
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3. The urinary 3TG concentration may be of use clinically as an





125I FIBRINOGEN UPTAKE TEST
On the day prior to operation the patient was given 110 yCi of
125
I fibrinogen (Radiochemical Centre, Amersham) intravenously.
The patient's legs were then marked with indelible crosses at 5 cm
intervals from the posterior aspect of the knee joint down the
middle of the back of the calf to the ankle and at 5 cm intervals up
along the medial aspect of the thigh in the line of the femoral vein
to within 10 cm of the inguinal ligament. The first scan was
performed later the same day.
Using a Pitman Ratemeter the maximum precordial count was
obtained and the ratemeter was set to record this as 100%. With
the patient's legs elevated to 30° - 40°, counts were obtained at
the marked points on each leg and recorded as a percentage of the
maximum precordial count.
The scans were repeated on day 1 after operation and on
alternate days thereafter. If the scan became positive, daily
scanning was performed.
A scan was classified as positive if it fulfilled one or more
of the following criteria maintained for at least 24 hours:
1. a rise of 20 percentage points relative to the same area on
the pre-operative scan.
2. a rise of 20 percentage points relative to the adjacent areas.
3. a rise of 20 percentage points relative to the same area on
the opposite leg on the same day.
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Scanning continued until day 11 or until the day the patient
was discharged from hospital.
The thyroid was blocked with iodide - potassium iodide, 60 mg
t.i.d. orally or sodium iodide, 100 mg b.d. intravenously - before
and during the period of scanning.
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APPENDIX B
THE RADIOIMMUNOASSAY FOR BETA-THROMBOGLOBULIN
Venous blood was collected using 21 gauge needles and
polypropylene syringes and 2.7 ml were transferred immediately to a
siliconised glass tube containing 0.1 ml of 10% EDTA, 0.1 ml of
1 Jig/ml prostaglandin E^ and 0.1 ml of 30 mM theophylline maintained
below 4°C in melting ice. After mixing and within 12 hours the
sample was centrifuged at 1,900 g for 1 hour at 0°C and the top
third of the platelet poor plasma removed for assay.
Aliquots of plasma (0.01 ml) were taken and diluted to 0.2 ml
with 0.05 M sodium phosphate buffer, pH 7.5, containing 2% horse
125
serum. I labelled purified pTG was added in 0.05 ml of diluent
followed by 0.25 ml sepharose-coupled rabbit anti-|3TG antiserum at a
dilution to bind about 50% of tracer. The tubes were mixed gently for
1 hour; the antibody-bound protein was separated from the free 3TG
125
by centrifugation and the I in the residue (antibody-bound fraction)
was measured.
Using graphs prepared from standard concentrations, the




All statistical analyses were performed with a 'Commodore'
pre-programmed statistical calculator.
Data suitable for analysis with a 2 x 2 table were assessed by
the X2 test using Yate's correction. If the total of the table was
< 20 or any individual cell had < 5, the Fisher Exact test was
used.
As most of the data on $TG concentrations did not conform to a
normal distribution, the median has been used throughout as a
summary statistic. Analysis was by the non-parametric Wilcoxon
Rank Sum tests. If the numbers in the groups exceeded 25 x 50,
the groups were 'normalised' by conversion to their natural
logarithms and then analysed by Student's t test. Much of the
population data did conform and was assessed by the t test without
prior 'normalisation'.
Correlation was assessed by the standard r coefficient which
assesses how closely the data corresponds to a straight line.
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APPENDIX D
REVIEW OF THE LITERATURE ON BETA-THROMBOGLOBULIN 1980-1983
Further investigations have been reported on the mixture used
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to stabilise the blood before plasma separation. Randi et al.
reported their comparison of EDTA and Theophylline with the combina¬
tion including Prostaglandin El. The mean value and the range were
significantly greater when the Prostaglandin was omitted. They also
commented on the value of the ratio of $TG to PF4. As PF^ is very
rapidly cleared from the circulation a rise in sample PF^ is more
indicative of in vitro release. Therefore a high 3TG:PF4 ratio
indicates in vivo rather than in vitro release. Contrary to
expectation they found a higher ratio without the Prostaglandin than
with it but this did not reach statistical significance. Franchi et
224
al. also confirmed the findings of this study by showing that ETP
produced significantly lower values than ET alone. In a study of
240
blood at room temperature, Turnbridge et al. showed that EDTA
enhanced platelet release and that citrate was marginally better at
preventing release. Prostaglandin El, however, successfully
stabilised the blood for up to 3 hours. They do suggest that a more
-6 -4
concentrated solution of prostaglandin be used (2 x 10 M or 2 x 10 M).
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Further comment on the $TG:PF4 ratio was made by Arocha-Pinango.
They showed occasional very high or very low ratios in normals which
further confirms the finding of this study of occasional spurious
results. They found the highest incidence of abnormal ratios in
pre-eclamptic patients and also in the puerperium. This suggests
that these patients have a high in vivo release as well as having
platelets which release very readily when handled. This could be due
ii
to the increased number of young, active platelets at these times.
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Kaplan and Owen, in a review article, make the very valid comment
that studies of the clearance of $TG and PF^ after serum infusions may
be affected by platelet release induced by thrombin in the serum. To
overcome that problem the blood was processed in plastic bags to which
the majority of the thrombin adheres. The thrombin is also rapidly
cleared from the circulation so that any effect would be short-lived.
If it did engender further release in vivo, this should not
significantly affect the clearance rate as it is assessed on the
plasma concentrations after the initial redistribution period of about
30 minutes. By that stage any effect of the thrombin should have
passed.
An extensive study of the effect of membrane active drugs on the
233
alpha granule release was reported by Prowse et al. This project
was stimulated by the marketing of a new platelet stabilising
anticoagulant containing Procaine (Thrombotect) which permitted room
temperature processing. They tested a wide range of membrane active
drugs including local anaesthetics, anti-malarials, beta-blockers,
anti-anginals, anti-inflammatories and anti-helminthics. With
increasing concentrations of the drugs, the initial membrane stability
induced changes to a state of membrane instability and rupture. Many
of the drugs which prevented aggregation did not prevent alpha granule
release. Procaine and the anti-malarials, such as hydroxychloroquine,
prevent $TG ancj pp^ release at 20°C and therefore, if the blood is
stored at 0°C, it can be processed at room temperature. This avoids
the need for a cooled centrifuge.
iii
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Cella and Girolami studied the effect of different types of
heparin on platelet release. They confirmed the marked release of
PF^ which clears within an hour but failed to show any $TG release.
However, they only sampled for two hours and so may have missed the
late 3TG rise. They also looked at the effect of heparin on
aggregation and showed that, although adrenaline induced aggregation
was reduced, the response to collagen and ADP was enhanced. This
could possibly explain the late 3TG rise seen in the present study.
The reason for the marked PF^ release with heparin remains
229
controversial. Kaplan and Owen report that heparin does not
release PF^ in vitro and suggest that the PF^ is released from
endothelial binding sites. However, the process of preparation of
the platelets for in vitro studies may itself affect the platelets
and prevent them releasing the PF^. This would give a spurious
impression of lack of response to heparin.
Several groups have also studied the effects of Aspirin and all
of them have used more prolonged courses of Aspirin therapy than the
238
single dose used in our study. Santos et al. found that, after
receiving Aspirin in a dose of lg/day for three days, platelets from
healthy subjects showed a 31% reduction in (3TG release following
mechanical stimulation by stirring. There was no effect on plasma
$TG. Collagen and thrombin produced normal 0TG release whether or not
226
the platelets aggregated. Hoogendijk et al. were also unable to
demonstrate any change in plasma BTG after Aspirin in a dose of 200 mg
three times a day for one week in healthy subjects. These findings
correlate with the results of the present studies. There was no




In contrast, Viero et al. studied the effect of Aspirin in
abnormal platelet populations in patients with myeloproliferative
disorders. After Aspirin in a dose of 500 mg/day for 5 days they
showed that there was a reduction in plasma $TG but that it did not
reach normal levels. This indicates that Aspirin seems to have a
greater effect on abnormal platelets than on normal ones; a
property of therapeutic interest.
Further studies on the value of 0TG in the diagnosis of venous
thromboembolism have also been published. In 39 patients suspected
of having a DVT and 37 patients with symptoms suggestive of pulmonary
242
embolism, van Hulsteijn et al. quote a remarkable 100% sensitivity
and 96% specificity for the plasma STG assay. The 26 patients with
proven DVT had had symptoms for up to three days and in 5 patients
the thrombus was confined to the calf. This is in marked contrast
to the 71% sensitivity and 56% specificity in our study in a similar
group of patients. They also found raised plasma $TG concentrations
in patients with septic arthritis, rheumatoid arthritis and
malignancy but found that diminished renal function did not affect
it. A study of 36 patients after total hip replacement by Lane et
230
al. showed that all patients had elevated plasma pTG. The 13
who developed DVT had slightly higher concentrations but this did
218
not reach statistical significance. de Boer et al. found the
assay to be less reliable than van Hulsteijn in the diagnosis of 52
patients with DVT. They found the sensitivity of the plasma $TG to
be 35% and the specificity to be 80% but with the urine assay they
V
had a sensitivity of only 37% but a specificity of 100%. These
latter urine results contrast slightly with the sensitivity of 95%
and the specificity of 72% of our study. However, they also
comment that a third of patients, both with and without DVT, showed
considerable variations from day to day. The diagnosis of DVT
after elective operation in 36 patients using the $TG concentration
of an early morning urine specimen was investigated by Bolton et
215
al. They found a specificity of 83.3% and a sensitivity of
87.5% for the test. However, they did find that 92% of patients had
a rise in BTG after operation. By the third post-operation day 94%
of these raised concentrations had returned to normal. In the
present study the post operation urinary BTG sampling was discontinued
after 3 days as the results were variable. If sampling had been
continued in this group, some useful data may have been obtained.
BTG passes into most body fluids including saliva and Cooke et
217
al. report on a rather novel approach to the diagnosis of post-
operation DVT. They assessed the salivary BTG j.n 10 patients
following hip surgery and showed that the 6 patients who developed
DVT all had markedly elevated BTG concentrations whereas 3 of the 4
without DVT had no rise. This technique has the potential benefit
of avoiding the problem of in vitro release but could well be
affected by minor local pathology in the mouth such as ulceration.
A follow-up study on plasma BTG concentrations after venous
thromboembolism in non-surgical patients was reported by van Hulsteijn
241
et al. who found that all patients had elevated plasma BTG on
admission, only half still had elevated concentrations at 10 days
and all had returned to normal by one year.
vi
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Farrell et al. report an interesting study on lung diseases
diagnosed by ventilation and perfusion scanning. They found that
the plasma BTG concentrations were similar in patients with pulmonary
embolism and non-embolic parenchymal lung disease but that these two
groups differed significantly from normal. However, the overlap
between the groups with lung disease and the normals was considerable
which rendered the test of no clinical value.
Oestrogen-containing oral contraceptives are a known risk
221
factor for the development of DVT and Duncan et al. have studied
the plasma BTG concentrations in a group of women using oral
contraceptives and another group of smokers. They demonstrated
elevated concentrations in smokers with even higher concentrations
in those using oral contraceptives. However, patients who smoked
and used oral contraceptives had the same concentrations as those
who only smoked. A suggestion by the authors that the plasma BTG
may be a useful screening test for at risk groups is contentious on
two grounds. In the first case they were unable to show any
correlation between the plasma BTG concentration and the oestrogen
content of the oral contraceptive used. DVT is significantly commoner
with the high oestrogen content preparations. Secondly, evidence from
132 175
some of the major trials of DVT prophylaxis ' suggests that
smokers have a reduced incidence of deep vein thrombosis although they
do have an increased risk of arterial thrombosis. It is interesting
221
that in the study of Duncan et al. smoking partly corrected the
abnormality produced by the oral contraceptive.
Major infection seemed to be a potent cause of BTG release in
our post-operation study although minor local sepsis seemed to have
vii
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no effect. van Hulsteijn et al. studied 20 patients with
bacterial infections and found that only 3 had persistently elevated
237
plasma gTG concentrations. Rasi et al. however showed that
significantly elevated concentrations were found commonly in
patients with septicaemia but less often in patients with pneumonia.
They showed that the platelet count tends to rise after the first
three days but were unable to correlate this closely with the gTG
concentration. They comment, "Plasma gTG is not methodologically
influenced by the platelet count." This supports the statement on
page 51 of this thesis. In 5 patients with thrombocytopenia due to
acute leukaemia they found low gTG concentrations, similar to the
levels found in the patient with thrombocytopenia reported in this
study.
A further study of the effect of prosthetic cardiac valves on
234
plasma gTG has been reported by Pumphrey and Dawes who showed a
gradation in concentrations from the normal, through patients with
heterografts and single mechanical valves, to those with double
mechanical valves. They found that the plasma gTG was significantly
higher in patients who embolised while on anticoagulants than in
those who did not. Plasma gTG may therefore be a method of
screening for patients at risk of embolism.
The effect of myocardial and coronary artery disease on plasma
231
gTG remains contentious. Nichols et al. in an angiographic study
could not relate plasma gTG to the extent of angiographically proven
coronary artery disease but did relate it to the extent of regional
228
myocardial dysfunction. In contrast, Hughes et al. in a study of
viii
exercise induced myocardial ischaemia, failed to correlate the plasma
$TG with the extent of post-exercise ischaemia on ECG but did relate
it to the extent of coronary artery disease seen on angiography. In
both these studies the correlation was not close (r = 0.53) but was
significant.
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In acute myocardial infarction Hughes et al. showed that
plasma $TG was elevated in only about half of the patients whereas a
sixth of patients with non-coronary chest pain had elevated
236
concentrations. However, Rasi et al. using their own assay,
found that 72% of patients with acute myocardial infarction, had
elevated plasma $TG Qn the day of presentation. They felt that the
plasma $TG was proportional to the extent of myocardial damage or
stress to the body but make the telling comment, "The clinical
usefulness of the test is not straightforward."
A study of the effect of exercise in patients with peripheral
213
arterial disease was reported by Baele et al. who showed a
significant rise after 5 minutes of treadmill exercise. This rise
may be indicative of increased platelet damage in a hyperdynamic,
diseased peripheral circulation. If platelets are involved in the
28 49 204
development of atherosclerosis as suggested, ' ' increased
platelet activity may result in a worsening of the disease process.
However, there is no clinical evidence that exercise causes peripheral
arterial disease to progress more rapidly.
219 239
Most people with stroke tend to have normal 3TG concentrations '
239
but Stewart et al. did show that patients who had further
"vascular events" had significantly elevated $TG concentrations.
ix
These studies are all beset by the problems outlined in the
section on arterial disease. All patients with arterial disease
have diffuse disease whicn may have a variable effect on the plasma
$TG outwith the effect of the disease in the area studied.
Several authors have reported on the effect of chronic renal
225 232 244
failure on plasma 0TG concentrations. ' ' The plasma 0TG
244
tends to be elevated in relation to the degree of renal failure.
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Both Guzzo et al. and Petralito et al. suggest that the rise
is due to impaired renal handling of 0TG rather than to increased
platelet activity. If this is correct, the kidney must be an
important site of 0TG metabolism as the serum infusion study showed
that only a tiny proportion of the infused $TG was excreted in the
225
urine. Guzzo et al. showed that in 3 patients with successful
renal transplants the plasma 0TG returned to normal.
Venous thrombosis is more common in patients with advanced
223
malignancy and so Farrell et al. assessed the platelet activity
in patients with malignant disease by the plasma 0TG. They showed
that the patients with advanced disease had higher concentrations
than those with early tumours. This may be due to platelet
activation in an extensive abnormal tumour circulation. The
patients in the surgical study in this thesis with malignant disease
had plasma $TG concentrations slightly lower but not significantly
different from those with benign disease. However, all these
patients had early tumours and would be expected to have normal
concentrations. Bidet et al.214 report some interesting studies on
the effect of chemotherapy. Despite maintenance of the platelet
X
count, the plasma gTG fell immediately after the first dose of
chemotherapy. It rose only to fall again after the second dose.
They raise the possibility of using the plasma gTG to assess the
tumour burden and the effectiveness of chemotherapy.
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Douglas et al. also investigated patients before operation.
They found that patients with operable malignancy had similar levels
to those with benign disease but that both groups had significantly
higher concentrations than the control group. The mean age of the
control group was significantly lower than the two study groups.
However, they showed that the correlation of age with the plasma
gTG is not very close (r = 0.33). This lends support to the
findings in this study of a raised plasma gTG on admission to
hospital, possibly on the basis of stress. They also showed that
infection resulted in a marked rise in plasma gTG.
In summary, much of the recent literature has produced findings
in agreement with many of the studies in this thesis.
The further studies on the anticoagulant "cocktail" indicate
that the Prostaglandin is probably beneficial but that other membrane
active drugs such as Procaine have interesting potential. Aspirin
appears to have little effect on plasma gTG in normal patients but
may reduce spontaneous release from diseased platelets. Heparin
also has little effect on short term gTG release. Most authors
quote a poor accuracy in the diagnosis of venous thromboembolism
using the plasma gTG which is in agreement with this study. The
urinary gTG seems to be marginally better. The interesting
suggestion that other body fluids such as saliva may yield
xi
diagnostically useful $TG concentrations deserves further study.
The clinical value of $TG assessment in patients with arterial
disease remains doubtful, presumably because of the extensive areas
of potential platelet activation. Most studies are concerned with
attempting to correlate plasma $TG with a small part of an extensive
abnormal circulation* However, in patients with prosthetic heart
valves, the plasma $TG may be of value in the detection of patients
at risk of peripheral embolism.
Renal failure appears to increase plasma $TG, probably by
reducing its metabolism by the kidney, and extensive malignancy is
also associated with raised levels. An interesting potential use
in the assessment of response to chemotherapy deserves further study.
These investigations further confirm the opinion expressed in
this thesis that the assessment of |3TG is of value in carefully
controlled experimental situations but that its clinical value is




1. Aberg, M., Nilsson, I.M. and Hedner, V. Antithrombin. III.
After operation. Lancet, ii: 1337, 1973.
2. Abrahamsen, A.F. Platelet survival studies in man, with special
reference to thrombosis and atherosclerosis. Scandinavian
Journal of Haematology, Suppl. 3.: 1-53, 1968.
3. Alkjaersig, N.A., Fletcher, A.P. and Sherry, S. The mechanism
of clot dissolution by plasmin. Journal of Clinical Investigation,
38: 1086-1095, 1959.
4. Anderton, J.L., Fananpazir, L. and Dawes, J. Urinary
3-thromboglobulin in essential hypertension. British Journal of
Haematology, 44: 307-311, 1980.
5. Armitage, P. Statistical Methods in Medical Research, Ch. 16, pp.
433-438. Blackwell: Edinburgh, London. 1971.
6. Ashford, T.P. and Freiman, D.G. The role of the endothelium in
the initial phases of thrombosis. An electron microscopic study.
American Journal of Pathology, 50: 257-273, 1967.
7. Atkins, P. and Hawkins, L.A. Detection of venous thrombosis in
the legs. Lancet, 1217-1219, 1965.
8. Barnhart, M.I., Cress, D.C., Henry, R.L. and Riddle, J.M.
Influence of fibrinogen split products on platelets. Thrombosis
et Diathesis Haemorrhagica, 17: 78-98, 1967.
9. Becker, J. The relation of platelet adhesiveness to post¬
operative venous thrombosis of the legs. A clinical study.
Acta Chirurgica Scandinavica, 138: 781-786, 1972.
194.
10. Becker, J. Fibrinolytic activity of the blood and its relation
to post operative thrombosis of the lower limbs. A clinical
study. Acta Chirurgica Scandinavica, 138: 787-792, 1972.
11. Begg, G.S., Pepper, D.S., Chesterman, C.N. and Morgan, F.J.
Complete covalent structure of human 8-thromboglobulin.
Biochemistry, 171739-1744, 1978.
12. Berberich, J. and Hirsch, S. Die rontgenographische Darstellung
der Arterien und Venen am lebenden Menschen. Klinische
Wochenschrift, 2.: 2226-2228, 1923.
13. Bergentz, S.E. Dextran in the prophylaxis of pulmonary embolism.
World Journal of Surgery, 2.: 19-25, 1978.
14. Bergqvist, D. , Efsing, H.O. and Tallbbbk, T. An evaluation of
thermography for the diagnosis of deep venous thrombosis and as
a screening instrument for post operative venous thrombosis.
In: New Trends in Venous Diseases (Ed. A. Kappert). Hans Huber,
Bern, pp 65-70, 1977.
15. Bernheimer, A.W. and Schwartz, L.L. Effect of staphylococcal
and other bacterial toxins on platelets in vitro. Journal of
Pathology and Bacteriology, 89_: 209-223, 1965.
16. Besterman, E.M. and Gillett, M.P. Heparin effects on plasma
lysolecithin formation and platelet aggregation. Atherosclerosis,
17: 503-513, 1973.
17. Bizzozero, G. Uber einen neuen Formbestandtheil des Blutes und
lessen Rolk bei der Thrombose und der Blutgerinnung. Archives
of Pathology and Anatomy, 90: 261-268, 1882.
18. Bolton, A.E., Ludlam, C.A., Moore, S., Pepper, D.S. and Cash, J.D.
Three approaches to the radioimmunoassay of human 3-thromboglobulin.
British Journal of Haematology, .33^ 233-238, 1976.
195.
19. Bolton, A.E., Ludlam, C.A., Pepper, D.S., Moore, S. and Cash, J.D.
A radioimmunoassay for platelet factor 4. Thrombosis Research,
g: 51-58, 1976.
20. Bonnar, J. and Walsh, J. Prevention of thrombosis after pelvic
surgery by Dextran 70. Lancet, i: 614-616, 1972.
21. Browse, N.L., Clapham, W.F., Croft, D.N., Jones, D.J., Lea,
Thomas, M. and Williams, J.O. Diagnosis of established deep vein
125 . .
thrombosis with the I fibrinogen uptake test. British
Medical Journal, g: 325-328, 1971.
125
22. Browse, N.L. and Clemenson, G. Sequelae of an I-fibrinogen
detected thrombus. British Medical Journal, g: 468-470, 1974.
23. Browse, N.L., Clemenson, G., Bateman, N.T., Gaunt, J.I. and
Croft, D.N. Effect of intravenous Dextran 70 and pneumatic leg
compression on incidence of postoperative pulmonary embolism.
British Medical Journal, g: 1281-1284, 1976.
24. Browse, N.L., Gray, L., Jarrett, P.E.M. and Morland, M. Blood
and vein-wall fibrinolytic activity in health and vascular
disease. British Medical Journal, 1.: 478-481, 1977.
25. Burch, J.W., Stanford, Nancy and Majerus, P.W. Inhibition of
platelet prostaglandin synthetase by oral aspirin. Journal of
Clinical Investigation, 6^: 314-319, 1978.
26. Bygdeman, S. Experimental studies on the antithrombotic effect
of Dextran. Acta Chirurgica Scandinavica, Suppl. 387: 44,
1968.
27. Campbell, I.W., Dawes, J., Fraser, D.M., Pepper, D.S., Clarke, B.F.,
Duncan, L.J.P. and Cash, J.D. Plasma B-thromboglobulin in
diabetes mellitus. Diabetes, 26: 1175-1177, 1977.
196.
28. Carstairs, K.C. The identification of platelets and platelet
antigens in histological sections. Journal of Pathology and
Bacteriology, 90: 225-231, 1965.
29. Cash, J.D., Woodfield, D.J., Das, P.C. and Allan, A.G.E.
Diagnosis of suspected or occult pulmonary embolism. British
Medical Journal, 2-. 578, 1969.
30. Cazenave, J-P, Reimers, H-J., Greenberg, J., Niewiarowski, S.,
Packham, M.A. and Mustard, J.F. Modification of platelets that
affect platelet adherence to collagen or damaged aorta and
platelet survival (Abstract). Thrombosis et Diathesis
Haemorrhagica, 34: 907, 1975.
31. Cella, G., Zahavi, J., De Haas, H.A. and Kakkar, V.V.
Beta-thromboglobulin, platelet production time and platelet
function in vascular disease. British Journal of Haematology,
43: 127-136, 1979.
32. Clarke, R.L., Orandi, A. and Clifton, E.E. Induction of
fibrinolysis by venous obstruction. Angiology, 11: 367-370,
1960.
33. Clayton, S. and Cross, M.J. The aggregation of blood platelets
by catecholamines and by thrombin. Journal of Physiology
(London), 169: 82P, 1963.
34. Conley, C.L., Hartman, R.C. and Lalley, J.S. The relationship
of heparin activity to platelet concentration. Proceedings of
the Society for Experimental Biology and Medicine, 69: 284-
286, 1948.
35. Coon, W.W. and Coller, F.A. Some epidemiological considerations
of thromboembolism. Surgery, Gynecology and Obstetrics, 109:
487-501, 1959.
197.
36. Covey, T.H., Sherman, L. and Baue, A.E. Low dose heparin in
post operative patients. A prospective, coded study. Archives
of Surgery, 110: 1021-1026, 1975.
37. Davey, M.G. and Lilscher, E.F. Release reactions of human
platelets induced by thrombin and other agents. Biochimica et
Biophysica Acta, 165: 490-506, 1968.
38. Davies, G.C., Sobel, M. and Salzman, E.W. Elevated plasma
fibrinopeptide A and Thromboxane B2 levels during cardiopulmonary
bypass. Circulation, 61: 808-814, 1980.
39. Dawbarn, R.Y., Earlam, F. and Evans, W.H. The relation of
blood platelets to thrombosis after operation and parturition.
Journal of Pathology and Bacteriology, 31: 833-873, 1928.
40. Dawes, J., Smith, R.C. and Pepper, D.S. The release, distribution
and clearance of human 8-thromboglobulin and platelet factor 4.
Thrombosis Research, 12: 851-861, 1978.
41. Dawes, J., Smith, R.C., Borsey, D. and Aronstam, D. The value
of urinary B-thromboglobulin measurements in clinical situations
(Abstract). Thrombosis and Haemostasis, 42: 147, 1979.
42. Denham, M.J., Fisher, M., James, G. and Hassan, M.
B-thromboglobulin and heparin neutralising activity test in
clinical conditions (Letter). Lancet, i: 1154, 1977.
43. Deykin, D., Chun, R., Lopez, A. and Silversmith, P. The role
of the liver in serum-induced hypercoagulability. Journal of
Clinical Investigation, 45: 256-263, 1966.
44. Dhall, D.P., Bennett, P.N. and Matheson, N.A. Effect of
dextran on platelet behaviour after abdominal operations.
Acta Chirurgica Scandinavica, Suppl. 387: 75, 1968.
198.
45. Dmochowski, J.R., Adams, D.F. and Couch, N.P. Impedance
measurement in the diagnosis of deep venous thrombosis.
Archives of Surgery, 104: 170-173, 1972.
46. Dormandy, J.A. and Edelman, J.B. High blood viscosity: an
aetiological factor in venous thrombosis. British Journal of
Surgery, 60: 187-190, 1973.
47. Dos Santos, R. Sur 1'arteriographie. Bulletin et M6moires de
la Societe National de Chirurgie, 61: 585-590, 1935.
48. Dos Santos, R. Phl£bographie d'une veine cave infSrieure
suturee. Journal d'Urologie Medicale et Chirurgicale, 39:
586-589, 1935.
49. Duguid, J.B. Thrombosis as factor in pathogenesis of coronary
atherosclerosis. Journal of Pathology and Bacteriology, 58:
207-212, 1946.
50. Duncan, A. Beta-thromboglobulin levels and oral contraception.
(Letter). Lancet, ii: 631, 1979.
51. Egeberg, 0. Inherited antithrombin deficiency causing
thrombophilia. Thrombosis et Diathesis Haemorrhagica, 13:
516-530, 1965.
52. Eika, C. Platelet refractory state induced by heparin.
Scandinavian Journal of Haematology, 9j 665-672, 1972.
53. Eisenberg, S. Changes in blood viscosity, haematocrit value
and fibrinogen concentration in subjects with congestive heart
failure. Circulation, 30: 686-693, 1964.
54. Essien, E.M., Cazenave, J.P., Moore, S. and Mustard, J.F.
Effect of heparin and thrombin on platelet adherence to the
surface of rabbit aorta. Thrombosis Research, 13. 69-78, 1978.
199.
55. Evans, G. and Irvine, W.T. Long term arterial graft patency in
relation to platelet adhesiveness, biochemical factors and
anticoagulant therapy. Lancet, ii, 353-355, 1966.
56. Evans, G. and Mustard, J.F. Platelet surface reaction and
thrombosis. Surgery, J34: 273-280, 1968.
57. Evans, G., Packham, M.A. Nishizawa, E.E., Mustard, J.F. and
Murphy, E.A. The effect of acetyl salicylic acid on platelet
function. Journal of Experimental Medicine, 128: 877-894,
1968.
58. Fearnley, G.R., Balmforth, G. and Fearnley, E. Evidence of a
diurnal fibrinolytic rhythm; with a simple method of measuring
natural fibrinolysis. Clinical Science, ^6: 645-650, 1957.
59. Fenech, A., Hussey, J.K., Smith, F.W., Dendy, P.P., Bennet, B.
and Douglas, A.S. Diagnosis of deep vein thrombosis using
autologous indium-lll-labelled platelets. British Medical
Journal, 282: 1020-1022, 1981.
60. Field, E.S., Nicolaides, A.N., Kakkar, V.V. and Crellin, R.Q.
Deep vein thrombosis in patients with fractures of the femoral
neck. British Journal of Surgery, J59: 377-379, 1972.
61. Fisher, C.M. Observations of the fundus oculi in transient
monocular blindness. Neurology, 9333-347, 1959.
62. Flanc, C., Kakkar, V.V. and Clarke, M.B. The detection of venous
125 . . ,
thrombosis of the legs using I labelled fibrinogen. British
Journal of Surgery, _55: 742-747, 1968.
63. Fletcher, A.P., Alkjaersig, N., O'Brien, J. and Tulerski, V.G.
Blood hypercoagulability and thrombosis. Transactions of the
Association of American Physicians, 83^: 159-167, 1970.
200.
64. Gallus, A.S., Hirsh, J. and Gent, M. Relevance of pre operative
and post operative blood tests to post operative leg vein
thrombosis. Lancet, ii. 805-809, 1973.
65. Ganguly, P. and Sonnischsen, W.J. Binding of thrombin to human
platelets and its possible significance. British Journal of
Haematology, 34: 291-301, 1976.
66. Gillespie, W.A.G. Acute infections and wounds in Bailey &
Love's Short Practice of Surgery, 13th edn. (Eds. Rains 8c Capper).
Lewis, London, pp 1-21, 1965.
67. Grette, K. Studies on the mechanism of thrombin-catalyzed
haemostatic reactions in blood platelets. Acta Physiologica
Scandinavica, Suppl. 195: 1-93, 1962.
68. Gurewich, V. and Hutchinson, E. Detection of intravascular
coagulation by a serial dilution protamine sulphate test.
Annals of Internal Medicine, 75: 895-902, 1971.
69. Gurewich, V. , Hume, M. and Patrick, M. The laboratory diagnosis
of venous thromboembolic disease by measurement of fibrinogen/
fibrin degradation products and fibrin monomer. Chest, 64:
585-590, 1973.
70. Hadfield, G. Thrombosis. Annals of the Royal College of
Surgeons of England, 6: 219-234, 1950.
71. Haft, J.I. and Arkel, Y.S. Effect of emotional stress on
platelet functions in humans. (Abstract). Thrombosis et
Diathesis Haemorrhagica, 34: 890, 1975.
72. Hamer, J.D., Ashton, F. and Meynell, M.J. Factors influencing
prognosis in the surgery of peripheral vascular disease:
platelet adhesiveness, plasma fibrinogen and fibrinolysis.
British Journal of Surgery, 60_: 386-389, 1973.
201.
73. Han, P., Turpie, A.G.G. and Genton, E. Plasma beta thrombo-
globulin: differentiation between intravascular and
extravascular platelet destruction. Blood, J54: 1192-1196, 1979'.
74. Harker, L.A. and Slichter, S.J. Platelet and fibrinogen
consumption in man. New England Journal of Medicine, 287:
999-1005, 1972.
75. Hayem, G. Mechanisme de l'arret des hemorrhages. La Revue
Scientifique de la France et de l'Etranger, 30: 46-49, 1882.
76. Hills, N.H., Pflug, J.J., Jeyasingh, K., Boardman, L. and
Calnan, J.S. Prevention of deep vein thrombosis by intermittent
pneumatic compression of calf. British Medical Journal, JL:
131-135, 1972.
77. Hirsh, J. and McBride, J.A. Increased platelet adhesiveness in
recurrent venous thrombosis and pulmonary embolism. British
Medical Journal, 2_: 797-799, 1965.
78. Hirsh, J., Buchanan, M., Glynn, M.F. and Mustard, J.F. Effect
of streptokinase on haemostasis. Blood, 32: 726-737, 1968.
79. Hirsh, J., Gallus, A.S. and Cade, J.F. Diagnosis of thrombosis.
125
Evaluation of I fibrinogen scanning and blood tests.
Thrombosis et Diathesis Haemorrhagica, 32: 11-20, 1974.
80. Holmsen, H., Day, H.J. and Stormorken, H. The blood platelet
release reaction. Scandinavian Journal of Haematologg, Suppl.
£: 1-26, 1969.
81. Holmsen, H., Setkowsky, C.A., Lages, B., Day, J.H., Weiss, H.J.
and Scrutton, M.C. Content and thrombin induced release of acid
hydrolysates in gel-filtered platelets from patients with
storage pool disease. Blood, 4£: 131-142, 1975.
202.
82. Holt, J.C. and Niewiarowski, S. On the relation between low
affinity PF^ and &-thromboglobulin. (Abstract). Thrombosis and
Haemostasis, 42: 271, 1979.
83. Hovig, T. Aggregation of rabbit blood platelets produced in
vitro by saline "extract" of tendons. Thrombosis et Diathesis
Haemorrhagica, 9_: 248-263, 1963.
84. Hugues, J. and Lapiere, C.M. Novelles recherches sur 1'accolement
des plaquettes aux fibres de collagene. Thrombosis et Diathesis
Haemorrhagica, 1^: 327-354, 1964.
85. Isacson, S. and Nilsson, I.M. Defective fibrinolysis in blood
and vein walls in recurrent idiopathic venous thrombosis.
Acta Chirurgica Scandinavica, 138: 313-319, 1972.
86. James, H.L., Bradford, H.R. and Ganguly, P. Platelet fibrinogen
identity and initial observations on the mode of its degradation
by plasmin. Biochimica et Biophgsica Acta, 386 (1): 209-220,
1975.
87. Jarrett, P.E., Morland, M. and Browse, N.L. Idiopathic recurrent
superficial thrombophlebitis: treatment with fibrinolytic
enhancement. British Medical Journal, ^ (6066): 933-934, 1977.
88. Jarrett, P.E., Morland, M. and Browse, N.L. Treatment of
Raynaud's phenomenon by fibrinolytic enhancement. British
Medical Journal, 2_ (6136): 523-525, 1978.
89. Johnsson, H., Orinius, E. and Paul, C. Fibrinopeptide A in
patients with acute myocardial infarction. Thrombosis Research,
16: 255-260, 1979.
90. Joist, J.H., Dolezel, G., Lloyd, J.V., Kinlough-Rathbone, R.L.
and Mustard, J.F. Platelet factor 3 availability and the
platelet release reaction. Journal of Laboratory and Clinical
Medicine, JJ4: 474-482, 1974.
203.
91. Jones, D.R.B., Webber, A., Prescott, R.J., Allan, N.C. and
Ruckley, C.V. Fibrin-fibrinogen degradation products (FDP) in
thromboembolism and other diseases. Vasa, jj: 332-337, 1976.
92. Jones, N.A.G., Zahavi, J., de Haas, H.A., Clark, S.E.,
Leyton, J. and Kakkar, V.V. Platelet function in arterial
disease. (Abstract). Thrombosis and Hammostasis. 42: 147, 1979.
93. Kakkar, V.V., Howe, C.T., Flanc, C. and Clarke, M.B. Natural
history of post operative deep vein thrombosis. Lancet, ii:
230-232, 1969.
94. Kakkar, V.V. Medical treatment of deep vein thrombosis. British
Journal of Hospital Medicine, jl: 741-750, 1971.
95. Kakkar, V.V. and Scully, M.F. Thrombolytic therapy. British
Medical Bulletin, J4(2): 191-199, 1978.
96. Kaplan, K.L., Broekman, M.J., Chernoff, A., Lesznik, G.R. and
Drillings, M. Platelet alpha granule proteins: studies on
release and subcellular localisation. Blood, .53: 604-618, 1979.
97. Karpatkin, S. Heterogeneity of human platelets. I. Metabolic
and kinetic evidence suggestive of young and old platelets.
Journal of Clinical Investigation, 4JJ: 1073-1082, 1969.
98. Karpatkin, S. Heterogeneity of human platelets. II. Functional
evidence suggestive of young and old platelets. Journal of
Clinical Investigation, 4£: 1083-1087, 1969.
99. Kempi, V., Van Der Linden, W. and Von Scheele, C. Diagnosis of
deep vein thrombosis with 99mTc streptokinase. A clinical
comparison with phlebography. British Medical Journal, 4.:
748-749, 1974.
204.
100. Knight, L.C., Primeau, J.L., Siegel, B.A. and Welch, M.J.
Comparison of In111 labelled platelets and iodinated fibrinogen
for the detection of deep vein thrombosis. Journal of Nuclear
Medicine, .19. (8): 891-894, 1978.
101. Kopec, M., Budzynski, A., Stachurska, J., Wegrzynowicz, Z.
and Kowalski, E. Studies on the mechanism of interference by
fibrinogen degradation products (FDP) with the platelet function.
Role of fibrinogen in the platelet atmosphere. Thrombosis et
Diathesis Haemorrhagica, _15: 476-490, 1966.
102. Kowalski, E., Budzynski, A.Z., Kopec, M., Latallo, Z.S.,
Lipinski, B. and Wegrzynowicz, Z. Studies on the molecular
pathology and pathogenesis of bleeding in severe fibrinolytic
states in dogs. Thrombosis et Diathesis Haemorrhagica, 12:
69-86, 1964.
103. Lahnborg, G. Diagnosis of pulmonary embolism. Triangle, 16:
11-18, 1977.
104. Lambie, J.M., Barber, D.C., Dhall, D.P. and Matheson, N.A.
Dextran 70 in prophylaxis of postoperative venous thrombosis.
A controlled trial. British Medical Journal, 2^: 144-145,
1970.
105. Lazzarini-Robertson, A., Jr. Effects of heparin on the uptake
of lipids by isolated human and animal arterial endothelial
type cells. Angiologg, 12_: 525-534, 1961.
106. Ludlam, C.A., Moore, S., Bolton, A.E., Pepper, D.S. and
Cash, J.D. The release of a human platelet specific protein
measured by a radioimmunoassay. Thrombosis Research, 6^:
543-548, 1975.
205.
107. Ludlam, C.A., Bolton, A.E., Moore, S. and Cash, J.D. New
rapid method for the diagnosis of deep venous thrombosis.
Lancet, ;ii=: 259-260, 1975.
108. Ludlam, C.A. and Cash, J.D. Studies on the liberation of
3 thromboglobulin from human platelets in vitro. British
Journal of Haematology, £3: 239-247, 1976.
109. Ludlam, C.A. Evidence for the platelet specificity of 3
thromboglobulin and studies on the plasma concentration in
healthy individuals. British Journal of Haematology, 41:
271-278, 1979.
110. Ludlam, C.A., O'Brien, J.R., Bolton, A.E. and Etherington, M.
A comparison between the plasma concentration of immunologically
assayed platelet factor 4 and beta thromboglobulin and the
heparin thrombin clotting time. Thrombosis Research, ££>: 523-
530, 1979.
111. Lyttleton, J.W. The antithrombin activity of heparin.
Biochemical Journal, 58_: 15-23, 1954.
112. Majerus, P.W. Why Aspirin? (Editorial). Circulation, 54:
357-359, 1976.
113. Majerus, P.W. and Miletich, J.P. Relationship between
platelets and coagulation factors in haemostasis. Annual
Review of Medicine, 29: 41-49, 1978.
114. Manohar, M., Maheswaran, S.K., Frommes, S.P. and Lindorfer, R.L.
Platelet damaging factor, a fifth activity of staphylococcal
a toxin. Journal of Bacteriology, £4: 224-231, 1967.
115. flansfield, A.0. Alteration in fibrinolysis associated with
surgery and venous thrombosis. British Journal of Surgery,
59: 754-757, 1972.
206.
116. Mant, M.J., O'Brien, B.D., Thong, K.L., Hammond, G.W.,
Birtwhistle, B.V. and Grace, M.G. Haemorrhagic complications
of heparin therapy. Lancet, i: 1133-1135, 1977.
117. Manucci, P.M. and Sharp, A. A. Platelet volume and shape in
relation to aggregation and adhesion. British Journal of
Haematology, =13^ 604-617, 1967.
118. Martin, B.M., Feinman, R.D. and Detwiler, T.C. Platelet
stimulation by thrombin and other proteases. Biochemistry,
14: 1308-1314, 1975.
119. Matsuda, T., Seki, T., Ogawara, M., Miura, R., Yokouchi, M.
and Murakami, M. Comparison between plasma levels of 3-
thromboglobulin and platelet factor 4 in various diseases.
(Abstract). Thrombosis et Haemostasis, 42: 288, 1979.
120. Meadway, J., Nicolaides, A.N., Walker, C.J. and O'Connell, J.D.
Value of Doppler ultrasound in diagnosis of clinically
suspected deep vein thrombosis. British Medical Journal, .4:
552-554, 1975.
121. Millar, W.T. and Smith, J.F.B. Localisation of deep venous
thrombosis using technetium-99m-labelled urokinase. Lancet,
ii: 695-696, 1974.
122. Miller, J.L., Katz, A.J. and Feinstein, M.D. Plasmin
inhibition of thrombin-induced platelet aggregation. Thrombosis
et Diathesis Haemorrhagica, =33 (2): 286-309, 1975.
123. Mills, D.G., Borda, I.T., Philp, R.B. and Eldridge, C.
Effects of in vitro aspirin on blood platelets of gastro¬
intestinal bleeders. Clinical Pharmacology and Therapeutics,
15: 187-192, 1974.
207.
124. Milne, R.M., Gunn, A.A., Griffiths, J.M.T. and Ruckley, C.V.
Postoperative venous thrombosis. A comparison of diagnostic
techniques. Lancet, i_i: 445-447, 1971.
125. Minter, N. and Ingram, M. Density distribution of platelets.
(Abstract). Blood, J0_: 551, 1967.
126. Moniz, E. L'encephalography arterielle - son importance dans
la localisation des tumeurs cerebrales. Revue Neurologique,
2: 72-90, 1927.
127. Moore, S., Pepper, D.S. and Cash, J.D. The isolation and
characterisation of a platelet specific 3-globulin (3-thrombo-
globulin) and the detection of anti-urokinase and anti-plasmin
released from thrombin aggregated washed human platelets.
Biochimica et Biophysica Acta, 379: 360-369, 1975.
128. Morse, E.E., Jackson, D.P. and Conley, C.L. Role of platelet
fibrinogen in the reactions of platelets to thrombin.
Journal of Clinical Investigation, 44: 809-816, 1965.
129. Movat, H.Z., Mustard, J.F., Taichman, N.S. and Uriuhara, T.
Platelet aggregation and release of ADP serotonin and histamine
associated with phagocytosis of antigen-antibody complexes.
Proceedings of the Society for Experimental Biology and
Medicine, 120: 232-237, 1965.
130. Mueller-Eckhardt, C. and Liischer, E.F. Immune reactions of
human blood platelets. I. A comparative study on the effects on
platelets of heterologous antiplatelet antiserum antigen-
antibody complexes, aggregated gamma globulin and thrombin.
Thrombosis et Diathesis Haemorrhagica, 20: 155-167, 1968.
131. Mullick, S.C., Wheeler, H.B. and Songster, G.F. Diagnosis of
deep venous thrombosis by measurement of electrical impedance.
American Journal of Surgery, 119. 417-422, 1970.
208.
132. Multi Unit Controlled Trial. Heparin versus Dextran in the
prevention of deep vein thrombosis. Lancet, ii: 118-120, 1974.
133. Murphy, E.A. and Mustard, J.F. Coagulation tests and platelet
economy in atherosclerotic and control subjects. Circulation,
25: 114-125, 1962.
134. Mustard, J.F. and Murphy, E.A. Blood platelet economy during
moderate and intensive heparin therapy. Blood, 22_: 1-8, 1963.
135. Mustard, J.F. and Packham, M.A. Factors affecting platelet
function, adhesion, relear and aggregation. Pharmacological
Reviews, 22: 97-187, 1970.
136. Nachman, R.L., Weksler, B. and Ferris, B. Characterisation of
human platelet vascular permeability enhancing activity.
Journal of Clinical Investigation, 51^: 549-556, 1972.
137. Negus, D., Pinto, D.J., Le Quesne, L.P., Brown, N. and
125
Chapman, M. I labelled fibrinogen in the diagnosis of deep
vein thrombosis and its correlation with phlebography. British
Journal of Surgerg, 5j5: 835-839, 1968.
138. Negus, D., Pinto, D.J. and Brown, N. Platelet adhesiveness in
post operative deep vein thrombosis. Lancet, _i: 220-224, 1969.
139. Nicolaides, A.N. The prevention of post operative deep venous
thrombosis. 1972 Jacksonian Prize Essay.
140. Niewiarowski, S. Identification and separation of secreted
platelet proteins by isoelectric focusing. Evidence that low-
affinity platelet factor 4 is converted to beta thromboglobulin
by proteolysis. Blood, _55: 453-456, 1980.
141. Nossel, H.L., Yudelman, I., Canfield, R.E., Butler, V.P., Jr.,
Spandonis, K., Wilner, G.D. and Qureshi, G.D. Measurement of
fibrinopeptide A in human blood. Journal of Clinical
Investigation, J54: 43-53, 1974.
209.
142. Nossel, H.L., Butler, V.P., Jr., Canfield, R.E., Yudelman, I.,
Ti, M. , Spanondis, K. and Soland, T. Potential use of
fibrinopeptide A measurements in the diagnosis and management
of thrombosis. Thrombosis et Diathesis Haemorrhagica, 33:
426-434, 1975.
143. Nossel, H.L., Wasser, J., Kaplan, K.L., La Gamma, K.S.,
Yudelman, I. and Canfield, R.E. Sequence of fibrinogen
proteolysis and platelet release after intra uterine infusion
of hypertonic saline. Journal of Clinical Investigation, 64:
1371-1378, 1979.
144. Nussenzweig, V. and Seligman, M. Analyse par des m^thodes
immunocliniques de la degradation par la plasmine du fibrinogfene
humaine et de la fibrine, A differants stades. Revue
d'Hematologie, 15^ 451-466, 1960.
145. O'Brien, J.R., Etherington, M. and Jamieson, S. Refractory
state of platelet aggregation with major operations. Lancet,
ii. 741-743, 1971.
146. O'Brien, J.R., Etherington, M.D., Jamieson, S., Lawford, P.,
Lincoln, S.V. and Alkjaersig, N.J. Blood changes in
atherosclerosis and long after myocardial infarction and venous
thrombosis. Thrombosis et Diathesis Haemorrhagica, 34: 483-
497, 1975.
147. O'Brien, J.R., Etherington, M.D. and Shuttleworth, R.
0 thromboglobulin and heparin neutralising activity test in
clinical conditions. (Letter). Lancet, i: 1153-1154, 1977.
148. Okuno, T. and Crockatt, D. Platelet factor 4 activity and
thromboembolic episodes. American Journal of Clinical
Pathology, 67: 351-355, 1977.
210.
149. Olcott, IV, C. and Wylie, E.J. Platelet aggregation in
patients with severe atherosclerosis. Journal of Surgical
Research, 24 (4): 343-346, 1978.
150. Olson, P.S., Ljungqvist, U. and Bergentz, S.E. Analysis of
platelet red cell and fibrin content in experimental arterial
and venous thrombi. Thrombosis Research, j5: 1-19, 1974.
151. Ouchi, H. and Warren, R. Detection of intravascular thrombi
131
by means of I labelled plasmin. Surgery, _51: 42-49, 1962.
152. Pandolfi, M., Bjernstad, A. and Nilsson, I.M. Technical
remarks on the microscopical demonstration of tissue plasminogen
activator. Thrombosis et Diathesis Haemorrhagica, 27_: 88-98,
1972.
153. Payling-Wright, H. Changes in the adhesiveness of blood
platelets following parturition and surgical operations.
Journal of Pathology and Bacteriology, 54: 461-468, 1942.
154. Peabody, C.N., Kannel, W.B. and McNamara, P.M. Intermittent
claudication: surgical significance. Archives of Surgery,
109: 693-697, 1974.
155. Peuscher, F.W., Van Aken, W.G., Flier, O.T.N. , Stoepman-
Van Dalen, E.A., Cremer-Goote, T.M. and Van Mourik, J.A.
Effect of anticoagulant treatment measured by fibrinopeptide A
in patients with venous thromboembolism. Thrombosis Research,
18: 33-43, 1980a.
156. Peuscher, F.W., Cleton, F.J., Armstrong, L., Stoepman-
Van Dalen, E.A., Van Mourik, J.A. and Van Aken, W.G.
Significance of plasma fibrinopeptide A in patients with
malignancy. Journal of Laboratory and Clinical Medicine, 96:
5-14, 1980b.
211.
157. Prowse, C.V., Vigano, S., Borsey, D.Q. and Dawes, J. The
release of beta-thromboglobulin from platelets during the
clotting of whole blood. Thrombosis Research, Vlj. 433-442,
1980.
158. Quick, A.J. Salicylates and bleeding: the aspirin tolerance
test. American Journal of the Medical Sciences, 252: 265-269,
1966.
159. Radiochemical Centre, Amersham. 3 Thromboglobulin RIA Kit.
(Instructional Manual). 1977.
160. Rasi, V. Beta thromboglobulin in plasma; false high values
caused by platelet enrichment of the top layer of plasma during
centrifugation. Thrombosis Research, ^5: 543-552, 1979.
161. Registrar General's Reports for Scotland, 1945-1978. H.M.S.O.
162. Reimann, H.A. The blood platelets in pneumococcus infections.
Journal of Experimental Medicine, 40: 553-565, 1924.
163. Reimers, H-J, Kinlough-Rathbone, R.L., Cazenave, J.P.,
Senyi, A.F., Hirsh, J., Packham, M.A. and Mustard, J.F. In
vitro and in vivo functions of thrombin-treated rabbit platelets.
Thrombosis and Haemostasis, _35: 151-166, 1976.
164. Rosenthal, M.C., Niemetz, J. and Wisch, N. Haemorrhage and
thrombosis associated with neoplastic disorders. Journal of
Chronic Diseases, _1£: 667-675, 1963.
165. Ross, R., Glomset, J., Kariya, B. and Harker, L. A platelet
dependent serum factor that stimulates the proliferation of
arterial smooth muscle cells in vitro. Proceedings of the
National Academy of Sciences of the United States of America,
71: 1207-1210, 1974.
212.
166. Roth, G.J. and Majerus, P.W. The mechanism of the effect of
aspirin on human platelets. I. Acetylation of a particulate
fraction protein. Journal of Clinical Investigation, 56:
624-632, 1975.
167. Rowsell, H.C., Glynn, M.F., Mustard, J.F. and Murphy, E.A.
Effect of heparin on platelet economy in dogs. American
Journal of Physiology, 213: 915-922, 1967.
168. Rucinski, B., Niewiarowski, S., James, P., Walz, D.A. and
Budzinski, A.Z. Antiheparin proteins secreted by human
platelets. Purification, characterization and radioimmuno¬
assay. Blood, 53_: 47-62, 1979.
169. Ruckley, C.V., Das, P.C., Leitch, A.G., Donaldson, A.A.,
Copeland, W.A., Redpath, A.T., Scott, D. and Cash, J.D. Serum
fibrin/fibrinogen degradation products associated with post
operative pulmonary embolus and venous thrombosis. British
Medical Journal, 395-398, 1970.
170. Sano, T., Boxer, M.G.J, and Boxer, L.A. Platelet sensitivity
to aggregation in normal and diseased groups. A method of
assessment of platelet aggregability. Thrombosis et Diathesis
Haemorrhagica, 25_: 524-531, 1971.
171. Schmitt, H.E. Phlebography in the diagnosis of deep vein
thrombosis. In: New Trends in Venous Diseases (ed. A. Kappert),
Hans Huber, Bern, pp 41-44, 1977.
172. Sharma, S.C., Vijayan, G.P., Seth, H.N. and Suri, M.L. Platelet
adhesiveness, plasma fibrinogen and fibrinolytic activity in
young patients with ischaemic stroke. Journal of Neurology,
Neurosurgery and Psychiatry, 41_ (2): 118-121, 1978.
213.
173. Sigel, B., Felix, W.R., Popsky, G.L. and Ipsen, J. Diagnosis
of lower limb venous thrombosis by Doppler ultrasound
technique. Archives of Surgery, 104: 174-179, 1972.
174. Smith, R.C., Ferrington, C. and Ruckley, C.V. Calf muscle
technetium clearance and Doppler ankle pressure in patients
with intermittent claudication. Vasa, <5: 236-243, 1977.
175. Smith, R.C., Elton, R.A., Orr, J.D., Hart, A.J., Graham, D.F.,
Fuller, G.A., Rundle, J.S., MacPherson, A.I.S, and Ruckley, C.V.
Dextran and intermittent pneumatic compression in the
prevention of post operative deep vein thrombosis: a multi
unit trial. British Medical Journal, 952-954, 1978.
176. Spaet, T.H. and Kropatkin, M. Effect of intravenous blood
thromboplastin intermediates on clotting in rats. American
Journal of Physiology, 195: 77-80, 1958.
177. Spaet, T.H. and Erickson, R.B. The vascular wall in the
pathogenesis of thrombosis. Thrombosis et Diathesis
Haemorrhagica, Suppl. 221: 67-86, 1966.
178. Steele, P.P., Weily, H.S. and Genton, E. Platelet survival
and adhesiveness in recurrent venous thrombosis. New England
Journal of Medicine, 288: 1148-1152, 1973.
179. Stewart, G.J., Ritchie, W.G.M. and Lynch, P.R. A scanning and
transmission electron microscopic study of canine jugular veins.
Scanning Electron Microscopy (Part III) . Proceedings of the
Workshop on Scanning Electron Microscopy in Pathology, Research
Institute,Chicago, Illinois, 473-480, 1973.
180. Strandness, D.E. and Sumner, D.S. Ultrasonic velocity
detector in the diagnosis of thrombophlebitis. Archives of
Surgery, 104: 180-183, 1972.
214.
181. Thomas, D., Stein, M., Tanabe, G., Rege, V. and Wessler, S.
Mechanism of bronchoconstriction produced by thromboemboli in
dogs. American Journal of Physiology, 206: 1207-1212, 1964.
182. Thomson, C., Forbes, C.D. and Prentice, C.R.M. The potentiation
of platelet aggregation and adhesion by heparin in vitro and
in vivo. Clinical Science and Molecular Medicine, 45: 485-494,
1973.
183. Todd, A.S. The histological localisation of fibrinolysin
activator. Journal of Pathology and Bacteriology, 78: 281-
283, 1959.
184. Turpie, A.G. Personal communication, 1979.
185. Ueda, I. The effects of volatile general anaesthetics on
adenosine diphosphate-induced platelet aggregation.
Anesthesiology, J4: 405-408, 1971.
186. Van Creveld, S. and Paulssen, M.M.P. Isolation and properties
of the third clotting factor in blood platelets. Lancet,
23-25, 1952.
187. Van Nispen, J.W., Hageman, T.C. and Scherega, H.A. Mechanism
of action of thrombin on fibrinogen. The reaction of thrombin
with fibrinogen-like peptides containing, 11, 14 and 16
residues. Archives of Biochemistry and Biophysics, 182:
227-243, 1977.
188. Vargaftig, B.B. and Lefort, J. Acute hypotension due to
carrageenan, arachidonic acid and slow reacting substance C
in the rabbit: role of platelets and nature of pharmacological













Virchow, R. Die Verstopfung der Lungenarterie und Ihre Folgen.
Beitraege zue Experimentelle Pathologie und Physiologie,
1-8, 1846.
Virchow, R. Gaesmmelte Abhandhingen zur Wissenschaftlichen
Medicine, p.219. Meidinger John: Frankfurt, 1856.
Von Kaulla, K.N. Chemistry of Thrombolysis: Human Fibrinolytic
Enzymes, p. 79. Thomas Springfield: Illinois, 1963.
Walsh, P.N. The possible role of platelet coagulant activities
in the pathogenesis of venous thrombosis. Thrombosis et Diathesis
Haemorrhagica, 33: 435-443, 1975.
Walter, J.B. and Israel, M.S. Wound healing. In: Walter, J.B.
and Israel, M.S. (Eds.) General Pathology, pp.167-189. Churchill:
London, 1970.
Ward, A.S., Porter, N., Preston, F.E. and Morris-Jones, W.
Platelet aggregation in patients with peripheral vascular
disease. Atherosclerosis, 2R (1): 63-68, 1978.
Weily, H.S., Steele, P.P., Davies, H., Pappas, G. and Genton, E.
Platelet survival in patients with substitute heart valves.
New England Journal of Medicine, 290: 534-537, 1974.
Weiss, H.J. Platelets: physiology and abnormalities of
function. New England Journal of Medicine, 293: 531-541, 1975.
Welch, W.H. Thrombosis of veins of the neck and arm in case of
cardiac disease. Maryland State Medical Journal, 41: 142, 1899.
Wessler, S. Factors in the initiation of deep venous thrombosis.
In: Nicolaides, A.N. (Ed.) Thromboembolism, p.19. Medical &
Technical Publishing Co. Ltd., England, 1975.
216.
199. White, A.M. and Heptinstall, S. Contribution of platelets to
thrombus formation. British Medical Bulletin, 34_: 123-128,
1978.
200. Whitney, R.J. The measurement of volume changes in human
limbs. Journal of Physiology (London), 121: 1-27, 1953.
201. Williams, 0., Lyall, J., Vernon, M. and Croft, D.N. Ventilation-
perfusion lung scanning for pulmonary emboli. British Medical
Journal, _1: 600-602, 1974.
202. Witte, L.D., Kaplan, K.L., Nossel, H.L., Lages, B.A., Weiss, H.J.
and Goodman, D.S. Studies of the release from human platelets of
the growth factor for cultured human arterial smooth muscle
cells. Circulation Research, 412: 402-409, 1978.
203. Wood, E.H., Prentice, C.R.M. and McNicol, G.P. Association of
fibrinogen-fibrin-related antigen (FR-antigen) with post
operative deep vein thrombosis and systemic complications.
Lancet, U 166-169, 1972.
204. Woolf, N. and Carstairs, K.C. Infiltration and thrombosis in
atherogenesis. A study using immunofluorescent techniques.
American Journal of Pathology, Jl_: 373-386, 1967.
205. Wright, H.P. Adhesiveness of blood platelets in normal subjects
with varying concentrations of anticoagulants. Journal of
Pathology and Bacteriology, J53: 255-262, 1941.
206. Yao, S.T. Ultrasound in the transcutaneous assessment of blood
flow. British Journal of Hospital Medicine, 8_: 521-528, 1972.
207. Youden, W.J. Index for rating diagnostic tests. Cancer, jJ:
32-35, 1950.
217.
208. Zahavi, J., Cella, G., Dubiel, M. and Kakkar, V.V. The
variability of beta-thromboglobulin in healthy individuals.
Thrombosis et Haemostasis, 40: 565-567, 1979.
209. Zahavi, J. and Kakkar, V.V. 8-thromboglobulin - a specific
marker of in vivo platelet release reaction. Thrombosis et
Haemostasis, .44: 23-29, 1980.
210. Zucker, M.B. and Peterson, J. Inhibition of adenosine
diphosphate induced secondary aggregation and other platelet
functions by acetylsalicylic acid ingestion. Proceedings of
the Society for Experimental Biology and Medicine, 127: 547-
551, 1968.
211. Zucker, M.B. Effect of heparin on platelet function. Thrombosis
et Diathesis Haemorrhagica, _33: 63-65, 1975.
218.
Additional References
212. Arocha-Pinango, C.L. and Ojeda, A. Does the 3TG/PF4 ratio
have any value? Thrombosis et Haemostasis, 4j): 147, 1983.
(Letter).
213. Baele, G., Bogaerts, H., Clement, D.L., Pannier, R. and
Barbier, F. Platelet activation during treadmill exercise in
patients with chronic peripheral vascular disease. Thrombosis
Research. J23: 215-223, 1981.
214. Bidet, J.M., Ferriere, J.P., Besse, G., Chollet, P.,
Gaillard, G. and Plagne, R. Evaluation of 3-throraboglobulin
levels in cancer patients: effect of antitumour chemotherapy.
Thrombosis Research, dL9=: 429-433, 1980.
215. Bolton, A.E., Cooke, E.D., Lekhwani, C.P. and Bowcock, S.A.
Urinary 3-thromboglobulin levels as a diagnostic marker for
post-operative deep vein thrombosis. Thrombosis Research, Jj):
249-255, 1980.
216. Cella, G, and Girolami, A. Heparins and release. Thrombosis
et Haemostasis, 44: 105, 1980. (Letter).
217. Cooke, E.D., Bolton, A.E. and Levack, B. Salivary 3TG after
hip surgery. Lancet, ii: 1427, 1981. (Letter).
218. de Boer, A.C., Han, P., Turpie, A.G.G., Butt, R.,
Zielinsky, A. and Genton, E. Plasma and urine Beta-thrombo-
globulin concentration in patients with deep vein thrombosis.
Blood, £8: 693-698, 1981.
219. de Boer, A.C., Turpie, A.G.G., Butt, R.W., Duke, R.J.,
Block, R.F. and Genton, E. Plasma Beta-thromboglobulin levels
and serum fragment E in stroke. British Journal of Haematology,
50: 327-334, 1982.
219.
220. Douglas, J.T., Lowe, G.D.O., Forbes, C.D. and Prentice, C.R.M.
3-thromboglobulin and platelet counts - effect of
malignancy, age and obesity. Thrombosis Research, J25: 459-
464. 1982.
221. Duncan, A., de Pratti, V.J. and George, R.R. Elevated
3-thromboglobulin levels associated with smoking and oral
contraceptive agents in normal healthy women. Thrombosis
Research, 21: 425-430. 1981.
222. Farrell, R.J,, Duffy, M.J. and Duffy, G.J. Serum fragment E
and plasma B-thromboglobulin in patients with acute pulmonary
embolism and non-thromboembolic lung disease. Thrombosis
Research, 2J_: 231-234, 1982.
223. Farrell, R.J., Duffy, M.J., Moriarty, M.J. and Duffy, G.J.
Plasma concentrations of the platelet specific 3-thromboglobulin
in malignant disease. British Journal of Cancer, 4_1: 989-991,
1980.
224. Franchi, F., Canciani, M.T. and Mannucci, P.M. The
3-thromboglobulin test. Thrombosis et Haemostasis, 44_: 107,
1980. (Letter).
225. Guzzo, J., Niewiarowski, S., Musial, J., Bastl, C., Grossman, R.A.,
Rao, A.K., Berman, I. and Paul, D. Secreted platelet proteins
with antiheparin and mitogenic activities in chronic renal
failure. Journal of Laboratory and Clinical Medicine, 96:
102-113, 1980.
226. Hoogendijk, E.M.G., Ten Cate, J.W., Ludlam, C.A. and Bruin, T.
No effect of Aspirin on 3-thromboglobulin plasma levels in
healthy volunteers. Thrombosis Research, JL9: 257-262, 1980.
220 .
227. Hughes, A., Daunt, S., Vass, G. and Wick.es, J. In vivo
platelet activation following myocardial infarction and
coronary ischaemia. Thrombosis et Haemostasis, 133-135,
1982.
228. Hughes, A.S.B., Illsley, C.D.J, and Wilkinson, L. Platelet
activation during exercise induced myocardial ischaemia.
Thrombosis Research, 26: 425-430, 1982.
229. Kaplan, K.L. and Owen, J. Plasma levels of 3-thromboglobulin
and platelet factor 4 as indices of platelet activation in
vivo. Blood, j>7: 199-202, 1981.
230. Lane, D.A., Ireland, H., Wolff, S., Grant, R., Jennings, S.
and Allen-Marsh, T. Plasma concentrations of fibrinopeptide
A, fibrinogen fragment BB1-42 and 3-thromboglobulin following
total hip replacement. Thrombosis Research, 26: 111-118,
1982.
231. Nichols, A.B., Owen, J., Kaplan, K.I., Siacca, R.R., Cannon, P.J.
and Nossel, H.L. Platelet factor 4 and 3-throraboglobulin levels
in coronary heart disease. Blood, _§Q_: 650-654, 1982.
232. Petralito, A., Flore, C.E., Mangiafico, R.A. and Malatino, L.S.
Beta-thromboglobulin plasma levels in different stages of
hypertension. Thrombosis et Haemostasis, j|8: 241, 1982.
(Letter).
233. Prowse, C., Pepper, D.S. and Dawes, J. Prevention of the
platelet alpha granule reaction by membrane active drugs.
Thrombosis et Haemostasis, 25: 219-227, 1982.
234. Pumphrey, C.W. and Dawes, J. Elevation of plasma 3-thrombo-
globulin in patients with prosthetic heart valves. Thrombosis
Research, 22: 147-155, 1982.
221.
235. Randi, M.L., Fabris, F., Casonato, A. and Girolani, A. The
effect of anticoagulant mixtures on BTG and PF4 levels.
Thrombosis et Haemostasis, J6.: 569, 1981. (Letter).
236. Rasi, V. , Ikkala, E. and Torstila, I. Plasma 3-thromboglobulin
in acute myocardial infarction. Thrombosis Research, 25:
203-212, 1982.
237. Rasi, V., Ikkala, E. and Valtonen, V. Plasma 3-thromboglobulin
in severe infections. Thrombosis Research, 26_: 267-274, 1982.
238. Santos, M.T., Valles, J., Aznar, J. and Villa, P. Platelet
3TG release in vitro induced by mechanical and chemical
stimulus: correlation with the aggregation curve parameters.
Scandinavian Journal of Haematology, _29_: 368-372, 1982.
239. Stewart, M.E., Douglas, J.T., Lowe, G.D.O., Prentice, C.R.M.
and Forbes, C.D. Prognostic value of Beta-thromboglobulin in
patients with transient cerebral ischaemia. Lancet, ^ii: 479-
482, 1983.
240. Tunbridge, L.J., Watts, S.E. and Lloyd, J.V. Effect of EDTA
and PGE1 on 3-thromboglobulin liberation from platelets.
Thrombosis Research, 28757-764, 1982.
241. van Hulsteijn, H., Bertina, R. and Briet, E. A one year
.follow up study of plasma fibrinopeptide A and beta-thrombo-
globulin after deep vein thrombosis and pulmonary embolism.
Thrombosis Research, =27_: 225-229, 1982.
242. van Hulsteijn, H., Briet, E., Koch, C., Hermans, J. and
Bertina, R. Diagnostic value of fibrinopeptide A and
3-thromboglobulin in acute deep vein thrombosis and pulmonary
embolism. Acta Medica Scandinavica, 211: 323-330, 1982.
222.
243. van Hulsteijn, H., Fibbe, W., Bertina, R. and Briet, E.
Plasma fibrinopeptide A and $-thromboglobulin in major
bacterial infections. Thrombosis et Haemostasis, 48: 247-
249, 1982.
244. van Hulsteijn, H., van Es, A., Bertina, R. and Briet, E.
Plasma Beta-thromboglobulin and platelet factor 4 in renal
failure. Thrombosis Research, 24: 175-180, 1981.
245. Viero, P., Cortelazzo, S., Bassan, R. and Barbui, T. Effect
of Aspirin on platelet 5-hydroxytryptamine and Beta-thrombo¬
globulin plasma levels in patients with myeloproliferative
diseases. Thrombosis et Haemostasis, 48: 125-126, 1982.
